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Aldose Reductase and the sorbitol pathway
Introduction
Aldose Reductase (AR) is a cytosolic NADPH-dependent enzyme that catalyzes the reduc-
tion of various aldoses and aldehydes to the corresponding alcohols. It was first described 
in 1956 by Hers et al.1 as a glucose-reducing activity. The authors demonstrated that the 
conversion of blood glucose to fructose was used as an energy source for sperm cells. 
Today it is known that AR is the first and rate-limiting enzyme of the sorbitol pathway. 
Via this pathway glucose is first reduced to sorbitol by AR. In a second step sorbitol is then 
re-oxidized to fructose by an enzyme called sorbitol dehydrogenase (SDH) using NAD+ as 
cofactor. Galactose is an even better substrate for AR, but the corresponding product galac-
tiol is not further metabolized by SDH2;3. The net reactions of the sorbitol pathway for glu-
cose are conversions of glucose to fructose as well as of NADPH to NADH. 
Both enzymes are expressed in almost all human tissues4;5. However, the ratio of AR to 
SDH differs in different tissues6. The kidney, for example, is one of the tissues showing the 
highest concentrations of AR7. 
Under physiological conditions glucose is usually phosphorylated by the enzyme hexo-
kinase to glucose-6-phosphat which is then further metabolized using glycolysis or the 
pentose phosphate metabolism. Under raised blood glucose levels, as found in people suf-
fering from diabetes mellitus, up to one third of the available glucose is processed via the 
sorbitol pathway8;9. The accumulation of sorbitol on the one hand and the consumption of 
NADPH on the other have been postulated to be responsible for some of the late-onset 
complications of diabetes mellitus10-16. 
Structure of AR and related enzymes
AR belongs to the superfamily of the aldo-keto reductases (AKR). It comprises 315 amino 
acids and folds to an (β/α)8-TIM barrel structure with the catalytic site deeply buried at the 
center of the barrel17. The protein core is composed of eight parallel β-strands. Adjacent 
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strands are connected by eight parallel α-helices running anti-parallel to the β-sheets. The 
active site is located at the C-terminal end of the barrel. The bottom of the barrel is closed 
by two short anti-parallel β-strands near the N-terminus. Three large loops partially cover 
the top of the barrel. Two additional α-helices are found outside the barrel structure preced-
ing two of three additional loop regions in sequence. The cofactor NADPH binds at the 
bottom of the active site, with its nicotinamide moiety pointing towards the active site18;19. 
The shape and properties of the binding pocket of AR as well as the binding modes of dif-
ferent inhibitors in complex with AR will be discussed in great detail in the chapter on 
Comparative Crystal Structure Analysis (see page 43). 
Structurally related enzymes of the AKR family which also catalyze the pyridine nu-
cleotide-dependent reduction of carbonyl functions are abundant in most organisms. How-
ever, the accepted substrates differ between the single enzymes. AR and the very closely 
related enzyme aldehyde reductase reduce aldo and keto sugars as well as aromatic and 
aliphatic aldehydes20-22. Hydrosteroid dehydrogenase accepts steroids as substrates23, and 
the AR like prostaglandin synthase is responsible for the production of prostaglandin f2 al-
pha24. However, no strict rules can be applied for AR since substrate promiscuity is very 
pronounced for this enzyme. A broad variety of different substrates is accepted. Among 
these substrates are glutathiolated25;26, phospholipid27, saturated, and unsaturated28 aldehy-
des as well as 4-hydroxyalkenals28 and steroids29;30. The best known physiological substrate 
for AR is the 2-oxoaldehyde methylglyoxyal31-33. In general, many AR substrates are more 
hydrophobic than expected for an enzyme involved in sugar metabolism. 
Mechanism and kinetics of the AR catalyzed reaction
The reaction mechanism of AR follows a sequential binding of the involved molecules. 
The cofactor, NADPH, binds first and forms a binary complex with AR. Upon binding 
large movements in a protein region called the 'cofactor safety belt' are induced34. Thus, the 
cofactor becomes deeply buried in the protein. Subsequently, the ternary complex of sub-
strate, cofactor and protein, is formed. The substrate is kept properly aligned with respect 
to the cofactor by a network of hydrogen bonds with residues around the catalytic pocket. 
Then the hydride transfer takes place reducing the aldehyde to the corresponding alcoho-
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late. To finalize the reaction a proton needs to be transferred from the protein to the prod-
uct. Three residues around the active site are at suitable distances to act as proton donor: 
Cys 298, His 110, and Tyr 48. Kinetic35, computational36, as well as thermodynamic37 stud-
ies favor Tyr 48 as the source of the proton. After the product has been released, exchange 
of the cofactor is necessary to enable the next catalytic cycle. Therefore, the conformation-
al change which occurred during binding of the cofactor needs to be reversed. Several ki-
netic studies38-40 suggest that removing the cofactor from its binding site after the reaction 
is indeed the rate limiting step of the whole process.
Compared to other substrates, glucose is a rather poor substrate of AR having Km values 
in the range of 50-200 mM which is much higher than physiological concentrations41;42. 
However, less than 0.1% of glucose exists in the acyclic carbonyl form which is mandatory 
for binding to AR. It is, thus, conceivable that the enzyme processes significant amounts of 
glucose only if the glucose concentrations are pathologically high. Surprisingly, it has been 
shown that AR catalyzes the reduction of saturated and unsaturated medium- to long-chain 
(C-6 to C-18) aldehydes, which are generated during lipid peroxidation, with 103 to 104-
fold higher efficiency than glucose28;43;44. 
Several studies present results on post-translational modifications of AR to regulate the 
activity of the enzyme45-49. These modifications are in part held responsible for the reduced 
efficiency of hydantoine-based AR inhibitors such as sorbinil12;47. Furthermore, it was ob-
served that depending on the presence or absence of reducing agents the kinetic parameters 
of AR differed significantly50;51.  The same effects were encountered upon  in vitro thiol 
modifications using different agents43;52-55. Oxidative modifications55 and glutathiolation42;53 
of Cys 298, which is located directly at the binding site are deemed responsible for these 
effects. Thus, Cys 298 is considered to be a modulator for AR activity. Depending on the 
conditions of the reactions,  AR becomes either S-thiolated (inactivated) or S-nitrosated 
(activated). Therefore, nitric oxide (NO) is thought to be the physiological regulator of AR 
activity56;57. 
If NADPH is bound, the Cys 298 side chain is less prone to oxidative modifications. 
Due to the high binding affinity of NADPH to AR most of the enzyme in the cell will be in 
the complexed state. Exchange of the cofactor will only take place if substrate concentra-
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tions have reached a level where the catalytic reaction can occur. Thus, the switch for regu-
lating the AR activity by modifying the Cys 298 side-chain will only be available at situa-
tions of high substrate concentration. 
The sorbitol pathway and its influences on metabolism
Several hypotheses have been discussed with respect to the question how the activation of 
the sorbitol pathway may induce diabetic complications. Oxidative stress is one of the ma-
jor issues in this context. The sorbitol pathway contributes to oxidative stress in different 
ways:
• The increased activity of AR depletes its cofactor NADPH. A sufficient concentra-
tion of NADPH is required in cells due to its role as cofactor of glutathione reduc-
tase (GR). GR is responsible for several critical reductive metabolic steps, such as 
the detoxification of reactive oxygen species (ROS) and hydroperoxides. Thus, by 
consuming NADPH, AR weakens the ability of cells to protect themselves from 
oxidative stress. 
• In the second step of the pathway sorbitol is oxidized to fructose by SDH. Thereby 
NAD+ is reduced to NADH. However, NADH is the substrate of NADH oxidase, 
which in turn produces additional ROS58.
• The conversion of glucose to fructose is also problematic in itself, since fructose 
and its metabolites are more potent non-enzymatic glycation agents than glucose. 
The formed glycation products of these reactions are known to cause oxidative 
stress within cells. 
The accumulation of sorbitol within cells and the resulting increase of osmotic stress is 
the second hypothesis  discussed as  putative  explanation for  the occurrence of  diabetic 
complications. Since sorbitol can be oxidized by SDH to fructose, which then re-enters the 
glycolytic pathway, accumulation of sorbitol occurs primarily in cells and tissues where 
only low levels of SDH are present. For diabetic cataract it could be demonstrated that os-
motic  stress  is  the  main  reason for  this  complication59;60.  However,  it  remains  unclear 
whether this mechanism can be transferred to other diabetic pathological phenomena.
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Another factor, contributing in particular to diabetic vasculopathy, is the activation of 
protein kinase C (PKC) which is associated with the sorbitol pathway. PKC is activated by 
diacylglycerol (DAG)61. The concentration of the latter is elevated by raised blood glucose 
levels in many tissues. Several studies have shown that the elevated activation of PKC un-
der diabetic conditions could be prevented by AR inhibitors62-64. This might be due to the 
fact that fructose metabolites are precursors of the DAG synthesis65. Furthermore, there are 
hints that PKC is activated by oxidative stress66. 
Despite the large amount of knowledge about putative patho-physiological effects, the 
exact mechanism by which AR contributes to the development of diabetic complications 
remains unclear. Concerning the physiological function of AR, two main hypotheses are 
discussed in literature:
• osmoregulation in the kidney: sorbitol is one of the organic osmolytes that bal-
ance the osmotic pressure of extracellular hyperosmotic fluids during antidiuresis67-
70.  Considering  the  reported  increased  expression  of  AR  under  hyperosmotic 
stress71-73, it can be assumed that the enzyme plays an osmoregulatory role in the re-
nal homeostasis. 
• detoxyfication and housekeeping: the broad distribution of AR over different tis-
sues combined with the already discussed wide spectrum of substrates accepted by 
the enzyme suggest a role as a general detoxifying enzyme. In addition, AR might 
be involved in metabolizing environmental toxins74 as well as some drugs75. 
Again, despite a number of intriguing studies, the beneficial role of AR under physio-
logical conditions has not yet been entirely clarified.
Aldose Reductase inhibitors
Aldose Reductase inhibitors (ARI) have received considerable attention as potential thera-
peutic agents preventing for diabetic complications. A large variety of structurally diverse 
compounds have been identified as potent in vitro ARI. Currently known ARI can be di-
vided into different classes according to their structure76;77:
• acetic acid derivatives;
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• cyclic imides (hydantoins);
• phenolic derivatives ;
• pyridazinones;
• phenylsulfonylnitromethane derivatives;
• structurally diverse ARI from natural sources
Generally speaking, compounds derived from acetic acid show the highest in vitro affin-
ity towards AR. However, in many cases these compounds lack suitable in vivo potency. In 
contrast, the hydantoin-based molecules are superior concerning pharmacological efficacy. 
This behavior is usually attributed to the differing acidity of the two head groups. Car-
boxylic acids are fully deprotonated under physiological pH conditions. Thus, their ability 
to  penetrate  biological  membranes  is  limited.  Hydantoins,  however,  have  pKA values 
around 9. Thus, at physiological pH the protonated as well as the deprotonated forms are 
present in considerable amounts. Therefore, hydantions can more easily cross biological 
membranes in their uncharged protonated form, whereas the deprotonated polar form is 
needed to bind to the enzyme.
More than ten drugs have reached phase II or III clinical trials (see  Figure 1). All of 
them belong either to the carboxilic acid or the hydantoin groups. Only one ARI (epalre-
stat) is currently on the market. Most of the ARI were withdrawn before reaching the mar-
ket due to inadequate therapeutic potential or serious side-effects. The results for many of 
the clinical trials have recently been reviewed by Hamada et al.78 and will be summarized 
shortly in the following section.
The first ARI taken to clinical trials in the 1970s was alrestatin. Despite promising ini-
tial results, the development of alrestatin was stopped due to side-effects79;80. Numerous 
studies were carried out for sorbinil78. The compound failed to prove its efficacy in larger, 
statistically  more significant  studies.  Again,  side-effects  prevented the  compound from 
reaching the market81. Tolrestat made it to the market in Italy and other countries for the 
treatment of diabetic neuropathy82. However, in later studies tolrestat failed to confirm its 
efficacy83 and was suspected to  cause hepatic  damage84.  Therefore,  the compound was 
withdrawn. The clinical studies for ponolrestat were disappointing. This was probably due 
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to the poor penetration of the drug into human tissues85. Zopolrestat reached phase III of 
clinical trials86. However, the results of this study were never reported and further trials 
have been stopped. For zenarestat clinical trials were carried out in the US, Japan, and the 
UK. Again the compound looked promising, reached phase III, and was withdrawn without 
publishing the results of the final study87. For fidarestat a phase III trial was finished with 
encouraging results. However, the approval is still pending in Japan because of incomplete 
data88. Three additional ARI are in phase II or III clinical trials: NZ-31489, AS-320190, and 
minalrestat91. Epalrestat is the only ARI currently on the market and has been available for 
more than ten years by now. The results of several studies have supported the usefulness of 
epalrestat92-94. However, the duration of the studies may not have been long enough to as-
sess alterations in nerve functions. Only one longer study has been carried out, where it 
was shown that epalrestat minimized progression of early sensory deficits95. 
In summary the data from the different studies do not provide a conclusive picture about 
the clinical  potential  of  ARI.  While  some compounds,  such as tolrestat  and epalrestat, 
showed promising results, others failed to show beneficial effects. Clearly, there is still the 
need for the development of further ARI with better pharmacological properties78.
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Figure 1: AR inhibitors which reached phase II or III of clinical trials for diabetic  
neuropathy. Only epalrestat is currently on the market in Japan. 
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Why consider protein flexibility in structure-based drug 
design?
Proteins are dynamic systems. Their plasticity is a key characteristic of their function. To 
underline this hypothesis Eisenmesser et al.96 were able to show by NMR experiments that 
the characteristic enzyme motions necessary for catalysis are already present in the free en-
zyme and, thus, are an intrinsic property of the enzyme. Of course, inherent flexibility has 
consequences for the rational design of small molecules as inhibitors of protein function97-
99. Therefore, it is crucial to study and characterize the flexibility exhibited by a target en-
zyme of a structure-based drug design (SBDD) project. 
In recent years various attempts have been made to include protein flexibility into one 
of the most important steps of a SBDD project: the docking of small molecules into the 
binding site of a target enzyme100-112. The fundamental problem when considering protein 
flexibility is the enormous amount of degrees of freedom available to a protein. Therefore, 
all  suggested  methods rely  on  assumptions  and simplifications  to  keep  the  calculation 
times within reasonable boundaries for routine use in an industrial or academic environ-
ment. As a consequence, these methods only include a limited range of flexibility of the 
target protein. Rotamer libraries, ensembles of pre-generated structures or different tech-
niques  to  average  multiple  conformations  are  used  to  cope  with  side-chain  flexibility. 
Movements of the main chain or larger scale domain movements are usually not within the 
scope of these methods.
Knowing that current methods to consider protein flexibility are of reduced value for 
every day use, the question arises, whether one should deal with this problem at all. If a 
high-quality crystal structure of a certain protein conformation is available, then why not 
take this structure as a reference and start designing small molecules which address this 
pocket conformation?
Aldose Reductase (AR) is a good example for an enzyme which shows pronounced 
flexibility of its binding pocket and where many high-resolution structures are available. It 
exhibits an 'induced-fit' binding mechanism where three major binding-pocket conforma-
tions have been described113. A previous virtual screening approach with subsequent dock-
ing experiments which focused on the ultra-high resolution complex crystal structure with 
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idd 594114 resulted in hits which were active in the low micromolar range115. The binding 
mode determined later by means of X-ray crystallography is in good overall agreement 
with the proposed binding mode116 from  the docking studies using FlexX117.  Thus,  this 
project can be considered a success, since new inhibitors were discovered for a flexible en-
zyme using only one of the pocket conformations as template. However, the idea that one 
pocket conformation is sufficient to correctly predict the binding mode of AR inhibitors is 
misleading.  As with other  flexible  binding pockets,  unexpected changes  of  the  overall 
pocket conformation can occur, leading to a binding mode totally different than expected. 
To emphasize the need for including multiple discrete pocket conformations into the 
docking process, one example for such an 'undesigned' binding mode shall be discussed 
briefly. 
Da Settimo et al.118 published a series of AR inhibitors which were designed as potential 
analogues of the long known AR inhibitor tolrestat119, whose complex structure was solved 
already in 1997120. This inhibitor induces a conformation of the binding pocket which is 
still unique until today. The two most potent inhibitors  1 and  2 of the series inhibit AR 
with IC50 values of 140 and 550 nM, respectively (see Figure 2). The only difference be-
tween these two compounds is a different side chain in the 4-position of the ring scaffold. 
Figure 2: Chemical formulae of the AR inhibitor tolrestat and the two most most potent  
compounds from the series of Da Settimo et al.118. IC50 values for 1 and 2 are taken from 
the publication of De Settimo118, whereas the tolrestat value was published by Urzhumtsev  
et. al120. 
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The hypothesis that 1 and 2 induce a binding-pocket conformation similar to tolrestat is 
based on two observations: First, the high structural similarity to tolrestat analogs pub-
lished by Wrobel et al. in 1990121. In these compounds, the thioamide nitrogen of tolrestat 
is inserted into rigid cyclic structures. However, no complex crystal structure of AR with 
any of these analogs is available. The second observation is the good superposition of com-
pounds 1 and 2 with the protein-bound conformation of tolrestat (see Figure 3 A). 
To support the hypothesis of a binding mode of 1 and 2 similar to tolrestat, docking ex-
periments  were  carried  out  using  AutoDock  3.0.5122.  The  complex  crystal  structure  of 
porcine AR and tolrestat (pdb code: 1ah3120) was used as template and both inhibitors 1 and 
2 were docked into this structure. Subsequently, the best docking solutions for each com-
pound and the side chains of the corresponding binding-pocket residues were subjected to 
an energy minimization to further optimize the binding geometries. The resulting binding 
modes are shown in Figure 3 B (2) and Figure 3 C (1). In both cases the carboxylic func-
tion added in 2 position of the ring system addresses the catalytic subpocket. The overall 
binding mode of these docking solutions is indeed similar to the one of tolrestat. Thus, the 
authors conclude that this tolrestat-like binding mode is the most likely for their new AR 
inhibitors which is reasonable looking at the experiments carried out.
However, the binding pocket of AR can adopt at least three different conformations (see 
page 43) and AutoDock by itself can not handle protein flexibility. Thus, the program tries 
to fit the inhibitor into the predefined binding-pocket conformation and neglects all other 
Figure 3: A shows the superposition of 1 (green) onto the AR-bound conformation of the  
inhibitor tolrestat (white). B and C show the docking solutions for 2 (B) and 1 (C) with the  
PDB deposited structure of tolrestat (1ah3). All pictures were taken from Da Settimo et.  
al118. 
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possible binding modes. It is, therefore, instructive to dock both inhibitors not only to the 
pocket conformation of tolrestat but also to the two other main conformations. Besides tol-
restat, the sorbinil and the idd 594 complexes were chosen to represent these two addition-
al AR binding-pocket conformations. Sorbinil binds to the closed form of the specificity 
pocket and idd 594 addresses the specificity pocket, but in a different conformation than 
tolrestat. 
To allow best comparison with the results from Da Settimo et al., AutoDock122 3.0.5 
was used to dock 1 and 2 into all three pocket conformations. The search- and scoring grid 
for AutoDock was centered on the AR binding pocket. The grid size was set to 46 X 50 X 
54 points using a spacing of 0.5 Å. 100 runs of the Lamarckian genetic search algorithm 
were performed using a population size of 50 and an upper limit for the number of energy 
evaluations of 1.5x106. The parameters for mutation and cross-over were kept at their de-
fault settings of 0.02 and 0.80, respectively. The local energy minimization algorithm was 
limited to 300 steps.
The results  of  the  docking  experiments  for  compound  1 are  presented  in  Figure  4. 
Shown is the top-scoring docking solution for each pocket (sorbinil A (green), tolrestat B 
(silver), idd 594 C (yellow)), the corresponding AutoDock energy score, and a superposi-
tion of the docking solution with the bound crystallographic conformation of the corre-
sponding inhibitor. Reasonable docking solution of  1 are found for each of the binding-
pocket  conformations.  Surprisingly,  the  docking  solution  in  the  tolrestat  pocket  (B)  is 
scored worst, obtaining a score almost 1kcal/mol less favorable compared to the solution in 
the other two pockets. The solutions addressing the sorbinil and idd 594 pocket are scored 
equally. Furthermore, for the sorbinil pocket the carboxylic acid in 4-position of 1 address-
es the catalytic pocket. This is in contrast to the original design hypothesis where the car-
boxylic acid in 2-position is used for this purpose. Looking at the superpositions in the 
lower part of Figure 4, it can be seen that for the sorbinil pocket the docking solution and 
the bound conformation of the inhibitor show a very reasonable overlap. The carboxylic 
moiety addressing the catalytic pocket occupies the same point in space where the nitrogen 
and an oxygen of the hydantoin moiety of sorbinil are located, thus enabling the same in-
teractions with surrounding residues.  For  the other two cases the fit  of  the polar  head 
groups is not as convincing. Although in both cases the carboxy function in 2-position is 
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placed into the anion pocket, the conformations are different and the interaction geometries 
with the catalytic residues are not ideal. The rigid aromatic scaffold of 1 superimposes well 
with sorbinil and tolrestat. The fit with idd 594 is not convincing, since the corresponding 
ring systems are rotated by almost 45° against each other. 
Figure  4: Results for docking compound  1 into different binding pocket conformations 
formed with: sorbinil (A), tolrestat (B), and idd 594 (C). The best scored docking solutions  
for each pocket are shown in the upper part of the figure. In addition, the corresponding  
scores are given as computed by the scoring function implemented into AutoDock. In the 
lower part of the figure superpositions of compound 1 with the crystallographically deter-
mined  binding  mode  of  the  bound  inhibitor  in  the  corresponding  binding  pocket  are  
shown. 
As briefly mentioned, the only difference between compounds 1 and 2 is the length of 
the side chain in 4-position of the ring system. The corresponding docking results for com-
pound 2 are shown in Figure 5. 
As with compound 1 the docking solution in the sorbinil pocket is scored best, followed 
by the one in the idd 594 pocket. Again, docking into the tolrestat pocket results by far in 
the worst energy score. Compared to 1, the best docking solution in the sorbinil pocket has 
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been flipped, and it is now the carboxylic function in 2-position which addresses the anion 
pocket. For the tolrestat pocket, the best-scored solution has none of its carboxylic acids 
placed into  the  anion  pocket,  which  is  rather  unlikely,  since addressing this  pocket  is 
mandatory for every AR inhibitor. While the docking solution in the idd 594 pocket ad-
dresses the anion pocket, it places the second carboxylic-acid moiety into the hydrophobic 
specificity pocket, a fact which is very unlikely, in particular, since this part of the binding 
pocket is certainly not very suitable to accommodate a carboxylic function. In the sorbinil 
pocket the docking solution addresses the anion pocket in a favorable geometry with re-
spect to possible interaction partners, and the second carboxy function points towards the 
solvent. The superpositions in the lower part of Figure 5 reflect these findings very well. 
For sorbinil a good superposition is obtained, especially with respect to the polar head 
groups. For tolrestat and idd 594, however, the superpositions are less convincing.
Figure  5: Results for docking compound  2 into different binding pocket conformations 
formed with: sorbinil (A), tolrestat (B), and idd 594 (C). The best scored docking solutions  
for each pocket are shown in the upper part of the figure. In addition, the corresponding  
scores are given as computed by the scoring function implemented into AutoDock. In the 
lower part superpositions of compound 2 with the crystallographically determined binding  
mode of the bound inhibitor in the corresponding binding pocket are shown.
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Figure 6: In the upper part the crystal structures of compound 1 (A) and 2 (B) are shown 
in marine blue. In the lower part of the figure superpositions of the best docking solutions  
and the crystal structures are shown (compound 1: C, compound 2: D) The protein con-
formation used for docking is shown in green, the crystal structures including the ligand  
are shown in marine blue. The corresponding best scored docking solution is shown in sil-
ver. 
In summary, based on these docking experiments to multiple binding-pocket conforma-
tions, neither for compound  1 nor  2 a binding mode similar to tolrestat seems to be the 
most likely solution. Instead, a binding mode similar to sorbinil where the specificity pock-
et is in closed conformation, is favored by AutoDock and supported by visual inspection.
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Fortunately, crystal structures for both compounds in complex with AR could be solved 
in-house123 (Figure 6 A for 1, Figure 6 B for 2). Since the structures themselves are not part 
of this work, they will be discussed only as reference to validate the results obtained by the 
docking experiments.
The most important finding is that in both cases the specificity pocket is in a closed con-
formation, resulting necessarily in a different binding mode than adopted by tolrestat. In-
stead, the binding pocket is more similar to the sorbinil-bound conformation as indicated 
by the docking experiments. 
For compound 1 it is indeed the carboxylic function in 4-position which addresses the 
anion pocket (Figure 6 A). This is also in good agreement with the docking results in the 
sorbinil pocket. The carboxylic moiety of the 2-position points towards the solvent and 
forms an H-bond with the side-chain nitrogen of the nearby Trp 20, which rotates around 
its χ2 angle by ~30° compared to all other known AR structures. Thus,  1 induces a new 
conformation of the anion-binding pocket. Alternative conformations for the anion pocket 
have not been seen so far for AR, except for the structure of the apo enzyme (pdb code: 
1xgd)34. Instead of pointing upwards as in the docking solution, the aromatic ring system of 
1 points downwards (Figure 6 C). Besides the rotation of Trp 20 it displaces Trp 219, 
which becomes disordered. This binding mode of  1 is incompatible with all previously 
known AR conformations since it would clash with Trp 20 and Trp 219 in all other struc-
ture. Interestingly, among the 100 docking solutions from AutoDock there are 15 solutions 
where the aromatic ring system of 1 points downwards similar to the crystal structure and 
the 2-carboxylic function forms a hydrogen bond with Trp 20. However, the first of these 
solutions appears on rank 75 with an energy score of -9.6 kcal/mol, and the geometries do 
not match perfectly (see Figure 7 A). 
Compound 2 binds as intended with the 2-carboxylic function into the anion pocket (see 
Figure 6 B). The overall pocket conformation is very similar to the one of the sorbinil com-
plex. Phe 122 is the only binding-site residue which has to shift in order to accommodate 
the ligand. Again, this pocket conformation was correctly predicted by AutoDock to be the 
most favorable for accommodating ligand 2. The other carboxy function points towards the 
solvent and forms two H-bonds with the backbone N and the side-chain OG of Ser 302. 
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Comparing the docking solution and the crystal structure of 2 shows that the position of the 
carboxylic function addressing the anion pocket is very well predicted. This is also true for 
the sulfon moiety of  2. The entire ring system is shifted upwards in the crystal structure 
and the side chain in 4-position points in a slightly different direction. Three positions 
where ligand oxygens are placed in the docking solution are occupied by water molecules 
in the crystal structure (see Figure 7 B). This implies that these are good positions for hy-
drogen bonds and, thus, the placements of the oxygens of the docking solutions are reason-
able from this point of view. 
Figure 7: A shows the docking solution on rank 75 of compound 1 (silver) in the sorbinil-
pocket conformation (green) compared to the crystal structure (marine blue). The ring 
moiety of the docking solution of 1 points downwards instead of upwards as in the more  
favorably scored docking result. This binding mode is in better agreement with the crystal  
structure.  B shows a superposition of the best-scored docking solution from compound 2 
(silver) and the crystal structure (marine blue). The spatial positions occupied by the 4-po-
sition side chain oxygens in the docking solution show waters nearby in the crystal struc-
ture.
In summary, this example clearly demonstrates why it is important to include knowl-
edge about protein flexibility in a structure-based drug design project. In contrast to the 
failure to predict the binding modes of the two compounds using only one crystal structure 
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as template, the favored binding pocket conformation was predicted correctly by using 
multiple protein conformations as templates for docking. The overall  binding mode for 
compound  2 has been predicted reasonably well. Deviations were seen between docking 
solution and crystal structure that result in consequence to a slight movement of a phenyl 
alanine side and the attempted placement of the polar ligand substituent onto positions in 
the binding pocket previously occupied by water molecules. In addition, the exchange of 
the carboxylic function addressing the anion pocket for compound 1 was also predicted in 
the docking experiments. The strong conformational changes of the anion pocket and the 
consequences for the binding mode of compound  1 would have been hardly possible to 
predict by any method available today.
The question remains, whether using the corresponding native binding-pocket confor-
mations of 1 and 2 as templates for docking leads to improved binding-mode predictions. 
This would indicate that a suitable binding-pocket conformation is indeed a mandatory pre-
requisite to obtain reasonable binding modes from a docking experiment. In Figure 8 A the 
results for docking compound 1 into the corresponding crystal structure are shown. Due to 
an unusual conformation in the complex crystal structure of the N2 atom of compound 1, 
which adopts a tetrahedral geometry in the crystal structure rather than a planar one, exper-
iments for two different ligand setups were carried out. For the first docking experiment 
the ligand geometry extracted from the pdb file (silver, tetrahedral N2 geometry) was used 
unaltered, whereas for the second experiment the ligand (yellow, planar N2 geometry) was 
subject to an energy minimization prior to carrying out the actual docking experiment. 
However, only small deviations in the placement of the side chain attached to the N2 atom 
can be observed in the results for the two different setups, whereas virtually no differences 
are observed for the rest of the molecules. Using 1 Å rms deviation as cluster criterion, all 
100 generated docking solutions fall into the same cluster in both cases and none of the so-
lutions has an rmsd value higher than 0.82 Å with respect to the crystal structure. There-
fore, it can be concluded that predicting the binding mode of 1 correctly is feasible given 
the correct binding-pocket conformation.
The binding mode obtained for docking compound 2 into its crystallographically deter-
mined binding-pocket conformation (Figure 8 B) is very similar to the one resulting from 
docking to the sorbinil complex pocket conformation (Figure 6 D). This finding is reason-
Why consider protein flexibility in structure-based drug design? 19
able, since there are only small deviations between the two complex binding pocket con-
formations of 2 and sorbinil. However, if the three water molecules described in Figure 7 B 
are included in the docking process as part of the binding pocket, the docking solutions im-
prove significantly. The 88 top-ranked solutions show an rmsd below 1 Å with respect to 
the crystal-structure binding mode, thus also the binding mode for 2 can be correctly pre-
dicted if the actual state of the binding pocket is known.
On the one hand, this highlights the need for better methods to cope with protein flexi-
bility and the treatment of water; on the other hand, one should always be aware of unex-
pected changes in parts of the protein which had previously been regarded as rigid. 
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Figure 8: A shows the best scored docking solutions obtained from docking compound  
1 into the corresponding binding-pocket conformation obtained from crystallography 
(marine blue). Results for two different ligand setups are presented. The conformation 
shown in silver was obtained for using the ligand as extracted from the pdb file as input  
for docking. The ligand shown in yellow was subject to an energy minimization prior to  
carrying out the docking experiment. B depicts the top-scored docking results for dock-
ing 2 to its crystallographically determined binding-pocket conformation, respectively.  
C shows the best-scored docking solution for  2 which is obtained, if the three water  
molecules occupying the similar spatial positions in the complex crystal structure of 2 
where the side chain in 4-position is placed in B, are treated as part of the protein dur-
ing docking.
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Addressing protein flexibility and ligand selectivity by 
"in-situ cross-docking"
Introduction
To overcome the "single-structure-paradigm" in current methods for computational pro-
tein-ligand docking, we have recently introduced the "in-situ cross-docking" (ISCD) ap-
proach to simultaneously address multiple targets,124 using the grid-based AutoDock pro-
gram as search engine.122 While the feasibility of ISCD for dealing with well-differing 
binding sites and non-cross-reactive, tight-binding ligands had been demonstrated, it re-
mained to be shown whether it  could also be applied to different conformations of the 
same target (to address protein flexibility) or to closely related targets binding the same lig-
and with varying affinity (to address selectivity). Here, we investigate the first issue using 
aldose reductase as a test case, and the second using a recently introduced series of throm-
bin and trypsin inhibitors. 
Figure  9:  Comparison of  the three different  AR binding-site  conformers determined by  
crystal structure analysis,  as exemplified by the complexes with sorbinil  (red),  tolrestat  
(blue), and IDD549 (grey), seen from an identical perspective.
Aldose reductase (AR), a target against late-onset diabetic complications, catalyzes the 
reduction  of  aldoses  and  other  aldehydes  to  the  corresponding  alcohols.14 Its  substrate 
promiscuity is in part due to an “induced-fit”-like mechanism of ligand binding, whereby a 
specificity pocket can be closed or opened in different conformations, depending on the 
ligand being bound.113 Crystal structures of AR-inhibitor complexes have revealed three 
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major  binding-pocket  conformations,  best  represented  by  the  complexes  with  sorbinil 
(PDB 1AH0), tolrestat (1AH3), and IDD594 (1US0) as shown in Figure 9.
For docking and structure-based ligand design AR poses the obvious problem that a 
single conformation of the protein is not sufficiently representative as target structure; in-
stead, at least the three major conformations need to be addressed. In standard docking, 
this would be done sequentially, using each protein conformer for separate docking simula-
tions, thus requiring for each ligand as many separate simulations as there are protein con-
formers to investigate. With ISCD, instead, the conformers can be combined to a single 
search space such that only one simulation must be run per ligand. 
Results and Discussion
Using 1AH0, 1AH3, and 1US0 as structures for the three AR binding-site conformers, sep-
arate AutoDock grids were first calculated for each of them (further details about the meth-
ods are provided as Supporting Information A) and AutoDock runs were carried out on the 
separate single grids, proving that the experimental binding mode can indeed be repro-
duced by standard flexible docking (sorbinil to 1AH0: docking result on rank 1 shows a 
root-mean-square deviation, RMSD, of 0.26 Å with respect to the crystal structure; tolre-
stat to 1AH3: 0.94 Å; IDD594 to 1US0: 1.39 Å for rank1, 0.84 Å for rank 2).
Ligand RMSD [Å] Ed [kcal/mol] Cluster size N  2 Å≤  
RMSD
Sorbinil 0.26 -9.38 96 96
Tolrestat 1.00 -11.77 35 51
IDD594 0.84 -12.16 5 6
Fidarestat 0.51 -9.58 52 99
Zenarestat 1.37 -13.15 8 15
Pyridazinone 0.49 -10.98 30 34
Table 1: Results of 100 ISCD runs for 6 AR ligands, using the joined 1AH0-1AH3-1US0  
grid. For each ligand, the top-ranked docking result is reported, with the RMSD to the ex-
perimental binding mode, the docking score (“docked energy” Ed), the size of the top-
ranked result cluster, and the total number of results showing an RMSD less than 2 Å.
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To setup ISCD, the single grids were combined to a joined grid with repulsive layers be-
tween them.124 The joined grid representing all three binding-site conformers was used to 
test whether ISCD is able to identify the native binding pocket of a given ligand (sorbinil, 
tolrestat, and IDD594) in a single docking calculation. For this purpose the same standard 
docking parameters were used as applied before in the single-binding-site docking. 
Table 1 illustrates that with ISCD the native binding pocket and binding mode is indeed 
found in all three cases: for each ligand, the top-ranked cluster corresponds to the correct 
binding mode in the correct protein conformer, and the cluster size (corresponding to the 
occurrence frequency of the result) is excellent for the most rigid ligand (sorbinil) and fully 
acceptable for the most flexible compound (IDD594). 
Figure  10: Chemical formulae of the AR inhibitors investigated by ISCD: sorbinil (A),  
tolrestat (B), IDD594 (C), fidarestat (D), zenarestat (E), and the pyridazinone inhibitor  
(F).
Since the inhibitors tested so far were exactly the ligands of the protein conformers used 
to construct the joined grid, a further test for running ISCD with the joined 1AH0-1AH3-
1US0 grid was carried out using the compounds fidarestat and zenarestat (cf. Figure 10). In 
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the crystal structure, fidarestat (PDB 1PWM) shows a sorbinil-like binding mode, whereas 
zenarestat (PDB 1IEI) binds to a similar AR conformer as IDD594 (to date, no other ligand 
than tolrestat is known to induce a 1AH3-like conformation). 
For zenarestat, ISCD correctly suggests preferential binding to the 1US0 conformation 
(cf. Table 1): the top-ranked result shows a clear score difference of 1.14 kcal/mol with re-
spect to binding modes in other pockets, and all top 15 results yield an RMSD <1.4 Å with 
respect to the crystal structure (after best-fit alignment of the 1IEI protein structure with 
1US0). For fidarestat, the correct binding mode is obtained in almost all of the 100 runs, 
though in two different pockets: 47 times in the 1AH0 pocket (with an RMSD of 0.69 Å 
after best-fit alignment of the 1PWM protein structure with 1AH0) and 52 times in the 
1US0 pocket (RMSD 0.51 Å after best-fit alignment of 1PWM with 1US0). Both results 
show a virtually identical score (-9.46 kcal/mol versus -9.58 kcal/mol, respectively), in-
dicative of the fact that although 1US0 corresponds to the open conformation and fidarestat 
is expected to bind to the closed conformation (1AH0), the 1US0 conformation is also 
compatible with the native fidarestat binding mode. This is in contrast to sorbinil, where a 
clash with Cys298 in 1US0 precludes docking in the native mode. Fidarestat shows a larg-
er distance to Cys298, thus allowing a near-native binding mode to be observed also in 
1US0.
In a further test, predictive docking was carried out for a new and very potent sulfonyl-
pyridazinone inhibitor for which no crystal structure was available at that time (compound 
24 described by Mylari et al.125 , cf. Figure 10). ISCD suggested a binding mode similar to 
IDD594, with the clearly best score achieved in the 1US0 pocket and 34 out of 100 runs 
ending up with this solution. The correctness of the prediction was later confirmed by the 
crystal structure of the pyridazinone-AR complex126, which yields an RMSD of 0.49 Å for 
the docking result after superposition of the protein in the new crystal structure with 1US0.
Taken together, the results indicate that with ISCD alternative protein conformations 
can  successfully  be  addressed  simultaneously.  The  major  advantage  of  the  method, 
however, is that differences among the target structures need not to be confined to small 
side-chain reorientations. Accordingly, issues of selectivity with respect to different targets 
can also be addressed. While in the original proof-of-concept very different proteins (and 
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ligands with no expected cross-reactivity) were used124, here the selectivity with respect to 
two closely related enzymes is investigated. 
Figure 11: Chemical formulae of the seven trypsin and thrombin ligands investigated by  
ISCD.
The serine proteases thrombin and trypsin and a set of seven new inhibitors with vary-
ing selectivity  for  thrombin were used for  this  purpose  (derivatives 1-7 in  Fokkens et 
al.127). The inhibitors consist of a common rigid non-peptidic core, substituted in position 1 
with different aliphatic and aromatic groups, as shown in Figure 11 (ligands 3 and 6 differ 
only with respect to the core ring system). The selectivity ratio of the inhibition constants 
Ki(trypsin)/Ki(thrombin) ranges between 2.6 for ligand 4 and 760 for ligand 1 (measured 
for the racemic mixture).127 For all ligands except ligand 4, crystal structures in complex 
with trypsin could be obtained127;128, for ligands 1, 2, 3, and 6 crystal structures in complex 
with thrombin are available as well127-130. The structures show that all ligands share a com-
mon binding mode and that exclusively the (+)-enantiomer is bound to the enzyme; this is 
also the enantiomer displayed in Figure 11 and used in all docking calculations. 
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Using the crystal structures of trypsin and thrombin in complex with ligand 1, grids 
were calculated for the two binding sites and combined to one joined grid. As shown in Ta-
ble 2, performing ISCD with 50 independent runs per ligand revealed energetically pre-
ferred binding to thrombin: for all seven ligands, the top-ranked result was found in the 
thrombin grid, whereas the best-ranked docking result for trypsin occurred between rank 2 
and 7.  All  best-ranked trypsin  results  are  structurally  correct,  as  indicated  by  the  low 
RMSD values. For thrombin, this is the case for five of the seven ligands, since the top-
ranked result for ligand 5 and 7 does not show the presumably correct binding mode (for 
both ligands no experimental complex structure with thrombin is available). 
Thus, looking at the best-ranked result in each grid, ISCD reveals the correct binding 
mode of all ligands for trypsin and of five ligands for thrombin. In addition, the binding 
preference is correctly predicted: for all ligands, the better score is observed for thrombin, 
with a difference of 0.17 - 2.39 kcal/mol in favor of thrombin, roughly correlating with the 
experimental affinity difference. Despite this energetic preference, however, the large ma-
jority of favorable binding modes is found in the trypsin grid (cf. Table 2 and Figure 12). 
Apparently, the trypsin binding site represents a well-defined and easily accessible local 
minimum, whereas the global optimum given by the thrombin binding site is more difficult 
to reach with a finite stochastic search in this large search space. Even with different or en-




















N  2 Å≤  
RMSD
Lig1 7 -11.43 0.54 42 42 1 -13.72 0.90 2 8
Lig2 5 -11.66 0.52 40 40 1 -13.11 0.89 3 9
Lig3 3 -11.51 0.85 42 42 1 -13.65 0.85 3 6
Lig4 2 -12.21 0.86 7 43 1 -13.28 1.06 1 1
Lig5 5 -10.84 1.10 28 29 1 -11.70 8.60 5 2
Lig6 4 -11.20 0.97 1 39 1 -13.59 1.03 5 9
Lig7 2 -12.59 0.55 45 45 1 -12.76 8.65 1 0
Table  2: Results of 50 ISCD runs for the joined trypsin and thrombin grid. The columns  
have the same meaning as in Table 1. The RMSD was calculated for the common ligand  
substructure consisting of the core ring system and the benzamidine anchor, which is the  
part of the ligands that is well defined in all available crystal structures.
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Figure 12: ISCD docking results for ligand 3, illustrating the members of the three best-
ranked clusters, which together cover 96% of the results (48 of 50 docking runs). Clusters  
1 and 2 are found in thrombin (blue) and contain three results each; cluster 3 is found in  
trypsin (yellow) and contains 42 closely overlapping results. The borders of the two grids  
joined to a single ISCD grid are shown; the gap between them corresponds to the repul-
sive layer required for avoiding artifacts.
While it may be argued that converging to the global minimum with a probability of 
≤16% is not sufficient, it is also necessary to see that full convergence to the global opti-
mum would not be desired in ISCD, because otherwise binding to the protein showing 
lower affinity would not be found at all. Instead, ISCD should indeed reveal all experimen-
tally observable binding modes, and the best-ranked result in each grid should provide the 
correct binding mode for the corresponding protein, as observered here for most of the lig-
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ands.  (Further  details  about  the  results,  as  well  as  results  of  separate  docking runs  to 
trypsin and thrombin are provided as Supporting Information B.)
Summary and Conclusion
In summary, this study has shown that addressing protein flexibility and ligand selectivity 
with ISCD is feasible. With a single docking calculation, the appropriate binding-site con-
formation can be selected from three different alternatives in case of the flexible AR en-
zyme. Likewise, a single docking calculation is sufficient to reveal the preferred binding 
modes of a given ligand for two closely related proteins, trypsin and thrombin. 
Alternative approaches for dealing with protein flexibility in ligand docking are avail-
able, such as FlexE100 (which had also been tested on AR100) and grid-based averaging101;107 
(which we have applied to AR for comparative purposes; cf. Supporting Information C), 
but these are all restricted to relatively small structural differences among the investigated 
systems. ISCD does not have this limitation and can be applied to protein structures of any 
desired difference. 
The challenge, however, will be to develop efficient protocols for simultaneously con-
sidering more than two or three structures in order to extend the scope of ISCD.
Supporting Information A: Computational Methods
Protein setup and grid calculations. 
For aldose reductase (AR), the following three PDB structures corresponding to different 
binding-site conformers were used: 1AH0 (complex with sorbinil), 1AH3 (complex with 
tolrestat), and 1US0 (complex with IDD594). 
For trypsin, the complex structure with ligand 1 was obtained in house by X-ray crystal-
lography and deposited in the PDB under code 1Y3U127. The structure of thrombin in com-
plex with ligand 1 was kindly provided by Hoffmann La Roche (Basel, Switzerland)129;130. 
Water molecules and ligands were removed from the complexes, and polar hydrogens 
were added to the proteins using the PROTONATE utility distributed with AMBER131. 
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Partial atomic charges from the AMBER united atom force field were assigned to the pro-
tein atoms, and solvation parameters were added with the ADDSOL utility of AutoDock 
3.0122.
In the actual docking process, AutoDock uses a grid-based representation of the protein. 
Accordingly, for each point in a regularly spaced grid and for any probe of interest (i.e., 
any ligand atom types and a probe charge), the interaction energy of that probe with the en-
tire protein is calculated and saved in files that serve as look-up tables for faster energy 
evaluation upon docking. Therefore, grids were generated with the help of AutoGrid, using 
a grid spacing of 0.5 Å in case of the AR structure and of 1 Å in case of trypsin and throm-
bin. 
First, a separate standard binding-site grid was calculated for each protein. Each grid 
was centered on the corresponding active site and had a dimension of 23 Å × 25 Å × 27 Å 
in case of AR and 30 Å × 30 Å × 30 Å in case of trypsin and thrombin; this is sufficiently 
large to include the entire binding site and significant parts of the surrounding surface. 
To perform in-situ cross-docking (ISCD), the grids were joined to a single large grid 
readable by AutoDock. In case of AR, the joined grid consisted of the grids calculated for 
1AH0, 1AH3, and 1US0; in case of trypsin and thrombin, the joined grid consisted of the 
grids calculated for each of the two separate proteins. Since only already available grid 
files had to be manipulated, AutoGrid was not required at this stage. The manipulations 
corresponded to a linear alignment of the two grids along the x-axis. To avoid docking re-
sults across the border of the two grids (which, in structural terms, would be pure artifacts), 
a “spacer” was inserted between the grids (1 Å in case of the AR grids, 3 Å in case of 
trypsin and thrombin). Each grid point in the spacer region was assigned an energy value 
of +100 kcal/mol, leading to a “repulsive layer” in which no docking run would terminate.
Ligand setup
Coordinates of the AR ligands were taken from the corresponding PDB files, with the 
exception of the pyridazinone compound (F), which was generated with Sybyl132 since no 
crystal structure was available at that time. Coordinates of ligand  1 binding to thrombin 
and trypsin were taken from the complex structure with thrombin. Using Sybyl, ligands 2-7 
were built based on the coordinates of ligand 1. 
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Hydrogens were added to the initial ligand structures, the structures were subjected to 
short energy minimization using the Tripos force field in Sybyl, and atomic charges were 
assigned according to the Gasteiger-Marsili formalism133, which is the type of charges used 
in calibrating the AutoDock free energy function. 
The minimized structures were superimposed with the experimental binding mode of 
ligand 1 in trypsin and thrombin, respectively; the binding modes obtained this way served 
as reference for the RMSD measurements of the docking results. 
Finally, the compounds were setup for docking with the help of AutoTors, the main pur-
pose of which is to define the torsional degrees of freedom to be considered during the 
docking process. Accordingly, the following numbers of rotatable bonds were defined: 0 in 
sorbinil, 5 in tolrestat, 6 in IDD594, 1 in fidarestat, 4 in zenarestat, 2 in the pyridazinone 
compound; 4 in ligand 1 to ligand 6, and 5 in ligand 7 (the bond between the aromatic ring 
and the amidine group in 1-7 was kept fixed at a torsion angle of 10°).
Docking 
Docking was carried out with AutoDock 3.0, using the empirical free energy function and 
the Lamarckian Genetic algorithm (LGA)122. 
The standard protocol used an initial population of 50 randomly placed individuals, a 
maximum number of 1.5×106 (AR) or 3.0×106 (trypsin, thrombin) energy evaluations, a 
mutation rate of 0.02, a crossover rate of 0.80, and an elitism value of 1. For the local 
search, the pseudo Solis and Wets algorithm was applied, using a maximum of 300 itera-
tions per local search. The probability of performing local search was 0.06, and the maxi-
mum number of consecutive successes or failures before doubling or halving the local 
search step size was 4. 
With this protocol, 100 independent runs were carried out for each ligand in case of AR, 
50 in case of trypsin and thrombin. Results differing by less than 1 Å RMSD were clus-
tered together and represented by the result with the best docking score in the cluster.
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Supporting Information B: Docking to trypsin and thrombin
For comparative purposes, standard docking runs with the individual (separate) grids were 
carried out for trypsin and thrombin. The results obtained with the same settings as used in 


















N ≤ 2 Å 
RMSD
Lig1 1 -11.43 0.49 50 50 1 -13.85 0.92 16 39
Lig2 1 -11.67 0.48 50 50 1 -13.08 0.80 8 42
Lig3 1 -11.48 0.54 50 50 1 -13.81 0.90 22 41
Lig4 1 -12.29 0.67 11 50 1 -13.27 1.05 17 22
Lig5 1 -10.85 1.10 40 43 1 -11.70 8.95 9 6
Lig6 1 -11.35 1.02 1# 50 1 -13.58 1.00 19 41
Lig7 1 -12.57 0.51 50 50 1 -12.91 2.36 4 5
#The result on rank 2 shows a cluster size of 49 (E
d
 = -11.17 kcal/mol, RMSD = 0.60 Å).
Table 3: Docking results with separate grids for trypsin (left) and thrombin (right). In each  
case, 50 independent docking runs were carried out. For each ligand, the top-ranked dock-
ing result  is reported,  with the root-mean-square deviation to the experimental binding  
mode (RMSD), the docking score (“docked energy” Ed), the size of the top-ranked result  
cluster, and the total number of results showing an RMSD less than 2Å. The RMSD was  
calculated for the common ligand substructure consisting of the core ring system and the  
benzamidine anchor, which is the part of the ligands that is well defined in all available  
crystal structures.
Except for the different occurrence frequencies, the results are very similar to those ob-
tained with ISCD. The docking runs for trypsin reproduce the native binding mode in vir-
tually all cases. Also the thrombin results show good occurrence frequencies of the correct 
binding mode (with the exception of ligand  5 and  7,  as  further discussed below).  The 
scores are in all cases almost identical to those observed by ISCD (with a maximum differ-
ence of 0.16 kcal/mol). The score differences between thrombin and trypsin (i.e.,  ΔEd = 
Ed(thrombin) – Ed(trypsin) ) are comparable to the experimental ΔΔG values as estimated 
from the corresponding Ki ratios (cf. Fokkens et al.127), as they allow to separate the highly 
selective thrombin ligands (1,  2,  3,  6) from those with low selectivity for thrombin (4,  5, 
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7). A more quantitative agreement is not to be expected, given that the accuracy of the 
AutoDock scoring function in reproducing experimental binding free energies is approxi-
mately 2 kcal/mol122 and racemate data are considered as experimental reference.
The separate-grid docking results also indicate that the problems for ligands 5 and 7 in 
ISCD are not primarily due to the ISCD method. In fact, even when docking to thrombin 
alone, a near-native binding mode is not obtained on the first ranks. The reason, however, 
is not necessarily a short-coming of the docking procedure, since for both ligands a crystal 
structure with thrombin could not be obtained and the actual binding mode can only be as-
sumed. 
Furthermore, in the crystal structures with trypsin, the phenyl and benzyl substituent of 
ligand 5 and 7, respectively, is not visible in the electron density, thus pointing to disorder 
or flexibility of these side chains. It is likely that in the geometrically more restrictive envi-
ronment of the thrombin binding site these substituents can not be well-placed without 
small conformational changes either in the neighboring protein residues or in the central 
ring system.
Supporting Information C: Docking to multiple conformers by 
grid-based averaging
As  an  alternative  approach  to  incorporate  protein  flexibility  in  grid-based  docking,  a 
weighted averaging of grids calculated for different binding-site conformers has been sug-
gested101;107. In this method, a "normal" grid is used (covering geometrically only one bind-
ing site), but every grid point holds a weighted average energy calculated from the alterna-
tive protein conformations. This "clamped-grid" approach101 was tested here with the AR 
conformers. The separate grids calculated for the three AR conformers 1AH0, 1AH3, and 
1US0 (cf. above; grid spacing 0.5 Å, grid dimension 23 Å × 25 Å × 27 Å), were averaged 
according to the procedure described by Österberg et al.101: the weight is given a value of 1 
if the interaction energy of the grid point is less than 0 kcal/mol; if the energy is greater 
than 0 kcal/mol, a small weight of 0.0001 is applied. Upon averaging, the weights are nor-
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malized to give a sum of 1. The resulting "clamped-grid" was then used for docking, with 
all parameters and settings kept identical to the other AR docking runs.
The results are summarized in  Table 4. While the correct binding mode was obtained 
with high fidelity for sorbinil and fidarestat,  and with sufficient quality and occurrence 
frequency for tolrestat, the method failed to produce good results for IDD594, zenarestat, 
and the pyridazinone ligand. For IDD594 one result with 2.00 Å RMSD was obtained on a 
very  low rank,  all  other  results  showed  much  larger  deviations.  For  the  pyridazinone 
compound, reasonable binding modes started occurring at rank 3, but the two top ranks did 
not yield the correct binding geometry.
Ligand RMSD [Å] Ed [kcal/mol] Cluster size N  2 Å RMSD≤
Sorbinil 0.32 -8.95 100 100
Tolrestat 1.72 -10.90 3 31
IDD594 2.39 -11.11 1 1
Fidarestat 0.73 -9.27 99 100
Zenarestat 7.19 -11.04 35 0
Pyridazinone 7.13 -8.99 3 22
Table 4: Results of 100 “clamped-grid” docking runs for the six AR ligands. For each lig-
and, the top-ranked docking result is reported, with the root-mean-square deviation to the  
experimental binding mode (RMSD), the docking score (“docked energy” Ed), the size of  
the top-ranked result cluster, and the total number of results showing an RMSD less than  
2Å.
The advantage of the grid-averaging approach over ISCD is that a grid of normal size 
(as for a single binding site) can be used. However, the averaging process smears out cer-
tain differences among the conformations, and the ligands being docked seek for optimal 
features which arise from different conformations, but which may not be realizable in a 
single  protein  conformation.  In  some cases  this  combinatorial  power  of  the  averaging 
method might  lead to better  results since new possible binding modes might be found 
which would have been missed otherwise. 
For AR, this advantage seems not to be given, since a clear differentiation between the 
alternative conformations is possible. Furthermore, rescoring (and structural interpretation) 
of docking results may sometimes be difficult, since there is no structural representation of 
the clamped grid in terms of a corresponding protein structure. Such difficulties do not 
34 Addressing protein flexibility and ligand selectivity by "in-situ cross-docking"
arise with the simpler ISCD method. It does not allow for the recombination (generation) 
of new conformations, but it is also not limited to a certain amount of conformational dif-
ferences.
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Introduction
High quality  structural  data  are  the  basis  for  any  structure-based  drug  design  project. 
Nowadays computational methods are abundantly used at various stages of the drug devel-
opment process134-136. The success of many of these methods relies on accurate structural 
information about the binding mode of a given inhibitor, its interactions with the protein, 
and the conformation of the binding pocket itself. X-ray crystallography is the method of 
choice to deliver this information137-141. Improvements in the technology, fine-tuned experi-
mental procedures as well as the increased availability of synchrotron radiation sources 
have taken great impact on the quantity and quality of the available crystal structures. 
Despite the enormous wealth of protein structures, there is an intrinsic danger in a coor-
dinate file downloaded from the PDB. These files contain the exact positions for each atom 
of the system. The coordinates are given with a precision of three positions after the deci-
mal point, suggesting that a protein is a rigid system of atoms which basically do not move. 
This is a misleading assumption, since proteins are of course dynamic systems. Different 
types of motions which occur on different time scales are ubiquitous in proteins: thermal 
atomic fluctuations, motions around torsional angles, displacements and librations of single 
amino acids, secondary structure elements or even entire protein domains. These motions 
are not a design flaw of nature, but are essential to evolve the biological function of the 
protein. However, while moving from physiological conditions to the environment of a 
protein crystal many of these motions are either inevitably restricted or become less pro-
nounced by the experimental conditions, especially due to the low temperature at which 
crystal structures are measured. 
The dynamical behavior of molecular systems is of utmost importance to understand 
protein-ligand  interactions  and  has  to  be  considered  in  structure-based  drug  design 
projects. One of the many ways in which flexibility can influence drug design is the occur-
rence of an ''induced-fit'' binding mechanism. In this case, a protein can accommodate dif-
ferent ligands by adapting its binding pocket to the shape of the ligand. Aldose Reductase 
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(AR) is such a protein. Its biological function is to reduce various aldoses and alcohols to 
the corresponding alcohols using NADPH as cofactor. Not much is known about its func-
tion under physiological conditions. However, a role as general detoxifying enzyme is dis-
cussed11;12.  Therefore,  it  is  mandatory for this enzyme to operate on various substrates, 
since otherwise, for every aldehyde which hsa to be reduced, a special enzyme would be 
needed. Thus, a flexible binding pocket is a prerequisite for an enzyme having a broad 
range of substrates. Very similar properties have been attributed to the recently intensively 
studied P450 enzymes which play a crucial role in the metabolism of xenobiotics142.
AR is build-up of 315 amino acids and folds to an α/β-TIM-Barrel structure (Figure 13). 
Eight parallel β-sheets are surrounded by eight anti-parallel α-helices. The eight β-strands 
enclose a tightly packed hydrophobic core formed by their side-chains. In the next layer of 
the barrel hydrophobic side-chains of the α-helices are packed against hydrophobic side-
chains of the β-sheets. Thus, the barrel is equipped with a shell of hydrophobic residues. 
As with most enzymes of this fold143 the active site is formed by the loop regions that con-
nect the β-strands with the adjacent α-helices. The TIM-barrel fold provides the stable and 
rigid framework for the catalytic reaction, whereas the binding site itself is built-up from 
loop regions. 
For AR, many high-quality crystal structures are available which were determined in 
complex with a large variety of ligands. Thus, from a structural point of view, AR is a very 
well  characterized enzyme. A previous comparative analysis113 of the crystal  structures 
available at that time gave insight into the binding pocket of AR. The pocket can be divid-
ed into two sub-pockets: one where the catalytic reaction takes place, i.e. the anion or cat-
alytic pocket; and another, which is named specificity pocket. 'Induced-fit' phenomena are 
executed only by the specificity pocket, which can adopt at least two different opened and 
a closed conformation leading to three major pocket conformations. Not all residues within 
the specificity pocket show the same degree of flexibility. A small loop region near the C-
terminal end of the protein is used to facilitate most of the adaptations, a behavior which 
will be analyzed in more detail in this study. In recent years many high-resolution struc-
tures  of  AR in complex  with  different  ligands  have been determined.  They provide  a 
wealth of information which has not been considered in the last comparative crystal struc-
ture analysis113. The adaptations resulting from binding of a variety of different ligands can 
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now be analyzed in greater detail. In addition to the analysis of available crystal structures, 
ten molecular dynamics (MD) simulations were carried out to further investigate the flexi-
bility of this enzyme. In total seven different complex simulations and three simulations of 
the holo enzyme were carried out. Using a multitude of different complex structures as 
starting geometries for MD simulations improves the mapping of the conformational space 
of the enzyme, thus providing a better data basis for examining the conformational space 
of the protein.
Figure 13: Overall fold of AR; α-helices are shown in red, β-sheets are depicted in yel-
low, and loop regions are shown in green. The cofactor is shown in a ball-and-stick rep-
resentation.
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Besides its interesting structural features, AR is also a relevant drug target. It is the first 
enzyme of the sorbitol pathway. As with AR itself, the physiological role of the whole 
pathway is still  not fully understood. However, if the human body is faced with raised 
blood glucose levels, some of the excessive glucose is processed via the sorbitol path-
way144. Elevated blood glucose levels are frequently found with patients suffering from dia-
betes mellitus. Through the conversion of glucose to sorbitol cellular NADPH is consumed 
and not available for other processes. Thus, oxidative stress is induced in the cells. Further-
more, sorbitol accumulates within the cells and increases the osmotic stress of these cells. 
The two combined factors are made responsible for many of the late-onset diabetic compli-
cations such as retinopathy and angiopathy145-147. In numerous studies inhibition of AR has 
shown to alleviate these complications62;88;148;149. Consequently, AR has become a drug tar-
get to counteract these effects. 
Materials and Methods
Crystal structure analysis
Comparison of available crystal structures was carried out using Relibase+ Version 2.1150-
152.  The  inhouse  structures  of  human AR in complex  with  the  JFD compound116,  47d, 
zopolrestat153, sorbinil (see Appendix B), and tolrestat153 were added to Relibase+ using the 
Relibase+ data processing module. Querying the resulting database for aldose reductase 
structures with a resolution of ≤ 2.5 Å results in 38 hits. For three entries (1abn, 1dla, and 
1mar) only the coordinates for the Cα atoms are deposited in the PDB154. Based on the ul-
tra-high resolution structure of the inhibitor idd594 in complex with AR (1us0114) a 'similar 
binding sites' search was performed using a minimum sequence identity of 95%. This dis-
cards structures of non-human species and results in a dataset of 29 protein chains of which 
four structures of AR mutants were removed (2agt, 2acu, 1az1, 1az2). For the inhibitor fi-
darestat and its stereoisomers four different structures are available: two for the native lig-
and (2-S,4-S configuration) (1pwm, 1ef3) and one for the isomers 2-R,4-S (1x97) and 2-
S,4-R (1x98). 1pwm was chosen as representative for the native ligand due to its higher 
resolution, whereas both structures for the stereoisomers were included. For the inhibitor 
idd 552 also two different structures are available. However, in these two cases the protein 
was crystallized under different pH conditions: pH 5 (1t41) and pH 8 (1t40), respectively. 
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Since it is known that changing the pH of the crystallization conditions can influence the 
resulting crystal structure155, both structures were included in the dataset. Also for the Pfiz-
er compound two structures are available126: one at 0.95 Å resolution (1z8a) and one which 
diffracted to 1.43  Å (1z89). For the high-resolution structure, the occupancy of the in-
hibitor in the binding pocket is only ~50%, whereas for 1z89 the inhibitor possesses full 
occupancy. Therefore, the latter included in the dataset. 
Finally, the structure of AR in complex with DEG (2f2k)156 was removed, since the in-
hibitor shows an average B-factor of 77 Å2 at 100 % occupancy in comparison to 21 Å2 of 
the surrounding protein. It is therefore questionable, whether meaningful structural conclu-
sions can be drawn from such a structure. The resulting dataset comprises the 20 remaining 
structures. The pdb codes and chemical formulas of the bound ligands are shown in Table
5. 
Removal of the non-human complex structures as well as the mutated forms provides an 
unbiased data sample only affected by adaptations of one single protein species induced by 
the different bound ligands. All possible superimposed consequences arising from muta-
tions or sequence differences of the protein remain unconsidered. However, possible influ-
ences of deviating crystallization conditions remain and it is very difficult to trace and 
quantify such effects. 
The only mutant structure which was added to the dataset was the apo form of the en-
zyme (1xgd)34. This structure was obtained from an Arg268Ala mutant. According to the 
authors the mutation decreases the affinity of the cofactor to the enzyme and was crucial to 
obtain an NADPH-free structure. The mutation is located more than 12 Å away from the 
binding pocket, thus the impact on the binding-pocket conformation is presumably low. 
All structures in the dataset were superimposed based on the residues within 6 Å of the 
ligands. All subsequent data analyses were carried out using built-in Relibase+ features. All 
values for assessing differences between the structures were kept at their default values. 
Therefore, Cα movements of single residues were considered significant if greater than 0.5 
Å, the threshold for movements of side-chain centers was set to 1 Å, and torsional angles 
were considered distinct if more than 10° apart.  Visual inspection of the superimposed 
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structures as well as measurements of main-chain torsion angles were performed using Re-
liview, the visualization tool of Relibase+.
structure res.[Å] ligand name ligand structure structure res.[Å] ligand name ligand structure
1pwl 1.10 minalrestat 1t40 1.80 idd552
1us0 0.66 idd594 947d* 1.42 47d
1pwm 0.92 fidarestat 9jfd* 1.55 jfd
1t41 1.05 idd552 9sbi* 1.47 sorbinil
















1z3n 1.04 lidorestat 2acr 1.76 cacodylate
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structure res.[Å] ligand name ligand structure structure res.[Å] ligand name ligand structure
1el3 1.70 idd384 2acs 1.76 citrate
1iei 2.50 zenarestat 1xgd 2.10 none
Table 5: AR crystal structures used for analysis. The first column gives the pdb code, the 
second the crystallographic resolution, the third and fourth contain the name of the ligand  
and its 2D chemical formula.
* in-house crystal structure which was added to Relibase+ using the data processing tool
MD simulations
Starting geometries for each protein ligand complexes were taken from the corresponding 
crystal structures. Starting geometries for the simulations of the holo enzymes were de-
rived by extracting the  ligands sorbinil,  tolrestat  and idd 594 from their  corresponding 
crystal structures. All preparing steps and simulations were carried out with the AMBER 
8.0157 suite of programs, using the Cornell et al.158 force field in the variant of the parm99 
parameter set159. Parameters for the ligand were taken from the GAFF force field160 and as-
signed using ANTECHAMBER. Parameters for the cofactor NADP+ were taken from a 
previous study by Sotriffer et al113. Atomic charges for both, the ligand and the cofactor, 
were calculated by fitting to the HF/6-31G* electrostatic potential using the conformation 
observed in the crystal structure. The corresponding ab-initio calculations were performed 
with GAUSSIAN98161, the restrained electrostatic potential fit with the ANTECHAMBER 
program using the RESP method162;163. Hydrogen atoms were added using AMBER tem-
plates. The simulated protein system thus consisted of 316 amino acids or 5071 atoms, plus 
the cofactor with 73 atoms and the ligand atoms. The crystal structure was subjected to a 
short initial energy minimization in vacuo using 20 steps of steepest descent followed by 
180 steps conjugate gradient minimization. After addition of two sodium counterions to 
ensure neutrality (placed at minima of the electrostatic potential), the systems were solvat-
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ed in a box of TIP3P164 water molecules, which resulted in box sizes of ~80Å x 65Å x 75Å 
and a total of ~9000 water molecules. The MD simulations were then started by heating the 
solvent to 300K over a period of 20 ps and cooling to 100 K over a period of 5 ps, keeping 
the solute fixed. After this procedure, the entire system was gradually brought to 300 K 
over a period of 25 ps. The simulation was then carried on for 6050 ps under constant tem-
perature and pressure (NPT), applying periodic boundary conditions. The temperature was 
kept constant by coupling to a heat bath via the Berendsen algorithm165. Pressure was ad-
justed by isotropic position scaling using a Berendsen-like algorithm. Covalent bonds to 
hydrogen atoms were constrained by the SHAKE166 algorithm and a time step of 2 fs was 
used. A cutoff of 8 Å was applied to the van der Waals interactions, while the electrostatics 
were treated by the Particle Mesh Ewald method167. The simulations were carried out with 
the SANDER MD module of AMBER 8.0. For analysis, energy data were saved every 10 
time steps, solvent and solute coordinates every 0.5 ps. All results presented refer to the 6.0 
ns trajectories which exclude the first 100 ps required for temperature adjustment and equi-
libration.
Generation of 2D rms plots
To obtain this plot every 10 ps snapshots were extracted from the simulation and fitted to 
the starting structure using the Cα atoms only. This leads to an ensemble of 600 snapshots 
representing the time course of the simulation. Using the 2drms command of the PTRAJ 
module of AMBER 8157 a pairwise rmsd matrix based on the binding site atoms between 
the individual snapshots was calculated. This matrix was then plotted using the program 
PLOTMTV. The pairwise rmsd values between the individual snapshots are color-coded 
on a relative scale using a color ramp raising from green over yellow to red. 
Docking with AutoDock
All docking experiments were carried out using AutoDock 3.0.5 122 which is a grid-based 
docking  tool  using  a  Lamarckian  genetic  algorithm as  search engine  and a  force-field 
based scoring function as fitness function. If not noted otherwise, 100 runs of the genetic 
algorithm were performed for each docking experiment. A population size of 50 and a 
maximum number of energy evaluation steps of 1.5x106 were applied. The grid consisted 
of 46 x 50 x 54 points with a spacing of 0.5 Å between the single grid points. Mutation and 
crossover rate were set to 0.02 and 0.80, respectively. The local energy minimization was 
Extending charted space: comparative MD simulations of Aldose Reductase 43
set to a maximum of 300 steps. For the docking experiments using the 'in-situ' cross-dock-
ing approach, the grids and settings were used as previously described124;168. 
Results and Discussion
Comparative crystal structure analysis
Since a previous preliminary analysis of available crystal structures113 many novel high-
quality structures of potent inhibitors in complex with AR have been deposited in the pro-
tein data bank (PDB154) or solved in our laboratory, thus expanding the experimental basis 
to analyse binding-site flexibility of AR. Considering these new examples allows removing 
limited resolution structures and structures from non-human or mutated enzymes.
The following comparative crystal structure analysis is carried out roughly following 
the strategy published by Sotriffer et al.113. As already briefly mentioned in the introduc-
tion, this analysis demonstrated that the AR binding pocket can be divided into two sub-
pockets: an 'anion binding pocket' where the cofactor as well as the residues involved in 
catalysis are located and a hydrophobic 'specificity pocket'. The flexibility of the binding 
pocket  is  almost  entirely  confined to  the region of  the specificity  pocket,  whereas  the 
residues of the anion pocket show considerably larger spatial conservation.
As mentioned in Materials and Methods, 20 high-quality complex structures of human 
AR plus an apo and a holo structure are available. In contrast to the previous analysis no 
mutant or porcine AR are included in the dataset. Thus, the PDB structures of sorbinil and 
tolrestat in complex with porcine AR were replaced in the present study by their human 
complex counterparts. Additionally, in the last analysis only three structures of ligands ad-
dressing  the  specificity  pocket  were  included:  tolrestat,  idd594,  and  zenarestat.  In  the 
meantime, many structures of inhibitors addressing this specificity pocket have been pub-
lished. Also for structures solved in our laboratory the emphasis was put on ligands pene-
trating into the specificity pocket. Hence, to extend the scope and relevance of our previous 
study considering a larger dataset, we present the results analyzing structural differences of 
the binding pocket based on multiple ligands addressing the specificity pocket.
As a starting point for the analysis the proposed holo conformation (1ads) of the enzyme 
was chosen. The results for this analysis are presented in Table 6. With the exception of the 
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apo form of the enzyme (1xgd), all pockets superimpose very well, showing rmsd values 
below 0.9 Å. 
protein chain rms binding site (Å) Δ Cα
Δ side 
chain
2acr 0.10 0 0
2acq 0.12 0 0
1el3 0.16 0 0
1x96 0.19 0 0
1x98 0.20 1 0
9sbi 0.22 0 0
1x97 0.22 1 0
2acs 0.23 0 0
1pwm 0.26 1 0
9jfd 0.44 3 2
947d 0.59 6 5
9tol 0.62 10 7
1z89 0.71 5 2
1t40 0.72 5 5
1z3n 0.73 5 5
9zop 0.74 4 5
1pwl 0.76 7 6
1t41 0.76 8 5
1us0 0.77 8 5
1iei 0.81 10 6
1xgd 2.86 21 11
Table 6: Binding-site analysis based on the holo reference structure 1ads. The second col-
umn reports the the rmsd considering the Cα atoms of the binding-site residues. The third  
column gives information on significant Cα movements (if any) with respect to the refer-
ence structure using a threshold of 0.5 Å. The fourth column contains information on the  
number of significant side-chain movements using a threshold of 1.0 Å. The movement is  
measured between the centroids calculated for all the heavy atoms within the side chain,  
for both, reference and superimposed chains. The values are sorted according to their as-
cending rmsd with respect to the binding-site residues.
Based on the rms deviation, the dataset can be divided into three clusters. The first nine 
structures with low rmsd values ≤ 0.26 Å form the first cluster. The rmsd values of the next 
cluster range from 0.44 Å for the JFD complex to 0.81 Å for the zenarestat-bound structure 
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1iei. These 11 structures form the second cluster. The structure of the apo form (1xgd) ex-
hibits much larger rms deviations, thus forming its own cluster; the reasons will be dis-
cussed below. 
Besides the overall fit of the binding-site residues, the number of Cα atoms moving by 
more than 0.5 Å is reported in Table 6. Again the first nine structures show very little devi-
ations compared to the holo structure. Six of them have no Cα atom displacement exceed-
ing 0.5 Å. Only the structures with fidarestat or one of its isomers (1pwm, 1x97, 1x98) 
































§      
1iei 0.5 0.5 0.8 0.5 2.1 1.3 1.6 0.8 8#
1pwl 0.7 0.8 0.8 2.3 1.9 1.1 0.5 7
1t40 0.6 1.1 2.2 1.9 1.2 5
1t41 0.6 0.9 0.5 1.3 2.4 1.9 1.1 0.5 8
1us0 0.5 0.8 0.5 0.8 2.1 1.8 1.1 0.5 8
1z3n 0.5 1.2 2.4 1.9 1.2 5
1z89 0.8 0.6 2.2 2.0 0.9 5
947d 0.5 0.7 2.1 1.6 1.0 0.6 6
9jfd 0.6 1.5 1.2 3
9tol 0.5 0.6 0.7 0.7 1.1 1.9 1.4 1.0 0.8 9##
9zop 1.3 2.3 1.8 1.3 4
noc§ 1 1 1 2 1 1 3 6 4 10 11 11 10 4 2
Table 7: Size of the Cα displacements for crystal structures of the second cluster from Ta-
ble 6 with respect to the reference structure 1ads, using a threshold of 0.5 Å. Additionally,  
in the last column and row the total number of observed displacements is presented. 
§ number of changes; # the missing 2 residues are Pro 310 and Asn 160 which are shifted  
by 0.7 and 1.0 Å, respectively;  ## the missing residue is Tyr 209 which is shifted by 0.6 Å
None of the structures in cluster 1 shows a deviation of the side-chain centers by more 
than 1 Å. However, for the χ2 torsional angle of Leu300 two distinct states can be seen. 
The reference angle from the holo structure is ~-135° and in many of the other complex 
structures of cluster 1 it falls into the range of 70-75°. The flipped hydrophobic side chain 
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of Leu 300 exposes very similar spatial requirements and structural features towards the 
binding pocket. The question arises whether this observation can be regarded as a distinct 
difference between the individual structures or whether the corresponding electron densi-
ties allows for an ambiguous assignment. Given the little deviations with respect to struc-
tural features between these nine crystal structures, one can conclude that all are very simi-
lar to the holo structure. As a consequence, the protein can obviously bind any of the lig-
ands within this cluster without the requirement to perform major 'induced-fit' adaptations. 
Within the second cluster the variability between the individual structures increases sig-
nificantly. Between three and ten Cα atoms are displaced by more than 0.5 Å with respect 
to the holo structure. Thus, all of these examples show significant differences between holo 
and complexed form of the enzyme. The JFD (9jfd) structure shows the least amount of 
displacements,  whereas tolrestat  (9tol)  and zenarestat  (1iei)  show the most pronounced 
changes. Details about the residues involved in adapting to the different ligands are given 
in Table 7.
The C-terminal loop region ranging from Cys 298 to Ser 302 is mainly responsible for 
the changes related to the ''induced-fit'' adaptation. Except for the JFD and tolrestat com-
plexes, the Leu 300 Cα atom moves at least 2 Å with respect to the holo structure in order 
to accommodate this set of ligands. Interestingly, this also affects the neighboring residues: 
Leu 300 and 301 are displaced in all cases, whereas Ala 299 and Ser 302 are shifted in 10 
out of 11 cases, with the only exception of the JFD complex. In the latter case, a compara-
bly small moiety penetrates into the corresponding region of the binding pocket. Hence, lo-
cal movements in terms of Cα shifts restricted to Leu 300 and 301 are apparently sufficient 
to adapt the specificity pocket to this ligand. 
Also Trp 219 shows a considerable amount of flexibility. Its Cα position is shifted in six 
out of the eleven cases. This residue is attached to a larger loop region, called the 'cofactor 
safety belt'19;34. The electron density for this loop region of the protein is often insufficient-
ly defined, supposedly indicating elevated levels of intrinsic flexibilities. From a biochemi-
cal point of view, this loop plays an important role in binding and releasing the cofactor. 
Hence, flexibility of this loop region is mandatory for the biological function of the en-
zyme, which relates to the exchange of the cofactor as the rate-limiting step. 
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The Cα atoms of Cys 298 and 303 are shifted four times. Cys 298 is at the N-terminal 
end of the small C-terminal loop region which shows the highest flexibility. Thus, move-
ments affecting this loop region affect also the backbone of Cys 298. The position of Cys 
303 is partly responsible for the size of the specificity pocket at the far end of the anion 
pocket. Hence, it adopts its position in a way to give sufficient room depending on the size 
of the ligand moiety penetrating into the specificity pocket. 
Phe 122 is shifted in three cases between 0.6 and 0.7 Å. It is located in a loop region di-
rectly above Leu 300 and borders the upper part of the specificity pocket. 
An interesting case is Thr 113 whose Cα atom is shifted in two cases. The correspond-
ing ligands are idd 594 and zenarestat, which both place a bulky bromine atom into the dis-






















1iei 2.0 1.1 3.7 1.2 2.3 2.1 6
1pwl 1.0 4.5 4.2 1.2 1.2 1.1 6
1t40 1.1 4.6 3.9 1.2 1.2 5
1t41 1.4 4.4 4.2 1.2 1.3 5
1us0 4.2 4.1 1.1 1.0 1.2 5
1z3n 1.2 4.5 4.4 1.2 1.2 5
1z89 4.2 4.4 2
947d 1.1 4.8 3.8 1.1 1.4 5
9jfd 4.0 3.1 2
9tol 1.0 2.5 1.2 3.4 2.1 1.3 1.2 7
9zop 1.2 4.7 3.8 1.3 1.1 5
noc§ 1 1 2 7 11 11 9 8 3
Table 8: Movements of side-chain centers of all structures of cluster 2 from Table 6 with 
respect to the holo conformation of the enzyme 1ads. As for Table 6 the movement is deter-
mined between the centroids calculated for all the heavy atoms within the side-chains of  
the reference and the superimposed chains. Displacements are reported, if they are larger  
than a threshold of 1 Å.
§ number of changes
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below Thr 113, is shifted in the complexes with these two ligands. The other residues men-
tioned in  Table 7 are shifted only once, as observed in the zenarestat (1iei) and tolrestat 
(9tol) complexes, two structures which will be discussed in more detail below. 
Movements  of  the side-chain centers  are  analyzed in  Table 8.  As expected,  similar 
trends are observed as reported in Table 7. The majority of the ''induced-fit'' movements re-
sulting from ligand binding occur in the C-terminal loop. Leu 300 and 301 are involved in 
all 11 cases, whereas Ser 302 and Ala 299 are found to move in only nine and seven cases, 
respectively. For the Pfizer compound and the JFD compound no movements of Ser 302 
are observed. This can be attributed to overall smaller movements necessary to accommo-
date  these  comparatively  small  ligands.  Consequently,  Leu  300  and  301  are  the  only 
residues which significantly shift their side-chain positions upon binding one of these two 
ligands. 
A residue which shows a surprisingly high rate of side-chain shifts compared to its Cα 
movements is Cys 303. In eight of the cases, the side chain moves away from its holo posi-
tion once a ligand addresses the specificity pocket. The side chain of Tyr 309 is moved in 
three cases. The corresponding ligands are minalrestat, idd 594, and zenarestat. As shown 
above, the latter two are also responsible for the Cα shifts of this residue, most likely in-
duced by a bromine atom in the vicinity of Tyr 309. Interestingly, also minalrestat has a 
bromine at the corresponding position. Thus, a movement of Tyr 309 seems to occur only 
if a bulky atom or group is placed in its vicinity. Finally, the side-chain centers of Phe 115, 
121, 122 are occasionally involved in the 'induced-fit' adaptations. 
Not all relevant motions induced upon ligand-binding can be captured solely consider-
ing Cα and side-chain center movements. Changes of side-chain torsional angles virtually 
conserving the positions of side-chain centers or Cα atoms can also be of relevance for the 
exposure of recognition determinant  features.  All  torsional  angles  were measured on a 
scale ranging from -180° to 180°. The results from this analysis are presented in Table 9. 
In general, the amino acids exhibiting the highest degrees of flexibility with respect to Cα 
atom and side-chain center movements also show the largest torsional variances. Hence, 
the Cys 298 to Leu 301 loop region displays the highest diversity with respect to the corre-
sponding side-chain torsion angles. The Cys 298 side chain adopts three distinct conforma-
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tions. In the holo structure, the χ1 angle is 167° and the sulfur points away from the bind-
ing pocket. However, the side chain can also rotate to values about 70° (1t41), orienting the 
sulfur atom towards the binding pocket. Interestingly, in the ultra-high resolution structure 
with idd594 (1us0), Cys 298 shows a split conformation with values of 158 and 74°. Addi-
tionally, values around 120-130° are also possible, as can be seen in the zopolrestat struc-
ture. This value represents a conformation where the sulfur lies in bisecting position be-
tween the other two orientations. 
Leu 300 shows dramatic variations in both its χ1 (holo: 110°) and χ2 (holo: -136°) an-
gles. If the specificity pocket is addressed by a ligand, χ1 fluctuates between 60 and 90°. 
However, values between 140 and 160° can also be seen. The highest deviation can be ob-
served for the tolrestat complex, where χ1 adopts a value of -174°. The χ2 angle is con-
fined to two distinct states in the complexes, corresponding to torsions of ~60° and close to 
180°. The next residue in the sequence, Leu 301, also shows a high degree of variability. 
However,  since  its  side  chain  points  away  from the  binding  pocket  into  the  solvent, 
changes are most likely not relevant for the recognition of small molecules in the binding 
pocket. 
To accommodate tolrestat, Phe 122 χ1 is shifted by 14° (169 to -177°). Changes of fur-
ther residues are primarily observed in the zenarestat complex (1iei). Thr 113 shows a shift 
of the χ1 angle from -72 to 132°. Tyr 309 also adopts a unique position: instead of forming 
an H-bond with the backbone carbonyl of Ala 299, Tyr 309 is rotated around its χ1 angle 
and points now towards the ligand. A water molecule is found in the former position of the 
Tyr 309 OH atom. 
The conformations observed within the zenarestat structure are in many ways unique. 
Positional changes are more frequent than in the other structures. However, it remains un-
clear whether these changes can solely be attributed to restraints imposed by the ligand, 
considering that this structure exhibits by far the lowest resolution (2.5 Å) in the dataset. 
Hence, it cannot be ruled out that some of the observed 'abnormalities' are related to the 
higher uncertainty of the atomic positions.
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Residue torsion 1ads 1iei 1pwl 1t40 1t41 1us0 1z3n 1z89 947d 9jfd 9tol 9zop
TYR 48 χ1 178 166
GLN 49 χ1 161 172 176 173 174
GLN 49 χ2 176 -170 -171 -168 -171 -168
LYS 77 χ1 -162 -143
LYS 77 χ2 -173 -126
LYS 77 χ3 -173 150 86
LYS 77 χ4 74 92 163
TRP 79 χ1 62 77
CYS 80 χ1 180 153
TRP 111 χ2 93 82 83
PRO 112 χ1 -103 -138
THR 113 χ1 -72 132
THR 113 χ1 173 13
PHE 115 χ1 -177 -67 173
PHE 115 χ2 -15 -135
PHE 122 χ1 169 -177
PHE 122 χ2 83 95 -94 -97 -92 -85 -93
ASN 160 χ1 177 -31
TYR 209 χ2 68 86 57 56 54
TRP 219 χ2 84 96
CYS 298 χ1 167 139 86 71 127 155 119
LEU 300 χ1 110 72 69 91 166 62 152 79 65 140 -174 71
LEU 300 χ2 -136 158 63 46 170 60 -175 64 59 50 175 71
LEU 301 χ1 137 163 64 76 69 62 57 80 57 98 170 85
LEU 301 χ2 0 -65 61 54 58 66 55 -80 62 -176 -177 33
SER 302 χ1 -60 -81 -44 -40
CYS 303 χ1 174 76
TYR 309 χ1 62 106
TYR 309 χ2 72 54
PRO 310 χ1 -93 -107
PHE 311 χ1 176 -169 -171
Table  9: Torsional analysis for structures addressing the specificity pocket. Values are  
listed if deviating by more than 10° from the corresponding value in the holo structure  
1ads. All angles are given in °, the reference angles of 1ads are shown in bold face. 
In addition to the positions of the amino-acid side chains, the conformation of the back-
bone plays a major role in the recognition of small ligands. Unfortunately, no built-in func-
tions to automatically analyze changes in the backbone beyond Cα-movements exist in Re-
libase+. Hence, these changes were assessed by visually inspecting the superimposed bind-
ing pockets and measuring the corresponding torsion angles using Reliview. 
Among the residues of the binding pocket only the C-terminal loop stretch of Cys 298 
to Leu 300 shows noticeable variations of the backbone which exceeds beyond simple Cα 
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atom shifts. Detailed analyses of the backbone torsional angles of this loop region are pre-
sented in Table 10. 
Cys 298 Ala 299 Leu 300
ψ φ ψ φ ψ
1ads 92 -108 4 47 51
1el3 97 -105 -3 46 44
1iei -34 44 -37 17 121
1pwl 100 -152 157 -150 -150
1pwm 97 -114 7 43 52
1t40 95 -160 164 -141 123
1t41 93 -166 162 -132 130
1us0 107 -154 165 -156 113
1x96 101 -114 2 48 54
1x97 98 -110 0 47 58
1x98 100 -108 0 46 53
1xgd 85 -106 1 41 61
1z3n 105 -175 167 -142 133
1z89 97 -144 153 153 114
2acq 97 -108 1 43 59
2acr 98 -113 4 46 58
2acs 91 -112 2 48 54
947d 100 -167 75 -70 126
9jfd 98 -143 76 -71 112
9sbi 100 -115 -4 51 53
9tol 75 -87 -40 50 60
9zop 102 -155 -155 -165 112
Table  10: Backbone torsion flexibility in the C-terminal loop region Cys 298 - Leu 300.  
Values of the torsion angles are given in °.
Starting at the N-terminal end of the segment, the ψ angle of Cys 298 coincides in most 
cases between 90 and 105°. Two exceptions can are apparent: the structures of zenarestat 
(1iei) and tolrestat (9tol). For zenarestat the torsion changes by ~130° and adopts a value of 
-34°. This results in a flip of the carbonyl function of Cys 298, which usually points to-
wards the binding pocket. Here, instead, this carbonyl function points upwards towards the 
solvent. However, this flip is partly compensated by the next two torsions, which adopt un-
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usual values compared to the other structures. For the complex with tolrestat, the Cys 298 
and Ala 299 main-chain torsions also adopt unique values. These torsion angles enable the 
unique position of the Leu 300 side chain observed in this complex. Except for 1iei and 
9tol, the φ angles of Ala 299 cluster around two different values. If either no ligand is 
bound or the bound ligand does not address the specificity pocket, the values for φ Ala 299 
fall between -115 and -105°. If the ligand, however, addresses the specificity pocket, the φ 
angle adopts values around -143 and -175°. Thus, this torsion can be considered to act as a 
hinge which facilitates the opening and closing of the specificity pocket. 
The ψ angle of Ala 299 shows a similar but not identical behavior. If the specificity 
pocket is closed, the torsion angle adopts values between -3° and 7°. However, if the speci-
ficity pocket is addressed, two different states can be seen: the angle can either fluctuate 
between -155° and 167° or have values around 75°. The latter corresponds to a conforma-
tion where the backbone nitrogen of Leu 300 forms an H-bond with the ligand. Hence, 
with the open specificity pocket this conformation only occurs if the corresponding ligand 
presents a suitable H-bond acceptor to the Leu 300 backbone, as seen in the 47d and JFD 
structures. A clear dependence on the bound ligand can also be observed for the φ (Leu 
300) angle. A closed specificity pocket corresponds to values between 43° and 51° in φ 
(Leu 300) and 44° - 59° in ψ, respectively. For the open pocket two clusters are seen for φ 
Leu 300. One shows a relatively large variability within the conformations, with values be-
tween -132° and 153°. This cluster corresponds to the conformation where no H-bond is 
formed with the inhibitor. Within the other cluster the φ angle adopts values of ~-70° and 
the N-H of the Leu 300 is spatially aligned to facilitate H-bond formation with a bound in-
hibitor. This dependence of the backbone torsional angles on the presence of an H-bond to 
the inhibitor is lost for ψ Leu 300, where the only noticeable difference is apparent be-
tween the opened (>110°) and closed (~50°) specificity pocket. 
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Figure  14:  Chemical  formulas and superposition of  zenarestat  (red)  and idd594 
(salmon) based on a fit of the binding site residues. Both structures superimpose  
very well and use the same moiety to addresses the specificity pocket.
Again one has to note that the backbone conformations for the zenarestat and tolrestat 
complex are unique, which can be clearly deduced from the binding mode in case of tolre-
stat. For zenarestat the driving forces which promote these unique backbone conformations 
are not easily identified.  Figure 14 shows a superposition of the bound conformations of 
zenarestat and idd594 based on the binding-site residues fit  as calculated by Relibase+. 
Both structures superimpose quite well and show the same structural features in those parts 
which address the specificity pocket and the C-terminal loop region. However, different 
conformations of many binding-site residues are observed in the two complexes, for rea-
sons which remain ultimately unclear apart from the mentioned lower resolution of 1iei.
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Figure 15: Backbone conformations of the Cys 298 - Leu 300 stretch. In the upper picture  
the three major conformational clusters are given. The holo conformation (1ads), which  
represents  the closed specificity  pocket,  is  shown in blue,  the conformation where the  
specificity pocket is open and no hydrogen bond is formed with the ligand is shown in  
salmon (1us0) and the corresponding conformation with an H-bond  is given in purple. In  
the lower picture the holo conformation is shown in blue, whereas two unique conforma-
tions are given in green (tolrestat) and red (zenarestat). 
By analyzing the backbone flexibility of the C-terminal loop region it becomes clear 
that  this  part  of  the protein is  of  utmost  importance for  understanding the mechanism 
which enables the enzyme to accommodate a variety of different ligands. As shown by the 
analysis of the torsional angles, within this region the leverages are located which enable 
the opening and closing of the specificity pocket. Figure 15 shows representative examples 
for the different conformations found for the backbone of this small loop stretch. In the up-
per picture the three major conformational clusters are displayed. The holo conformation 
(1ads) representing the closed specificity pocket is shown in blue, the conformation of the 
open specificity pocket with no hydrogen bond formed towards a suitable ligand moiety is 
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shown in salmon (1us0), and the corresponding conformation with an H-bond present is 
given in purple. In the lower picture the two remarkably different conformations of tolre-
stat (green) and zenarestat (red) are shown in comparison to the holo conformation. 
Figure 16: Representative structures which illustrate the conformational flexibility of  the  
C-terminal loop region including the side chains. The backbone flexibility, which is illus-
trated in  Figure 15, is amplified by the Leu 300 side chain. Thus, this residue shows  
enormous positional variability. 
Considering movements of Cα atoms and torsion angles in an isolated way is clearly not 
sufficient to describe the full conformational space of the AR binding pocket. Accordingly, 
Figure 16 shows a composite picture of the residues Cys 298 to Leu 300 for selected struc-
tures which represent the major conformations seen in the dataset. 
Departing from Cys 298, the side chain of this residue adopts three different conforma-
tions. As indicated by the side-chain analysis, the sulfur of Cys 298 can either point into or 
off the binding pocket, and it can adapt an intermediate orientation. 
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Moving on to Ala 299, a remarkable flexibility in the backbone torsions is revealed. On 
the one hand, this flexibility enables a flip of the main-chain conformation as indicated by 
in the different orientations of the carbonyl function. On the other hand the opening and 
closing of the specificity pocket is facilitated by this part of the backbone. 
For Leu 300 three main conformations can be distinguished: the first corresponds to the 
closed form of the specificity pocket, the second to the opened form, and the third to the 
unique conformation of the tolrestat-bound structure. Within the cluster of the open speci-
ficity pocket conformations one can further dissect the backbone conformations with re-
spect to the already discussed formation of an H-bond to the ligand. Independent of the 
opened or closed state of the specificity pocket the side chain of Leu 300 itself can adopt 
different conformations in which the CG atom points either towards or off the binding 
pocket.
In summary, what picture can be drawn about the binding pocket of AR and its 'in-
duced-fit' effects? 
Based on the analysis of the crystal structures one can divide the binding pocket of AR 
into two different sub-pockets. The first sub-pocket is the cavity where the catalytic reac-
tion takes place. As the name suggests, the residues involved in catalysis35;169;170 as well as 
the cofactor22 border this cleft. The corresponding residues are Trp 20, Val 47, Tyr 48, Trp 
79, and His 110. The positions of these residues are very well conserved among the differ-
ent structures. Despite very low thresholds, hardly any variations could be noticed. This 
behavior has been described earlier113.  Such a behavior is to be expected for a sub-site 
within a binding pocket which contains the catalytic residues171. In order to catalyze the re-
duction of  aldehydes,  a  precise  alignment  of  the substrate,  the cofactor  as  well  as  the 
residues involved in stabilizing reaction intermediates is mandatory. Therefore, structural 
integrity is a key feature for this sub-pocket. 
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Figure 17: Different representations of the AR binding pocket. A shows a 2D representa-
tion of the AR binding pocket with its two sub-pockets. The amino acids are color coded  
with respect to the flexibility observed in the comparative crystal structure analysis. Blue  
indicates the least and red the highest amount of flexibility. B depicts a superposition of  
the binding-site residues of the three major binding pocket conformations. The closed 
specificity  pocket  (sorbinil  complex)  conformation  is  shown in  green,  the  two major  
opened conformations are shown in blue (tolrestat) and red (idd 594). C shows a surface 
representation of the different binding pocket conformations with the corresponding lig-
and shown as sticks. The chosen complexes and the color coding are the same as for B. 
The second important sub-pocket for the functionality of the enzyme is the specificity 
pocket. It is a hydrophobic pocket which is composed by the residues Thr 113, Phe 115, 
Phe 122, Leu 300, Cys 303, and Tyr 309. The accessibility and shape of this pocket varies 
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depending on the bound inhibitor. Despite this variability,  the available crystal structures 
suggest that the intrinsic flexibility is limited to only a handful of residues. 
Opening and closing of the specificity pocket is mainly determined by Leu 300 as gate-
keeper. The spatial position of the Leu 300 side chain with respect to Trp 111 determines 
whether the specificity pocket is in an open or closed state. Trp 111 plays an important role 
within the binding pocket of AR: it connects the catalytic anion pocket and the specificity 
pocket. The nitrogen of its aromatic side chain helps to anchor bound inhibitors to the ac-
tive site of AR by forming an H-bond with the respective polar head group of the inhibitor. 
The aromatic ring system of the side chain is involved in hydrophobic interactions with the 
aromatic or hydrophobic moiety of the ligand penetrating into the specificity pocket. If no 
ligand is bound, the side chain performs hydrophobic contacts to the Leu 300 side chain, 
thereby closing the specificity pocket. 
While Leu 300 can be considered as amplifier for the opening mechanism of the speci-
ficity pocket, the analysis of the available crystal structure showed that the whole loop 
stretch from Cys 298 to Leu 300 is involved in regulating the opening and closing as well 
as the shape of the specificity pocket. Within the backbone of this loop region intrinsic 
flexibility  is  found,  which  is  amplified  by  the  Leu 300 side  chain.  In  Figure  17 A a 
schematic overview of the AR binding pocket is presented and the amino acids are colored 
according to their observed flexibility, ranging from 'rigid' (blue) to highly flexible parts 
(red). 
Superimposed structures of the binding-pocket residues representing the corresponding 
conformations are shown in Figure 17 B, whereas Figure 17 C shows the different shapes 
of the pockets. As expected, the catalytic pocket superimposes very well wheras spatial di-
versity is observed for the specificity pocket. 
It has been shown in previous studies, that the binding modes of ligands addressing the 
specificity pocket in an open conformation are incompatible with the other binding pocket 
conformations113.  However,  this  issue deserves revision:  How different  are  the binding 
modes of inhibitors addressing the same of the three overall pocket conformation? How do 
these differences compare with differences seen for inhibitors addressing one of the parent 
pocket conformations? To analyze this issue, four complex structures representing the dif-
Extending charted space: comparative MD simulations of Aldose Reductase 59
ferent binding-pocket conformations were selected: sorbinil for the closed conformation; 
idd594 for the open pocket with no H-bond formed between Leu 300 and the ligand; 47d 
for the similar open pocket but with this H-bond present, finally, tolrestat representing its 
own unique binding conformation. 
To analyze the compatibility of the binding modes of the four reference ligands with re-
spect to the other structures in the dataset, all structures were subsequently superimposed 
to the four representative binding pockets, respectively. The results are shown in Table 11, 
where the number of clashes between the ligands bound to the four above-mentioned cor-
responding reference structures and all other superimposed structures of the dataset is giv-
en. A clash is defined as a distance between two atoms smaller than the sum of their vdW 
radii as implemented in Relibase+.
The binding mode of sorbinil (9sbi) is largely compatible with most of the other com-
plex structures. This can be expected since it is a rather small ligand which binds to the 
closed  form  of  the  specificity  pocket.  Between  zero  and  three  clashes  are  observed. 
Sorbinil would experience most clashes if placed into the tolrestat binding pocket (5 clash-
es). No clashes are observed for the binding pocket of two ligands which bind to the closed 
form of the specificity pocket (1ads, 1el3). Interestingly, also the binding pocket conforma-
tion of the Pfizer compound complex (1z89) could well accommodate sorbinil in its bind-
ing mode, although the Pfizer ligand binds to the open state of the specificity pocket. Most 
of the clashes between the bound conformation of sorbinil and the other binding pocket 
conformations occur with Tyr 48, which is surprising, since Tyr 48 superimposes very well 
across all structures. However, the comparatively large hydantoin head group of sorbinil 
might be responsible for this unexpected finding. Furthermore, Cys 298, Phe 122, His 110, 
and Trp 111 show small clashes with sorbinil in some of the structures. No major differ-
ences in terms of the number of clashes can be detected between structures which address 
the specificity pocket to those who do not.
Idd 594 (1us0) shows a different behavior. Structures addressing the specificity pocket 
show between three and six clashes with the bound conformation of idd 594. The involved 
residues are Trp 111, Phe 122, Trp 219, and Ala 299. Interestingly, the most compatible 
binding pocket is formed in the 47d complex, where, in contrast to the idd 594 complex, an 
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H-bond between the ligand and Leu 300 is formed. For complexes which do not open the 
specificity pocket, the number of clashes with idd 594 increases to eight to 11 bad contacts. 
Not surprisingly, Leu 300 and Trp 111 are responsible for most of the clashes, since these 
residues are responsible for opening the specificity pocket. 
Table  11: Analysis of the mutual compatibility of different binding modes. Given is the  
number of clashes of the ligand bound to the respective reference structure with the corre-
sponding structure in column 1. A clash is defined as a contact shorter than the sum of the  
vdW radii as implemented in Relibase+. All structures corresponding to the same cluster  
of Table 6 are colored equally: closed specificity pocket (green); opened no H-bond (red);  
opened with H-bond (yellow); tolrestat conformation (blue). Within the columns 2 to 5,  
structures belonging to the same cluster as defined in Table 6 are colored in light gray.
reference complex structure
idd 594 (1us0) sorbinil (9sbi) 47d (947d) tolrestat (9tol)
1ads 8  None 10  14  
1el3   8  None 10  14  
1iei 3  3  6  11  
1pwl 4  1  3  12  
1pwm 9  1  10  15  
1t40   3  3  3  11  
1t41   6  2  5  10  
1x96   9  2  11  14  
1x97   8  3  11  14  
1x98   9  2  11  14  
1xgd 9  1  10  12  
1z3n   5  1  2  9  
1z89   3  None 1  11  
2acq 11  2  12  15  
2acr 9  2  12  15  
2acs 10  3  13  15  
947d   2  2  - 11  
9jfd   8  2  9  12  
9sbi   9  - 10  13  
9tol   14  5  13  -
9zop   3  3  4  13  
1us0 - 2  2  11  
Extending charted space: comparative MD simulations of Aldose Reductase 61
The situation for the structures exhibiting a hydrogen bond between the ligand and Leu 
300, as represented by the 47d complex, is similar to the idd 594 case. Between ten and 13 
clashes with the bound conformation of 47d are observed for conformations where the 
specificity pocket is in a closed state. As expected, complexes with ligands addressing the 
open conformation show significantly less (1-5) clashes. 
The most incompatible binding mode with respect to all complexes in the dataset is the 
one of tolrestat. At least 9 clashes (mostly 11-15) are present for any of the comparisons. 
Leu 300 and Phe 122 clash in every structure, but there is virtually no binding-site residue 
which is never involved in any of the clashes. 
In summary, none of the larger reference ligands opening the specificity pocket would 
be fully compatible with any of the other structures even if they address the same overall 
binding-pocket conformation. This illustrates that the protein undergoes slight adjustments 
and adaptations that are specific for the bound molecule.
One structure published by Bohren et. al.34 in 2005 has been neglected so far but de-
serves discussion in greater detail: the crystal structure of the apo form of AR at 2.1 Å res-
olution. To obtain this structure it was necessary to introduce the R268A mutation. In the 
holo form of AR this Arg forms a salt bridge to one of the phosphate groups of NADPH. 
By removing this interaction site, the affinity of AR towards its cofactor is sufficiently re-
duced to obtain a structure with an unoccupied cofactor binding pocket. 
In  Figure 18 A, a superposition of the binding site residues of the sorbinil  complex 
(9sbi) and the apo structure (1xgd) based on a Cα-atom fit is shown. Overall, the binding-
site residues match very well, except for some differences in the side-chain positions of 
Trp 20. This residue is adjacent to the cofactor and it is reasonable that its position is shift-
ed upon NADPH binding. 
However, not all parts of the structure superimpose with similar low rmsd values. In 
Figure 18 B the area surrounding the cofactor-binding cleft is shown. The most striking 
difference between the two structures is the position of the 'cofactor safety belt'. This loop 
region hosting residues 214 to 226 is characterized by high temperature factors. Trp 219, 
which is usually located adjacent to the binding pocket, is moved by as much as 17 Å go-
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ing from apo to holo conformation. Instead of forming a sulfur-aromatic interaction with 
Cys 298, Trp 219 now experiences a cation-π interaction with the side chain of Arg 293. 
Figure  18:  Superposition of  the apo structure (1xgd,  green)  and the sorbinil  complex 
structure (9sbi, silver) based on a Cα fit for all protein residues. The cofactor (yellow) of  
the sorbinil structure is included for orientation purposes.  A shows the superposition of  
the binding pocket residues. Except for Trp 219 all residues superimpose very well.  B 
shows a view towards the cofactor binding pocket. The dramatic shift in the orientation of  
the cofactor safety belt can be observed. Trp 219 is moved 17  Å between the two struc-
tures. Arg 268 from the sorbinil complex is also included: in the complex structure it forms  
a Coulomb interaction with the C2-phosphate group of NADP+. The Arg268Ala mutation 
eliminates this interaction.
Considering the superposition of the amino acids adjacent to the cofactor safety belt, it 
is  interesting  to  notice  that  the  residues  preceding  the  loop region  overlap  very  well, 
whereas this is not the case for the residues following the C-terminal end of the loop re-
gion. Due to the movement of the whole loop, the cleft where the cofactor binds is uncov-
ered and the mandatory exchange of the cofactor preceding each reaction cycle is enabled. 
This large movement is most likely facilitated by the backbone torsional changes of the 
three residues Gly 213 (ΔΨ=162°), Ser 214 (ΔΨ=85°, ΔΦ=71°), and Ser 226 (ΔΨ=59°, 
ΔΦ=70°). As for the 'induced-fit' adaptations in the small C-terminal loop region from Cys 
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298 to Leu 300, the enzyme uses the backbone conformation of a few residues as hinges 
about which the loop is moving in a relatively rigid fashion. 
Comparative MD simulations analysis
The comparative analysis of crystal structures describes the experimentally observed con-
formational space of the binding pocket, thus it can be seen which parts of a binding pock-
et tend to adopt different conformations or are restrained to one conformation. 
However, X-ray structures represent both, time and spatial averages and are measured at 
rather low temperatures (100 K). The analysis of crystal structures might suggest that pro-
teins are rigid frozen-in systems with some flexible regions that cannot be located in the 
experimental electron density. The ultra-high resolution 0.66 Å structure of AR114 indicates 
that the rigidity seen in crystal structures exaggerates reality due to limited resolution. Al-
most one third of all amino acids in this structure are present in multiple conformations, in-
dicating higher degrees of flexibility than normally expected. The same experience could 
be collected with other systems resolved to very high resolutions. 
To overcome these limitations of crystal structure determinations, complementary tech-
niques have to be consulted. Nuclear magnetic resonance spectroscopy (NMR) can be used 
to elucidate the three-dimensional structure of macromolecules and to detect binding of 
small molecules to proteins172. Therefore, it is frequently used in structure-based drug de-
sign173-175. Instead of one definite model, NMR experiments result in an ensemble of con-
formations which are in agreement with the spatial restraints set by the experiment. Thus, 
NMR probably indicates in a more appropriate way where proteins exhibit flexibility176;177. 
However, not all proteins are suitable for NMR experiments, particularly since the size of a 
macromolecule can become the limiting factor. 
From a  computational  point  of  view molecular  dynamics  (MD) simulations  are  the 
method of choice to assess the dynamic properties of a protein178. Using MD simulations, a 
trajectory of snapshots is generated representing the states of the system at a given point in 
time. Due to the inherent assumptions and simplifications of the model used for the simula-
tions, formation and breaking of bonds cannot be simulated. Conformational changes and 
flexibility of amino acids, however, are certainly within the scope of the method. There-
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fore, MD was chosen as a tool to obtain deeper insights into the flexibility of the AR bind-
ing pocket. 
Simulations of AR complexes
To examine the intrinsic flexibility of AR, MD simulations of seven AR complexes were 
carried out. In addition, three simulations of the holo enzyme were conducted. All MD 
simulations  were started from experimentally  derived crystal  structure  coordinates  (see 
Materials and Methods) In the following section each simulation will be discussed briefly. 
After that the most interesting parts of the binding pocket, which show the largest amount 
of flexibility will be investigated further.
MD of AR in complex with sorbinil
The rigid inhibitor sorbinil binds to the enzyme with closed specificity pocket and shows a 
free energy of binding of ΔG = -9.1 kcal/mol. 
It utilizes a hydantoin moiety to anchor to the catalytic sub-pocket of AR. The analysis 
of crystal structures (see above) has shown that for the sorbinil complex the binding pocket 
adopts a conformation which is likely to be very similar to the holo form of the enzyme. 
Figure 19 depicts some of the key data to analyze the MD simulation of this complex. The 
average Cα rmsd across the entire simulation is 1.16 (±0.10) Å with respect to the starting 
structure. Thus, the overall structure and fold of the protein are very well conserved during 
the simulation. The average rmsd value for the binding site residues is 0.93 (±0.13) Å. For 
the first picoseconds an increase of the Cα rmsd can be observed. This increase is not re-
flected for the binding site residues where no drift can be seen for the first part of the simu-
lation. 
Analysis of the 2d-rms plot for the binding-site residues fluctuations indicate a clear 
separation into three clusters. Two larger clusters emerge at the beginning and the end of 
the simulation. As indicated by the 'cross-correlation' between these two clusters they are 
similar to each other, whereas the smaller cluster in the central part is different compared 
to the other two. However, for a short period within the the small cluster the system returns 
to a conformation similar to the other clusters as indicated by the small 'cross-peak' next to 
frame 365. This clustering of the binding pocket conformations is also well reflected by the 
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binding site rms deviations shown in the center right plot of  Figure 19.  The deviating 
smaller cluster is accompanied by increased rms values in the same time frame. Figure 19 
also depicts the structural changes within the binding pocket that cause the clustering ob-
served in the 2d-rms plot. The first cluster is represented by the conformation shown in 
green, the corresponding structure from the second cluster is shown in silver. The most 
striking difference between these two snapshots is the conformational change of Phe 122. 
Its side-chain rotates and now points away from Trp 79. In a representative geometry of the 
third cluster, shown in yellow, the Phe 122 side-chain has flipped back and adopts an ori-
entation similar to the first cluster. 
Within the last cluster two states deviating from the rest of the simulation are observed. 
One is located around frames 445-450 and the other around frames 540-560. The structural 
change causing this deviation consists mainly of a movement at the position of Trp 219. 
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Figure 19: Overview over the MD simulation of sorbinil in complex with AR. In the upper  
left corner the starting conformation of the MD simulation is shown as obtained from the  
X-ray experiment. On the upper right corner a 2d-rms plot (see Materials and Methods)  
for all atoms being part of binding side residues is shown. In the center the rms values are  
presented as running averages with a window size of 20 snapshots (left: Cα atoms of the 
enzyme, right: all atoms of binding site residues). In the lower part the following represen-
tative snapshots for the clustering are given: 150 (green), 320 (silver), 500 (yellow)
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MD of AR in complex with tolrestat
As observed in the crystal structure analysis, tolrestat forces the specificity pocket of AR 
into a unique conformation, thus it is interesting to study whether this conformation affects 
the flexibility of the pocket. Tolrestat uses a carboxylate moiety as an anchor group and 
binds to AR with a free energy of binding of ΔG = -9.2 kcal/mol. 
An overview over the MD tolrestat complex simulation is given in Figure 20. The aver-
age Cα rmsd for the whole simulation is 1.24 (±0.16) Å. The corresponding rmsd for the 
binding site residues is 1.18 (±0.17) Å. Those for the Cα-atoms are slightly higher than in 
the case of the sorbinil simulation. Considering the evolvment over time of the rmsd values 
it becomes obvious that in the central part of the simulation the system drifts towards high-
er rmsd values. However, over the course of the simulation the system returns back to low-
er rmsd values compared with the starting geometry. These deviations mainly result from 
movements within the cofactor safety belt region. Especially the region next to Pro 222 
shows substantial  movements as indicated in  Figure 21.  The rms deviations of the Cα 
atoms parallel the rmsd values of the binding site residues. However, the mobility of the 
latter portions is not as pronounced as for the Cα atoms. These movements have only mi-
nor impact on the binding site since Trp 219, the only residue close to this region, shows 
no unusual movements during this time span. 
Concerning the 2d-rms plot a clear clustering is observed. Three major clusters can be 
extracted, two larger clusters in the beginning and at the end of the simulation and a small-
er one in the center. As indicated by the cross-correlations the similarity between the first 
and last cluster is higher than for each of them and the central part. Within the first cluster 
a short period can be detected where the system fluctuates between two distinct states. One 
is similar to the first and last cluster, the other shows remarkable similarity with the smaller 
cluster in the center. 
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Figure 20: Overview over the MD simulation of the tolrestat complex. Data are present-
ed similarly to Figure 19. Lower left column: snapshots representing the movements in  
the first cluster from snapshots 1-250: 100 (green), 163 (silver), 173 (yellow), 183 (blue).  
Lower  right  column:  representatives  for  the  three  main  clusters:  100  (green),  280 
(silver), 450 (yellow)
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Figure 21: Movements of the cofactor safety belt region in the tolrestat complex simula-
tion. Two snapshots depicting Trp 219 – Leu 227 from the tolrestat complex simulation  
are shown. The green conformation represents the first main cluster of the simulation and 
the silver structures shows the movements in this region which cause the formation of the  
smaller cluster in the middle of the simulation. 
At the bottom of  Figure 20 the structural changes which cause the clustering of the 
snapshots are depicted. In the lower left column, the conformational transitions occurring 
in the first large cluster are shown. Starting from the conformation shown in green the first 
transition at frame 160 is characterized by a concerted motion of the side-chains of Phe 
121 and Phe 122. In the conformation shown in silver both side-chains adopt a different 
conformation as previously. The next transition is characterized by a movement of Phe 122 
back to its original conformation while Phe 121 remains at the new position (yellow con-
formation). At frame 180 Phe 122 flips back into the intermediately populated conforma-
tion. Parallel to these side-chain movements the loop region around Ala 299 shows back-
bone movements. The lower right part of Figure 20 shows the changes associated with the 
transitions between the three main clusters. The variability of the side-chain conformations 
70 Extending charted space: comparative MD simulations of Aldose Reductase
of the Phe 121 and 122 is the main event observed in the binding pocket. In addition, side-
chain motions of Cys 298 and Cys 303 are observed towards the end of the simulation.
In summary, the cofactor safety belt region next to Pro 222 is the most flexible part in 
this simulation, whereas the side chains of Phe 121 and 122 turn out to be the most flexible 
binding site residues. Compared to the sorbinil simulation, the backbone next to Ala 299 
shows enhanced flexibility and additional side-chain flips of Cys 298 and 303 can be ob-
served.
MD of AR in complex with idd 594
The complex of the inhibitor idd 594 and AR has been solved to an unprecedented resolu-
tion of 0.66 Å114. 
As in the case of tolrestat a carboxylate moiety is used as anchor group in the anion 
binding pocket. Idd 594 addresses the specificity pocket via an aromatic moiety. A special 
feature of this ligand in the crystal structure is the placement of a bulky bromine atom into 
the distant part of this pocket forming a short contact to the side-chain oxygen of Thr 113. 
Idd594 binds with a free energy of binding of ΔG=-9.8 kcal/mol. 
Figure 22 shows the summary for the simulation of this complex. The mean Cα rmsd is 
1.08 (±0.08) Å. Both the absolute value as well as the standard deviation are lower than in 
the  previous  two  simulations.  The  overall  system remains  remarkably  stable  over  the 
course of the simulation. The corresponding values for the binding site residues are 1.40 
(±0.20) Å. Surprisingly, these values are higher than in case of sorbinil and tolrestat. 
For this simulation, no distinct clustering in conformational families is indicated by the 
2d-rms plot as in the other cases. The similarity between most of the snapshots throughout 
the simulation is very high. At the beginning, a small cluster can be seen expanding from 
frame 20 – 40. In addition, a cluster which clearly separates from the rest of the simulation 
can be found between frames 520 and 530. The associated changes are depicted in Figure
22. 
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Figure 22: Overview over the MD simulation of the idd594 complex. Data are presented 
similarly to  Figure 19. The snapshots representing the clustering are: 30 (green), 250  
(silver), 525 (yellow)
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The conformation describing the longest time span of the MD simulation is shown in 
silver. Thr 113 shows a flipped conformation of its side chain compared to the crystal 
structure, in which the oxygen of the side chain of Thr 113 forms an unusually short con-
tact to the bromine moiety of the idd 594 ligand. The distance between these two atoms in 
the crystal structure is 2.97 Å, which is shorter than the sum of the van-der-Waals radii for 
an oxygen and a bromine. As expected the force field is not able to model this feature cor-
rectly, therefore the Thr 113 side chain moves away to avoid the short contact.
The conformation representing the first cluster is shown in green. Three interesting ob-
servations can be made for this cluster. The backbone of Ala 299 adopts a different confor-
mation. Usually for this ligand the backbone nitrogen of this residue is oriented towards 
Tyr 309 in order to form an H-bond with its side-chain oxygen. Within this cluster, howev-
er, the nitrogen points towards the ligand which requires the observed flip of the backbone 
geometry in this region. The second feature is a rotation in the side-chain conformation of 
Cys 303. The third difference is the position of Trp 219 which is also involved in forming 
the most distinct cluster (shown in yellow) at the end of the simulation. In this case, the 
side chain rotates and presents its nitrogen atom towards the ligand. The more pronounced 
changes observed for this cluster are the movements of the side chains of Phe 121 and 122. 
These two residues adopt conformations similar to those observed in the previous simula-
tions. 
The results obtained from a previous simulation of the same protein-ligand complex car-
ried out by Sotriffer et al.113 match qualitatively the results obtained for this study. One has 
to note, however, that the structural changes and the clustering of the conformations of the 
binding pocket is not as pronounced as found by Sotriffer et al.113. The main differences be-
tween the two simulations are the force field used to simulate the ligand and the starting 
structures. The general amber force field (GAFF)160 was used in this study, whereas manual 
parameterization based on the Cornell et al. force field158 was applied in the earlier simula-
tion. In addition the previous simulation was based on a preliminary refinement of the ul-
tra-high resolution complex structure of idd 594 whereas this study used the final structure 
as found in the PDB114. Therefore, a quantitative agreement between the two simulations is 
not to be expected.
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MD of AR in complex with the Pfizer compound
When data about this compound were first published by Mylari et al.125 of Pfizer, the au-
thors claimed that this molecule was the first sub-nanomolar inhibitor of AR based on IC50 
values recorded from a kinetic assay. Free energies of binding derived from ITC experi-
ments in our laboratory126 indicated that binding of this compound to AR was significantly 
weaker than suggested by IC50 determination. According to these measurements the com-
pound is a low-micromolar binder. The Pfizer compound uses a pyridazinone moiety to an-
chor into the catalytic sub-pocket of the enzyme. The crystal structure126 shows that it ad-
dresses the specificity pocket similar to idd 594. 
The corresponding simulation summary is presented in Figure 23. The mean Cα rmsd is 
1.06 (±0.09) Å. Again, this is a minor deviation along a 6 ns simulation, indicating a high 
structural integrity of the overall geometry of the complex. The rmsd for the residues com-
prising the binding pocket is 1.18 (±0.14) Å.
In the beginning of the simulation low populated clusters representing short term fluctu-
ations are observed. For the reminder of the simulation the system becomes less prone to 
changes in conformations and remains within one large cluster. Within the last nanosecond 
the binding pocket adopts a different conformations. However, the structural differences 
between this last cluster and the preceding snapshots are rather moderate.
The changes evolving in the first turbulent phase of the simulation are presented in the 
lower left part of Figure 23. Three regions of the binding pocket are responsible for the dif-
ferent states indicated by the cluster analysis. Phe 122 fluctuates between two distinct side-
chain conformations, which is in line with the conformations seen in other simulations. Trp 
219 shows flexibility in its backbone, which is part of the 'cofactor safety belt'. No pro-
nounced changes are apparent for its side chain. The C-terminal loop region from Cys 298 
to Leu 300 is the third flexible region. In the present case, no major changes in the main 
chain conformation are observed. Instead, the main chain moves as a whole within this re-
gion. Affected by these movements is the position of Tyr 309 which follows the fluctua-
tions of the loop region to a certain degree. After this period of elevated flexibility in the 
binding pocket, the system adopts a conformation which is stable throughout the remaining 
part of the simulation. The picture in the lower right column of Figure 23 depicts the slight 
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changes occurring within the last nanosecond. The transition into the distinct cluster at the 
final end of the simulation is mainly caused by flips of the side chains of Cys 298, Cys 
303, and Thr 113. All of these residues have shown conformational changes of their re-
spective side-chains in other simulations.
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Figure 23: Overview over the MD simulation of the Pfizer compound complex. Data are  
presented similarly to Figure 19. Left: snapshots from first cluster showing high flexibili-
ty: 10 (green), 15 (light blue), 25 (magenta), 35 (yellow), 45 (salmon), 52 (silver), 60 
(dark blue), 80 (orange) Right: snapshots from the remaining two main clusters: 300 
(green), 550 (silver)
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MD of AR in complex with the zopolrestat compound
A structure of the inhibitor zopolrestat in complex with AR has been solved in 1993 by 
Wilson et al.179. However, for the pdb entry 1mar only coordinates of the ligand and the 
protein Cα trace are deposited. Since zopolrestat shows an interesting selectivity profile be-
tween AR and aldehyde reductase, the structure has been re-determined in-house by Hol-
ger Steuber153. Interestingly, dependent on the crystallization conditions, the backbone of 
Ala 299 and Leu 300 adopts different conformations. In one of the conformations a hydro-
gen bond is formed between the nitrogen of the aromatic moiety penetrating into the speci-
ficity pocket. In the other conformation this hydrogen bond is not formed. This behavior is 
described in more detail in chapter 'Expect the unexpected' (page 163). The MD simulation 
reported here was started with the X-ray conformation lacking the hydrogen bond.
Zopolrestat exhibits a carboxylate anchor to bind to the catalytic sub-site and, similar to 
most potent AR inhibitors, it addresses the specificity pocket. It binds to the enzyme with a 
free energy of binding of ΔG = -11.3 kcal/mol. 
Also in this case the general fold of the enzyme is very well preserved. The average Cα 
rmsd over the whole six ns trajectory is 1.10 (±0.12) Å. For the binding site residues a 
mean rmsd value of 1.27 (±0.11) Å is observed for all atoms. 
In the 2d-rms plot of the binding site residues two small clusters in the beginning and 
the end can be detected which do not share high similarity neither with the remaining part 
of the simulation nor with each other. The rest of the simulation splits in two clusters. The 
first of these clusters is interrupted by a few snapshots which show differences compared 
to the rest of the simulation.
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Figure 24: Overview over the MD simulation of the zopolrestat complex. Left: differ-
ences between the very first cluster present for the first 30 frames and the following 
conformation. Depicted snapshots: 20 (green), 100 (silver). Center: differences next to  
frame 145: 100 (silver), 145 (yellow). Right: mobility in the backbone: 300 (silver),  
383 (blue), 590 (light green)
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The green conformation in the lower left part of  Figure 24 represents the first small 
cluster in the beginning of the simulation. A flip of the side chains of Phe 122, Cys 298 and 
303 is responsible for the transition to the next larger cluster leading to the conformation 
shown in silver. Concerning the backbone conformation of Phe 122, it is interesting to see 
that for the majority of the simulation time the side chain remains in this flipped conforma-
tion. 
The structural differences responsible for the distinct cluster around frame 145 is shown 
in the lower central part of Figure 24. The system moves from the conformation shown in 
silver towards the one depicted in yellow. Again both Cys 298 and 303 exhibit a flip of 
their side chains. In addition, Trp 219 shows larger movements. However, it is especially 
the side-chain of Leu 300 which shows large flexibility and adopts a unique orientation 
compared to the rest of the simulation. 
Within the second half of the simulation the system remains quite stable. The little clus-
ter around frame 380 and the small deviations at the end of the simulation are caused by 
movements of the Ala 299 - Leu 300 backbone. Compared to the conformations adopted in 
the majority of the snapshots of this simulation the backbone rotates by 90°. Within the fi-
nal cluster this flip is accompanied by larger motions of this backbone region as a whole. 
Representatives for the different backbone conformations observed are given at the bottom 
on the right side of Figure 24. 
MD of AR in complex with the 47d compound
The 47d compound is a carboxylate type AR inhibitor published in 1997 by Kotani et al.180 
whereas the corresponding structure was solved in-house.  Due to its  high similarity to 
zopolrestat, 47d addresses the specificity pocket in similar manner using the same moiety, 
a benzo-thiazol portion.  The mean Cα rmsd is 1.14 (±0.15) Å, the rmsd of the binding 
pocket amino acids amounts to 1.15 (±0.17) Å. Responsible for the increase in the Cα rmsd 
for about one third of the simulation are significant movements in the loop region ranging 
from Phe 122 to Val 131. As shown in Figure 26, the Cα of Glu 126 moves about ~9.9 Å. 
Despite being a flexible loop region in the other simulations, movements of this magnitude 
are not observed for any of the other simulations. 
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Figure 25: Overview over the MD simulation of the 47d complex. The following snapshots 
representing the clustering are given in the lower picture: 50 (green), 170 (light blue), 230  
(magenta), 290 (yellow), 400 (salmon), 530 (silver), 580 (dark blue)
Analyzing the 2d-rms clustering in  Figure 25 many transitions between small clusters 
are observed. The first 140 snapshots show cross-correlations with snapshots from the sec-
ond part of the simulation. Between snapshots 140 and 320 three small clusters appear 
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which do not show high similarity with each other or the rest of the simulation. However, 
these three clusters are populated while at about the same time the pronounced movements 
of the 120s loop region mentioned above occurs. Additionally, close to frame 530 some 
snapshots emerge which depart from the rest of the simulation. 
Figure 26: Movement in the flexible loop region following Phe 122 in sequence.
Since a large number of small clusters appears in this simulation a superposition of rep-
resentative snapshots for many of these clusters is given in the lower part of Figure 25. The 
majority of the conformational transitions occur with Phe 121 and 122. Both adopt several 
distinct conformational states. Also Cys 303 shows a side-chain rotation and Trp 219 ex-
hibits  the  same  amount  of  flexibility  as  observed  in  other  simulations.  The  backbone 
stretch from Ala 299 to Leu 300 remains relatively rigid. No side-chain shift of Cys 298 
can be detected. These two observations can be rationalized by the fact that the inhibitor 
forms a hydrogen bond with the Leu 300 backbone nitrogen and places a carbonyl function 
into the region where a flipped Cys 298 side chain would be placed. Thus, features of the 
complexed inhibitor are likely to stabilize this otherwise flexible region. 
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MD of AR in complex with the JFD compound
The compound JFD was discovered as AR inhibitor by virtual screening as described by 
Kraemer et. al.115. As expected for a virtual screening hit which has not been further opti-
mized, JFD has only moderate binding affinity (ΔG=-7.5 kcal/mol) towards AR compared 
to the other inhibitors in this study. The compound addresses the specificity pocket in a 
similar way as the other inhibitors such as zopolrestat or 47d. However, as shown by the 
comparison of the available crystal structures, JFD induces less changes within the flexible 
backbone region next to Ala 299.
During the simulation the average Cα rmsd is  1.21 (±0.10)  Å,  and the binding-site 
residues experience the same value of 1.21 (±0.12) Å. The evolvement of these rmsd val-
ues with time is plotted in Figure 27. It is worth noticing that both rmsd values tend to fluc-
tuate less as the simulation continues. This is also reflected in the 2d-rms plot of the bind-
ing site residues where almost all snapshots from the second part of the simulation coincide 
in one big and homogeneous cluster. Between frames 440 and 450 conformations are sam-
pled which form 'cross-correlation' with the first section of the simulation. 
In due course of the first three nanoseconds of the simulation two clusters can be detect-
ed. The image in the lower left part of Figure 27 depicts the changes associated with the 
transition from the first cluster (shown in green) to the conformation adopted in frame 150 
(shown in silver). The backbone of Ala 299 rotates and the conformation of the Phe 122 
side chain changes. In addition, the Leu 300 side chain flips almost 180° around its χ2 an-
gle. This conformation is maintained throughout the rest of the simulation time. The con-
formation shown in yellow represents frame 250 in the region between the two larger clus-
ters. Here the Ala 299 backbone adopts yet another conformation and the Leu 300 side-
chain does amplify this movement. The Phe 122 side chain flips back to its previous orien-
tation. 
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Figure 27: Overview over the MD simulation of the JFD compound complex. Left:  
snapshots representing changes in the first half of the simulation: 70 (green), 150  
(silver), 250 (yellow). Right: changes occurring in the second part of the simula-
tion: 250 (yellow), 400 (light blue), 445 (orange)
The lower right part of Figure 27 shows the transitions in the second part of the simula-
tion. The conformation shown in yellow corresponds to the yellow conformation of the left 
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picture  (frame  250).  The  transition  to  the  large  cluster  dominating  the  second  three 
nanoseconds  results  in  consequence  of  the  recursive  side-chain  flip  of  Phe  122.  This 
flipped conformation is then retained for the rest of the simulation. Only for the small time 
frame close to frame 445 the Phe 122 swings back. Thus, Phe 122 predominantly adopts a 
conformation which deviates from the one observed in the crystal structure. The rest of the 
binding pocket is stable. Only Trp 219 and Cys 303 show some noticeable flexibilities. 
Simulations of the holo enzyme
All previous simulations were carried out with a ligand present in the binding pocket of 
AR. Residual flexibility of the binding pocket residues could be observed in all of the cas-
es. However, it appears likely that the conformational space available to the holo enzyme is 
larger than for any of the complexes, since bound ligands lock the binding pocket residues 
into certain conformational states.
To assess the conformational flexibility of uncomplexed AR, three different simulations 
were performed. To increase sampling, the simulations were started from three different 
crystal structures which represent the three known overall binding pocket conformations. 
The geometry adopted in complex structures of sorbinil, tolrestat and idd 594 were cho-
sen as archetypes for the three respective conformers. As indicated by the analysis of the 
available crystal structures, the sorbinil bound geometry is highly similar to the proposed 
holo form of AR. The protein conformation adopted in the idd 594 bound structure is rep-
resentative for all ligands addressing the specificity pocket despite the minor differences 
observed in the Relibase+ analysis. Finally, tolrestat has shown to induce the most pro-
nounced structural changes up to now in a unique fashion compared to all other structurally 
characterized ligands. In the following, these simulations will be named holo (sorbinil), 
holo (tolrestat), and holo (idd594), respectively. 
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Figure  28: Overview over the MD simulation of the holo (sorbinil). Left: conformations  
taken from the first large homogeneous cluster: 100 (green), 200 (silver), 300 (yellow),  
400 (blue). Right: structural differences between the large cluster and the one experienced 
at the end: 100 (green), 550 (orange)
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Removing the ligand from a crystal structure prior to starting an MD of the produced 
holo enzyme introduces different levels of perturbations to the systems depending on the 
binding mode of the removed inhibitor. 
In the case of sorbinil the perturbation are only minor. The mean rmsd for all Cα atoms 
of the enzyme is 1.24 (±0.12) Å and the corresponding rmsd for the binding site residues is 
1.34 (±0.23) Å. These values are slightly higher than in case of the complex simulations. 
However, on an absolute scale these deviations are still rather moderate. 
Considering the 2d-rms plot in Figure 28, only one large cluster is apparent. This indi-
cates that, in contrast to the complex simulation, no sudden transitions occur between sin-
gle conformational states. For the last 500 ps of the simulation a small cluster which is dif-
ferent compared to the other snapshots is observed. The movements resulting in this dis-
tinct cluster are rearrangements of Trp 219. This residue is also responsible for the increas-
ing rmsd values of the binding site atoms observed towards the end of the simulation. The 
large rms deviation between this cluster and the rest of the simulation and the resulting col-
oring of the 2drms plot makes it rather difficult to follow conformational changes occur-
ring within the first 5.5 ns of the simulation. 
The lower left part of Figure 28 shows conformations taken from the first large cluster 
of this simulation. Despite the fact that there is definitely motion in different region of the 
binding  pocket,  especially  for  Trp  219  and  Phe  122,  no  pronounced  conformational 
changes occur. These changes lead to the clustering of snapshots which has been observed 
similarly for the complex simulations. The lower right part in Figure 28 superimposes one 
frame from the first cluster with a snapshot from the second cluster. Here a movement in 
the side-chain of Cys 298 is observed. More pronounced, however, are the movements of 
Trp 219 which is attached to the 'cofactor safety belt' loop region. 
The next simulation under investigation is holo (tolrestat). In this case the Cα rmsd is 
1.25 (±0.15) Å and the binding site rmsd is 1.51 (±0.19) Å. The value for the binding pock-
et rmsd is higher than in the case of holo (sorbinil). However, this rmsd is determined with 
respect to the starting structure of the MD, which exhibits in case of tolrestat the specificity 
pocket in an open conformation. As can be seen from the 2d-rms plot of Figure 29 the clus-
tering is not very pronounced as already seen in the previous simulation. 
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Figure 29: Overview over the MD simulation of the holo (tolrestat). Snapshots depicted  
in the lower part: 100 (green), 275 (silver), 373 (yellow)
Both the 2d-rms plot and the time course plot of the binding site rms in Figure 29 expose 
the same snapshots in terms of continuous fluctuations. Between frames 250 and 300 as 
well as around frame 375 differences compared to the rest of the simulation can be detect-
ed. The specificity pocket is in closed conformation right from the beginning of the simula-
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tion. Hence, the changes to the closed form by transitions of Leu 300 and its surrounding 
backbone  have  already  occurred  during  the  minimization  and  equilibration  phase.  As 
shown in Figure 29 the transition from the first cluster (shown in green) to the cluster be-
tween frame 250 and 300 (shown in silver) is not directly caused by distinct conformation-
al changes, but more a result of motions in different parts of the binding pocket and, again, 
especially of Trp 219. The situation is different for the transition to the cluster next to 
frame 375 (yellow conformation). Here a side-chain rotation of Phe 122 and a flip in the 
backbone region of Ala 299 are observed. Both being motions which have also been ob-
served in the complex simulations.
The final holo simulation was started using the protein conformation of the idd594 com-
plex as a starting point. The rmsd values for the Cα atoms (1.16 (±0.14) Å) and the binding 
site residues (1.56 (±0.22) Å) are in agreement with the observations made for holo (tolre-
stat). Surprisingly, the clustering (see Figure 30) within the 2d-rms plot is much more pro-
nounced compared to the other two holo simulations. Eight distinct clusters, which differ 
in their size, can be distinguished. A network of cross-correlations between the single clus-
ters indicates that the system is fluctuating between different states. 
Two binding pocket regions are responsible for the clustering: the Phe 122 side chain 
and the Ala 299 – Leu 300 loop region. The Phe 122 side chain flips between the two con-
formational states already seen in the other simulations (lower left part of  Figure 30). A 
feature unobserved in the nine other simulations are the large movements of Leu 300. It 
fluctuates between conformations which either open or close the specificity pocket (lower 
right picture in  Figure 30). Combinations of the conformations of these two flexible re-
gions are responsible for the clustering and the cross-correlation among the different clus-
ters. Obviously, removing the ligand from the open specificity pocket conformation intro-
duces a large perturbation into the system, thus inducing elevated levels of flexibility into 
this part of the enzyme. Whether this is an artifact of the setup procedure or of any mean-
ing in terms of dynamic properties of this part of the enzyme is difficult to decide a priori. 
The fact that these kinds of motions are not seen in the other two holo simulations suggests 
that the sampling is dependent on the selected start geometry. However, given a simulation 
duration of 6 ns, a fully converged sampling of the phase space of a system of this size 
cannot be expected. 
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Figure 30: Overview over the MD simulation of holo (idd594). Left: snapshots represent-
ing the conformational sampling over the time course of the simulation: 20 (green), 100  
(light blue), 185 (magenta), 300 (yellow), 420 (salmon), 550 (dark blue), 590 (orange)  
Right: snapshots depicting the elevated flexibility of Leu 300 and the neighboring back-
bone (the same snapshots are used).
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Summarizing the results
Analyzing the individual MD simulations in a sequential order is a first step to trace the 
dynamical properties of the protein. However, considering multiple MD simulations from a 
comparative point of  view it  becomes difficult  to keep track of  all  individual changes 
found in single simulations. Additionally, one of the aims of an MD study should be to cor-
relate observations during MD simulations with evidence for dynamic behavior indicated 
in the crystal structures (summarized in Figure 31). To facilitate comparison of the results 
from the crystal structure analysis and the findings from the MD trajectories in terms of 
flexibility of different parts of the binding pocket,  Figure 32 gives an overview over the 
structural changes observed for the 10 MD simulations discussed above. The information 
about the multiplicity of different conformational states adopted in different crystal struc-
tures is color coded in the 2d representation of the individual amino acids, whereas the 
summary of the observed flexibility within the MD simulations is represented by the his-
tograms (see legend of Figure 32).
A good overall agreement can be observed between the results from MD and crystal 
structure analysis. The residues comprising the catalytic pocket (Trp 20, Val 47, Tyr 48, 
Trp 79, His 110) superimpose very well in the crystal structures (see Figure 31) and show 
only minor mobility during the MD simulations. This holds true for either the complexes 
as well as the different holo simulations. Thus, this region of the binding pocket is struc-
turally very well conserved, independent of the type of ligand bound or whether no ligand 
is accommodated. 
Trp 111 is a crucial residue within the binding pocket of AR. It can be classified as part 
of the catalytic pocket as well as part of the specificity pocket. It superimposes very well 
for  all  crystal  structures  and shows low fluctuations  in  all  individual  MD simulations. 
However, if no ligand is bound, this residues shows an increased level of flexibility. It 
seems that interactions with bound ligands stabilize the position of this residue. These in-
teractions include a hydrogen bond to the polar head group of the inhibitor as well as an 
aromatic face-to-face stacking interaction with the part of the ligand addressing the speci-
ficity pocket. 
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Figure 31: Summary of the crystallographically observed conformations of binding site  
residues. The shown superpositions are based on the Relibase+ superposition of binding 
site residues used for the crystallographic analysis. For each binding site residue all con-
formations  from the  data  set  used  to  analyze  the  conformational  variability  of  each 
residue are shown. 
Among the residues bordering the distant part of the specificity pocket, Phe 115 and Thr 
113 show only minor movements. Phe 115 remains in position independent of the actual 
conformation adopted by the specificity pocket. For Thr 113 the side-chain torsion χ1 per-
sists in a small angular range over the course of the simulations. Only in case of the Pfizer 
compound the simulation reveals two distinct states of this torsion angle. This rotation is 
responsible for the elevated mobility indicated for Thr 113 in Figure 32. 
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Figure  32: Summary of the flexibility of binding-site residues. Shown are the amino  
acids which comprise the binding pocket. The individual amino acids are color-coded  
with respect to their flexibility observed from the crystal structure analysis. Residues  
with little differences between the single crystal structures are shown in blue, residues  
with moderate flexibility are colored yellow and, finally, the most flexible parts of the  
binding pocket are colored in red. The histograms show the average rms deviations re-
ferring to the parent crystal structure and the standard deviation of the rmsd fluctua-
tions as 'error bars'. Thus, large columns in the histogram indicate considerable differ-
ences compared to the crystal structure, whereas extensive 'error bars' indicate pro-
nounced fluctuations. 
Cys 303 and Tyr 309 show elevated levels of motion. Tyr 309 does not superimpose 
perfectly in the different crystal structures (see Figure 31). During the MD simulations it 
does not change its conformational state. The side-chain torsions are stable throughout the 
simulations. The reason for its elevated flexibility is the mobility of its main chain. This is 
not surprising since Tyr 309 is located at the C-terminal end of the protein chain, with Phe 
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315 being the final residue. The C-terminus of AR is often inappropriately defined in elec-
tron densities. 
Figure 33: Dialsplots of Cys 303 χ1 angle.  In dialsplots the radius of the circle rep-
resents the time axis and the position on the circumference the value for the torsional  
angle itself. The red line indicates the mean value throughout the whole simulation,  
whereas  the  green  line  gives  the  value  obtained  from the  corresponding  crystal  
structure.
For Cys 303, however, the situation is different. This residue shows multiple conform-
ers with repspect its χ1 torsional angle. In every simulation two distinct states for this tor-
sion are observed. They correspond to the two orientations observed in crystal structures. 
As indicated in Figure 33, the distribution between these two states varies from simulation 
to simulation. For the Pfizer compound and the 47d simulation the flipped conformation is 
present in the majority of the snapshots. For the zopolrestat complex simulation three states 
are sampled for a short period of time. This indicates that different inhibitors allow differ-
ent amounts of flexibility in the distant part of the specificity pocket. However, no straight-
forward explanation can be given to rationalize these differences. The torsional changes of 
the side-chain are the explanation for the increased flexibility of this residue.
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Phe 122 shows a much higher degree of flexibility in the MD simulations than one 
would anticipate simply considering the conformational scatter in the crystal structures. As 
can be seen from Figure 31 the side-chain of Phe 122 does move in the superimposed crys-
tal structures to adapt to the bound ligand. However, these adjustments do not lead to ma-
jor differences in the torsional angles of the side-chains. Concerning the fluctuations in the 
MD simulations the situation is different. The large rmsd values and standard deviations 
apparent in Figure 32 indicate already that the movements of this residue are substantially 
larger than the scatter indicated by the different crystal structures. 
Figure 34 presents the χ1 angle of Phe 122 of all MD simulations as dialsplots. For each 
of the simulations, two rotameric states of this dihedral angle are sampled.  One corre-
sponds to the value observed in the crystal structures (green line), the other corresponds to 
the flipped conformation already discussed for the individual MD trajectories. In the case 
of 47d and the holo (idd 594) simulations three distinct rotameric states are sampled. How-
ever, the population of the single states along the trajectory differs. For the simulations of 
the Pfizer compound and holo (tolrestat) the flipped conformation is only rarely sampled, 
whereas for zopolrestat and holo (sorbinil) the flipped conformation is retained for almost 
the whole simulation. In the other simulations transitions between both states occur with 
Figure 34: Dialsplots of the χ1 angle of Phe 122 in all MD simulations. The data pre-
sentation is in analogy to Figure 33.
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varying frequency. In summary, this residue shows surprisingly high flexibility whether a 
ligand is bound or not. 
Figure 35: Dialsplots of the backbone torsions of the loop from Cys 298 to  
Leu 300. The data presentation is in analogy to Figure 33.
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Another residue with deviating properties between MD simulations and observed data 
scatter in crystal structures is Trp 219. As apparent in Figure 31, the Trp 219 side and main 
chain superimpose well for all holo and complex structures. Neither large movements in 
torsional space nor significant overall movements of the whole side-chain can be moni-
tored for this residue. However, as shown by Bohren et.  al.34,  the Cα atom of Trp 219 
moves by as much as 17 Å between apo and holo forms of the enzyme. This mobility is es-
sential for the function of the enzyme, since the 'cofactor safety belt' loop extending from 
residues 214 to 226 has to shift in order to enable the exchange of the cofactor after com-
pletion of the reaction cycle. Kinetic studies suggest that the exchange of NADP+ is the 
rate limiting step for one turn over of the enzyme38-40. Furthermore, considering the high 
affinity of the cofactor towards the enzyme (KdNADP(H) < 10nM181), it can be expected 
that movements of this magnitude occur on a time scale which is far beyond the scope of 
this study. However, the increased mobility of Trp 219 is an indication that the intrinsic 
flexibility of this part of the enzyme is to some extend covered by the simulations. 
As shown by the analysis of the available crystal structures, the part of the enzyme 
showing the highest degree of flexibility is the loop region from Cys 298 to Leu 300. This 
small  region determines the shape of the binding pocket and provokes the 'induced-fit' 
adaptations. Especially the backbone part of Ala 299 is essential for these adaptations. The 
high mobility of this region in the simulations has already been shown qualitatively for the 
individual simulations (see above). In order to perform a more quantitative analysis, Figure
35 plots the backbone torsion angles of the corresponding residues. These plots evidence 
pronounced flexibility for all considered torsion angles. Different states can be seen for the 
separate simulations, but also the overall picture of all simulations suggests similar find-
ings. Mostly they are adopted in consequence of the different binding modes of the in-
hibitors. Generally speaking, the two outermost dihedrals (φ Cys 298, ψ Leu 300) tend to 
be less scattered than the inner ones. Considering the inner dihedrals it becomes obvious 
that the ψ angles change in correlated fashion with the corresponding φ angles of the fol-
lowing residue. In many cases the proceeding φ angle shows anti-correlated movements to 
the ψ angles or vice versa canceling out the total rotation of the chain. Thus, the overall 
side-chain orientations of the respective residues are retained, while the backbone itself is 
allowed to flip. Furthermore, it becomes evident that different inhibitors allow a different 
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degree of flexibility within this region. In the case of sorbinil, which binds to the closed 
form of the specificity pocket, the backbone shows the least amount of flexibility. This is 
also reflected in the holo (sorbinil) simulation. Thus, one can conclude that flexibility of 
this loop is reduced once the specificity pocket is closed. This finding is underlined by the 
available crystal structures. Figure 36 shows a superposition of all available crystal struc-
tures where the specificity pocket is in a closed conformation. For each of these examples 
the backbone adopts the same conformation. Obviously, one preferred conformation exists 
for the closed form of the specificity pocket, however, if the specificity pocket is opened 
conformational variability in this region is intensified. 
Figure  36:  Superposition  of  all  crystal  structures  which  either  have  no  ligand 
bound or where the ligand binds to the closed specificity pocket conformation. All  
structures superimpose very well and especially in the backbone there is almost no  
conformational variability to be registered. 
The simulation of the tolrestat complex exhibits an unique behavior of this backbone 
stretch. The usually quite flexible torsions ψ Ala 299 and φ Leu 300 are exceptionally sta-
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ble over the course of this simulation, whereas the two backbone torsions of Cys 298 and φ 
Ala 299 are the most flexible ones compared to all other complex simulations. It seems that 
the unique side-chain conformation of Leu 300 imposes different restraints on the back-
bone which do not allow the same degree of flexibility as observed with other inhibitors. 
Analyzing the behavior of this backbone portion for the different holo simulations, it 
can be noticed that there are distinct differences depending on the starting geometry. As al-
ready mentioned, the conformations sampled for holo (sorbinil) confirm the ones observed 
in the sorbinil complex simulation and they are in agreement with the crystal structures.
However, for the cases of holo (tolrestat) and holo (idd 594) this part of the backbone is 
in a different conformation throughout the trajectories. Additionally, the observed flexibili-
ty is higher. Thus, it seems that on the time scale of several nanoseconds the sampling is 
different depending on the starting geometry, even if the movements involved are side-
chain movements and small shifts of the backbone. 
Figure 37: Dialsplots for the Cys 298 Chi 1 side-chain angle. The data presentation 
is in analogy to Figure 33.
To further examine the flexibility of this region, it is instructive to also include the side 
chains into the analysis. For Cys 298 (Figure 37) it can be observed that the side chain 
shows variability in most simulations. Two different conformers are sampled in most of the 
cases (one in case of 47d, three for holo (sorbinil)). This finding is in agreement with ob-
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servations from crystal structures. For example, in the ultra-high resolution structure of 
idd 594114 Cys 298 shows a double conformation. The decreased flexibility of this torsion 
angle in case of 47d can be rationalized with the fact that the ligand places a carbonyl 
group next to the spatial position of Cys 298, thus prohibiting a flip of this side chain.
The last interesting residue within this region is Leu 300. The two side-chain torsions of 
this residue are depicted in Figure 38. For most complex and holo simulations the χ1 angle 
of Leu 300 is stable throughout the trajectories. Again tolrestat is the exception. Within 
both the complex as well as the holo simulation of tolrestat the χ1 angle shows a consider-
able amount of flexibility. Again this behavior can be rationalized using findings from the 
crystal structure. Figure 39 A shows the inhibitor and the backbone region under consider-
ation together with the experimental electron density from synchrotron data (1.08 Å resolu-
tion)126. The 2FoFc density, contoured at 2σ, is shown in blue. At this contour level, all 
atoms of the inhibitor are well defined. This also holds true for most of the protein atoms in 
the region of the flexible C-terminal loop. However, the electron density for the side-chain 
atoms of Leu 300 is only poorly visible. This might indicate higher residual mobility or 
distribution over multiple states of this side chain. 
For the χ2 angle of Leu 300 different states are sampled. However, in this case the dif-
ferences between individual states are not crucial for ligand binding. A rotation about the 
χ2  angle  corresponds  to  a  rotation  of  the  terminal  branched hydrophobic  moiety  of  a 
leucine combined with slight adjustments of the position of the side chain. Nevertheless, 
overall conserved properties are exposed towards a bound ligand. Also in this case, the MD 
findings are in agreement with crystallographic evidence. Figure 39 B shows a superposi-
tion of the structures of human (9tol, green) and porcine (1ah3, silver) AR in complex with 
tolrestat. One can clearly see the difference in the Leu 300 χ2 angle. However, for a medi-
um resolution structure such as 1ah3 (2.30 Å) it remains questionable whether the position 
of this side-chain can be determined undoubtedly. In addition, this rotation about the Leu 
300 χ2 torsion can also be registered comparings structures with different inhibitors bound. 
Thus, the flexibility observed in the MD simulations for different inhibitors is not unrea-
sonable. 
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Figure  38: Dialsplots of the Chi1 and Chi2 torsional angles of Leu 300. The data  
presentation is in analogy to Figure 33.
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Figure 39: A shows the 2Fo-Fc electron density contoured at 2 sigma for the inhibitor  
tolrestat and the flexible C-terminal loop region. The side-chain atoms of Leu 300 are  
only poorly defined in the electron density, thus implying residual mobility of this side  
chain. B depicts the superposition of human (green) and porcine (silver) AR complex  
structure of tolrestat where a different side chain conformation caused by a rotation  
around the χ2 has been assigned to the electron density.
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Summarizing the previous analyses of the MD trajectories in general four regions in and 
next to the binding pocket are apparent showing considerable amount of mobility: Trp 219 
and the cofactor safety belt (i), Phe 122 and adjacent residues (ii), the distant part of the 
specificity pocket comprising Cys 303 and Tyr 309 (iii), and the loop region responsible 
for the 'induced-fit' adaptations ranging from Cys 298 to Leu 300 (iv). In the latter case the 
observed flexibility is in agreement with conclusions drawn from the comparative analysis 
of the available crystal  structures. Knowing that conformational variability observed in 
MD simulations and crystal structures cannot be compared on a quantitative scale, the flex-
ibility of the first three portions is more pronounced in the MD simulations than expected 
from the superposition of the X-ray structures. Thus, the question arises whether the move-
ments seen in the simulations corroborate experimental findings or whether they strongly 
exaggerate the situation due to artifacts in the applied force fields or insufficient relaxation 
of the geometries. 
The facts that protein structures derived from diffraction experiments represent both 
spatial and temporal averages which are measured at rather low temperature has already 
been addressed above. Another factor which can take substantial influence on the confor-
mations of the protein residues are contacts formed between individual molecules in the 
crystal packing. Due to the dense, symmetric and repetitive packing of molecules in crys-
tals,  contacts  between  symmetry-related  protein  molecules  are  formed.  These  contacts 
most likely do not occur if the protein is in solution under physiological conditions. Thus, 
it is instructive to study in more detail the properties for the different structures which 
serve as starting points for the MD simulations. 
A  crystal  packing  analysis  is  presented  in  Figure  40.  It  was  carried  out  using  the 
AreaIMol182 module of ccp4i183. All parameter settings were kept at the implemented stan-
dard values. The probe radius for the water molecule was set to 1.4 Å. The seven protein-
ligand complexes (sorbinil, tolrestat, idd594, Pfizer compound, 47d, zopolrestat, JFD com-
pound) which were used as input structures for the MD simulations were examined. The 
program computes the solvent accessible surface area (SASA) for each residue within the 
protein. Then the packing environment is generated and the SASA is recalculated for each 
residue. Atoms for which the SASA is smaller within the packing environment than for the 
isolated protein are indicated by blue spheres in Figure 40. Using this visualization tool, it 
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is possible to qualitatively assess which atoms are involved in crystal contacts. However, 
no quantitative conclusions about the type or strength of the involved interactions can be 
extracted from these diagramms. 
For six of the seven complexes at least one of the ligand atoms is involved in contact 
formation  to  symmetry-related  protein  molecules.  Only  the  JFD  compound  does  not 
change its SASA due to crystal packing. In case of the Pfizer compound only one atom is 
affected. Two atoms are involved in 47d, whereas sorbinil, idd594, and zopolrestat show 
differences for three atoms. Tolrestat reduces its SASA at four ligand atoms in the packing. 
These findings give a first idea that packing effects occur next to the binding pocket which 
might influence the conformations and/or flexibilities of some of the binding-site residues.
Three regions next to the binding pocket should be considered in detail. The first is Trp 
219 and the adjacent loop region, corresponding to the 'cofactor safety belt'. Only a few 
atoms of this loop are involved in crystal contacts. In fact, the temperature factors are rela-
tively high for the entire loop. Trp 219 is the only residue which is located directly at the 
binding pocket. Interestingly, in six of the seven complexes at least one atom of Trp 219 is 
forming crystal contacts. 
The second area of interest is adjacent to Phe 122. Glu 120, Phe 121, and Phe 122 form 
crystal contacts in all structures of the dataset. For Glu 120 and Phe 121, almost all atoms 
are affected, but also Phe 122 shows differences for main-chain and side-chain atoms in all 
cases. Many amino acids of the highly solvent-exposed loop proceeding Phe 122 in se-
quence are strongly involved in crystal packing effects. However, as for the cofactor safety 
belt, the B-factors for the residues in this region are in general noticeably higher than for 
the rest of the protein. Therefore, the positions of the side chains are less accurately de-
fined by the electron density obtained from the X-ray experiment. 
Spatially adjacent to this loop is the third interesting part: the small loop to which Tyr 
309 is attached. The side chain of Tyr 309 points towards the flexible loop next to Leu 300 
which mainly determines the binding pocket conformation. Tyr 309 itself is not directly in-
volved in crystal packing. However, the residues preceding Tyr 309 in sequence are affect-
ed in all cases. 
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Figure 40: Visualization of crystal contacts formed by the complexes used as MD start-
ing structures. Proteins are shown in cartoon view, the binding-side residues are shown  
as yellow sticks and the corresponding ligands are shown as silver sticks. Atoms reduc-
ing their solvent accessible surface area (SASA) in the crystal packing compared to with  
the isolated state are shown as blue spheres. Regions of special interest (see text) are en-
closed by oval shapes.
The loop region neighboring Leu 300 is not involved in crystal packing. The only ex-
ception is the 47d complex where the CD2 atom of Leu 300 reduces its SASA due to crys-
tal packing. 
In conclusion, crystal packing clearly affects residues directly adjacent to the binding 
pocket. While it is difficult to assess their influence on flexibility and thus on the accessi-
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ble conformational space of each individual amino acids, it cannot be ignored that some re-
gions might be artificially constrained to evolve their inherent flexibility or they are possi-
bly forced to adopt conformations which are not the preferred ones in solution.
Thus, there are good arguments to believe that the flexibilities noticed in the MD simu-
lations may be larger and different from those observed in the crystal structures. Further-
more, they possibly reflect the fact that during MD simulations the protein is examined in a 
different environment than in the X-ray experiment.
Implications for the binding pocket
Changes in torsion angles take predominantly local influences on the direct neighborhood 
of the involved residues. However, depending on the location and function of the affected 
residues, these changes can have dramatic effects on the total binding pocket. This is illus-
trated by the mobility of the Ala 299/Leu 300 backbone. Via local movements of the main 
chain, a new sub-pocket is created which alters the overall shape of the binding pocket 
quite dramatically. Considering the entire binding pocket, the question arises, how the flex-
ibilities observed in the MD simulations can influence the overall shape and properties of 
the binding pocket of AR. Are pocket conformations generated which have not yet been 
seen in crystal structures? If so, can these pocket conformations be exploited for structure-
based drug design projects, i.e. can they be addressed (and stabilized) by new inhibitors?
To answer the first question, it is necessary to analyze the effects that the four regions of 
elevated mobility (Trp 219, Phe 122, Tyr 309/Cys 303, and Ala 299/Leu 300) have on the 
overall morphology of the binding pocket.
Trp 219 borders the entry of the binding pocket and is a solvent-exposed residue. Fluc-
tuations recorded during the MDs drive this residue away from the ligand positions as seen 
in the crystal structures. However, no additional sub-pocket is generated which possibly 
could be addressed by potential ligands. Therefore, this part of the binding pocket is proba-
bly not a good candidate to explore novel binding pocket conformations. 
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Figure 41: Time course of the distance between the ring centers of Trp 79 and Phe 122  
for the individual trajectories. The value measured from the respective crystal structure  
is given as green line. Values are presented as running averages using a time window of  
20 frames (10 ps). Thus, the local fluctuations are smoothed and short term transitions  
between subsequent frames are canceled out. Maximum distances observed in each simu-
lation are given. 
The situation is different for Phe 122. Once its χ1 angle adopts the flipped orientation 
found in all simulations, an additionally expanded hydrophobic specificity pocket is pro-
duced directly above the ligand binding site. This new sub-pocket is bordered by Trp 79, 
Phe 115, and Phe 122. The distance between the ring centers of Trp 79 and Phe 122 is plot-
ted in Figure 41 for all studied simulations. The distance between the ring centers of these 
residues in crystal structures is about 5.4 – 5.7 Å. In the flipped conformation this distance 
expands tomaximally 9.8 Å.  Figure 42 shows the binding pocket with open specificity 
pocket and Phe 122 in flipped conformation. Trp 79 closes up the specificity pocket and in 
flipped orientation Phe 122 gives additional space between Phe 122 and Trp 79. 
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Figure 42: Binding pocket with open specificity pocket and Phe 122 in flipped conforma-
tion. The three residues aligning a small hydrophobic expansion of the pocket are shown 
in blue, the cofactor is depicted in green. All other binding site residues are shown in yel-
low. 
The last two regions of interest, Tyr 309 and the C-terminal loop region around Ala 299 
and Leu 300, have to be viewed as an assembly. As already mentioned, for Tyr 309 no ma-
jor torsional flexibility can be detected. Instead, a rigid body type movement of the residue 
as a whole can be observed. Thus, it is instructive to analyze the distance between the OH 
group of Tyr 309 and the Cα atom of Leu 300 to study whether concerted movements of 
these two residues alter the shape of the binding pocket. 
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Figure  43: Distance between Leu 300 and Tyr 309. The structure is viewed from top  
where the ligand is located. The picture was taken from the Pfizer compound crystal  
structure.
Figure 43 shows the residues from viewed from within the binding pocket, where ligands 
are placed. If the distance between them is enlarged, additional space is created 'below' the 
ligand. In  Figure 44 this distance is plotted over the course of the simulations. It can be 
seen that this distance shows great variations within some of the individual simulations, but 
also between different simulations. The movements of Leu 300 are in all cases larger than 
the ones observed for Tyr 309, thus, the fluctuations of Leu 300 within the single simula-
tions play an important role for this distance. This partially explains the low variations in 
the course of the sorbinil and holo (sorbinil) simulations where movements of Leu 300 are 
rather moderate. However, the movements of Leu 300 do not fully explain the differences 
in the Leu 300 – Tyr 309 distance seen in Figure 44. For some of the simulations the dis-
tance increases to values as large as 10 Å. Tyr 309 partly confines the binding pocket be-
low the respective ligand addressing the specificity pocket. Therefore, if Tyr 309 moves 
apart from the Leu 300 position, additional space is created, which is located below the 
part of the specificity pocket usually addressed by ligands. 
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Figure 44: Plots of the distance between OH of Tyr 309 and Cα of Leu 300 for the individ-
ual MD simulations. The distance value measured from the crystal structure is indicated  
by a green line. As in Figure 41, values are presented as running averages using a time 
window of 20 frames (10 ps). The maximum values observed for each simulation are giv-
en.
In summary, two interesting changes of the AR binding pocket might create additional 
space to host putative ligands. Above the specificity pocket additional space is established 
via the rotation of the Phe 122 side-chain and below the specificity pocket the same is pos-
sible through concerted movements of Tyr 309 and Leu 300 relative to each other. 
Addressing the new binding pocket conformations
Exploring the available conformational space of the AR binding pocket by comparative 
MD simulations has revealed potential new binding pocket conformations compared to the 
ones observed in crystal structures. However, no matter how careful the analysis of MD 
trajectories is carried out and how deliberate the results are interpreted, findings from MD 
simulations remain hypothetical as long as they are not supported by experimental observa-
tions.
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One way to provide evidence for the suggested findings from MD simulations is to collect 
experimental results from crystal structures. For many of the findings discussed in the pre-
vious sections this has been done and it was shown that MD simulations are in good agree-
ment with the observations from crystal structures. However, considering novel binding 
pocket conformers suggested by MD one runs into the problem, that there are no crystal 
structures to support the findings. Thus, the ultimate goal for such a study would be to find 
small molecules which bind to AR in a binding mode which stabilizes the binding pocket 
in one of the predicted new conformations. However, one will be faced with multiple chal-
lenges that need to be resolved. The first is to identify a snapshot from the MD simulation 
which is suitable for the subsequent docking and scoring step. The second problem is to 
find a suitable ligand scaffold which binds to AR with sufficient affinity. In addition, the 
scaffold has to allow ready accessible synthetic modifications at the positions which are 
suitable to address the putative new binding pocket conformations.
Figure 45: Molecules from the Pfizer inhibitor series published in 2005. IC50 values 
were taken from the publication by Mylari et al.184.
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Figure 46: Crystal structure of the Pfizer compound 1 is shown in A. For B, the phenyl  
moiety of molecule 4 from Figure 44 was manually placed into the crystal structure of 1.  
In C, a hypothetical flipped binding mode is shown, which was achieved by simply rotat-
ing the moiety addressing the specificity pocket. Regions where the hypothetical binding  
modes clash with the protein are shown in light gray.
In 2005 Pfizer published184 additional information about the ligand series from which 
the Pfizer compound used in this study emerged as the most potent AR inhibitor. The paper 
disclosed additional ligands (Figure 45, molecules  2,  3, and  4) which possess larger hy-
drophobic substituents in the position where the original Pfizer compound  1 exhibits a 
methyl group. As depicted in Figure 46 A, this group points towards the backbone of Cys 
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298 and Ala 299, a region which is known to be highly flexible. For molecules 2, 3, and 4 
the published IC50 (Figure 45) are only slightly higher than for  1. However, the binding 
modes of these ligands cannot be simply supposed as equal to compound 1. In Figure 46 B, 
the phenyl moiety of 4 has been manually added to the crystal structure of 1. As immedi-
ately obvious major clashes would be experienced between the phenyl moiety of the ligand 
and the protein backbone. As putative alternative binding mode a flipped conformation of 
the aromatic ring system of the ligand is suggested, which would place the phenyl ring in 
opposite direction. However, this would create major clashes with the residues Trp 79 and 
Phe 122, as shown in Figure 46 C. Thus, the Pfizer phenyl derivative 4 appears incompati-
ble with the binding mode of the original Pfizer compound 1. 
To investigate the compatibility of 4 with the confirmed AR protein conformers, dock-
ing experiments were carried out using AutoDock122 following the 'in-situ' cross-docking 
approach124;168.
The binding pockets of sorbinil, tolrestat and idd594 which are good representatives for 
the three major binding-pocket conformations, were used to compile the pasted grid. Hun-
dred runs of the genetic algorithm were carried out using a population size of 50 and allow-
ing for a maximum of 1500000 energy evaluations. These settings have proven to be suc-
cessful in predicting the correct binding mode of the original Pfizer inhibitor using exactly 
the same grid setup168.  The 19 best-scored solutions address the idd 594 pocket  which 
shows a conformation very similar to the pocket of 1. However, as shown in Figure 47 the 
docking solutions suggest a reversed binding mode. The phenyl moiety points into the cat-
alytic sub-pocket and the polar pyridazinon head group addresses the specificity pocket. 
Such a  binding mode does not  satisfy any of  the well-established interactions patterns 
found for AR inhibitors and is indeed very unlikely according to current knowledge about 
AR. It also underlines that automated docking can be quite misleading and must be rigor-
ously validated.
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Figure  47: Proposed binding mode for the 19 best scored docking solution of the  
'in-situ' cross docking carried out with the phenyl Pfizer compound into the binding  
pockets of sorbinil, tolrestat, and idd 594. 
Not all solutions were found in the idd 594 pocket, the tolrestat and sorbinil pocket were 
also addressed. As expected, the docking poses in these pocket conformations were even 
less convincing than the ones in the idd 594 pocket. In summary, none of the docking pos-
es found for 4 satisfies the known interaction patterns for binding to the enzyme. 
As a next step 4 was docked into the crystal structure of compound 1. The similarity be-
tween the two parent structures of the Pfizer compound and idd 594 in the crystalline phase 
are very high (Figure 48). Especially in the region of special interest, the flexible loop re-
gion next to Leu 300, the conformations are almost identical. Nevertheless different dock-
ing results are produced. 
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Figure 48: Superposition of the binding pockets of the Pfizer compound (silver) and 
idd 594 (green). Only subtle differences can be seen in the region around Leu 300. 
The docking solutions on rank 1 to 5 are again not in agreement with present knowledge 
about reasonable binding modes in AR. The pyridazinon moiety is not placed into the cat-
alytic pocket in a way to form essential hydrogen bonds with the protein. Figure 49 shows 
a docking solution which is found twice on position 6 and 7 out of 50 runs with the same 
settings as applied above. At first glance, this proposed solution is more in line with the ex-
pected binding mode of AR inhibitors. The pyridazinone moiety addresses the catalytic 
pocket and the aromatic moiety points into the specificity pocket. However, there are sev-
eral issues which have to be considered while assessing this docking solution. In order to 
place the large phenyl moiety the sulfone group has to move upwards compared to the 
crystallographically studied methyl derivative. As a result, the 'upper' oxygen of the sul-
fone group and the furan ring show short contacts (2.9 and 2.8 Å) with the Phe 122 side 
chain. In addition, the phenyl ring shows short contacts with the Ala 299 main-chain oxy-
gen (2.7 Å) and the side chain of Trp 219 (2.9 Å). The most severe clash occurs with the 
bulky sulfur atom of Cys 298, which is in only 2.8 Å distance. Thus, the docking solution 
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might propose a possible binding mode, but in order to accommodate the ligand, additional 
movements of the protein are necessary. 
Figure 49: Rank 6 docking solution from docking the Pfizer phenyl derivative 4 into  
the crystal structure of the original Pfizer methyl derivative 1. 
According to the different MD simulations, the region next to Leu 300 shows elevated 
flexibility. Thus, there might be the possibility that during the simulations conformations 
are sampled which provide more space to better accommodate  4 than the parent crystal 
structure of 1. 
Figure 50 shows a superposition of a snapshot from the trajectory performed on the 
crystalline complex of 1 together with the parent crystal structure. This snapshot shows pri-
marily two interesting features: on the one hand, the side-chain of Phe 122 is in a flipped 
conformation and, on the other hand, the distance between Tyr 309 and Ala 299/Leu 300 is 
increased. 
Extending charted space: comparative MD simulations of Aldose Reductase 115
Figure 50: Superposition of an MD snapshot (white) from a simulation with 1 and the 
parent crystal structure (green). Phe 122 is in flipped conformation and distance be-
tween Tyr 309 and Leu 300/ Ala 299 is enlarged. 
Using a pocket conformer generated by MD as input for a docking study with the aim to 
find a putative inhibitor for this new binding pocket conformation is a complex task. On 
the one hand, the selected snapshot should be significantly different from the conforma-
tions seen in known crystal structures. One the other hand, the used conformation should 
not exhibit obviously unrealistic features. Therefore, a snapshot from the complex trajecto-
ry of the original Pfizer methyl derivative 1 was selected by visual inspection. Taking the 
snapshot from the trajectory of the simulation of the complex with 1 has the advantage that 
large parts of the ligands are identical in both cases and similar behavior of the binding 
pocket can be supposed.
The selected MD snapshot was used for docking of  4 using AutoDock with the same 
settings as described above. Results are shown in Figure 51. In this solution the sulfur atom 
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of the sulfone moves downwards to place the phenyl ring between Ala 299 and Tyr 309. 
As a consequence, the pyridazinone moiety also slightly shifts its position, but all impor-
tant hydrogen bonds between the polar head group and His 110, Trp 111, and Tyr 48 can 
still  be formed. For this docking solution no short contacts between ligand and protein 
atoms occur.
Figure 51: Solution from docking 4 into the MD snapshot derived from the complex 
simulation of 1.
Both solutions generated either from docking 4 into the crystal structure with 1 or into 
the MD derived snapshot, do not appear as perfect solutions. However, the latter solution 
based on the MD snapshot as input emerges as a plausible suggestion considering better 
the possible space provided by the conformational plasticity of the binding pocket.
Ligand 4 might be a candidate to stabilize the Ala 299/Leu 300 backbone in a confor-
mation up to now unprecedented in crystal structures. However, a second flexibility fea-
tures has been seen in the MD simulations: this concerns the flip of the Phe 122 side chain. 
To lock this flipped conformation in one orientation a ligand would be required that places 
a hydrophobic moiety into this region. However, in literature no such ligand has been de-
Extending charted space: comparative MD simulations of Aldose Reductase 117
scribed as AR inhibitor. As an alternative a ligand of known binding mode can be substi-
tuted in a way that the available space next to Phe 122 is sufficiently addressed and the de-
sired flip is enforced. 
To suggest a synthetically accessible candidate, a benzodiazepine scaffold (Figure 52 5) 
was chosen, which offers the possibility to introduce different substitution patterns in the 
two positions addressing both new putative binding pocket features: the Phe 122 side-chain 
flip and the Ala 299/Leu 300 main-chain movement. Benzodiazepines have shown in pre-
vious studies to inhibit AR with moderate affinity185. However, no crystal structure of a 
suitable benzodiazepine inhibitor bound to AR is yet available.
Figure 52 shows the proposed molecules. Molecules 6 to 9, as well as 10 and 11 are se-
ries of molecules with the same skeleton but linker chains of deviating length to connect 
the seven-membered ring and the carboxylate function. All molecules where docked into 
the structure of  1 and the corresponding snapshot  from the MD simulation of  1 using 
AutoDock with standard settings as described above. No suitable docking solutions could 
be found for docking into the crystal structure, whereas docking into the MD snapshot lead 
to promising results.  The docked conformations of the molecules exhibiting the longer 
linker chain showed better scored docking modes. However, adding the linker chain intro-
duces a stereo center into 5-9 and 12. The docking solutions unanimously suggest that the 
S-enantiomer should better satisfy the stereochemical requirements to bind to AR. 
After visual inspection the best docking results were obtained for 6 and 12 which differ 
only by an oxygen in the linker chain. As a representative, the best scored docking solution 
for 6 into the snapshot used for docking the Pfizer phenyl derivative 4 is presented in Fig-
ure 53. As can be seen, the carboxylic acid head group addresses the catalytic site, whereas 
the benzodiazepine scaffold binds to the specificity pocket and two of the phenyl rings ad-
dress the new binding pocket features. 
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Figure 52: Proposed benzodiazepine-type AR inhibitors which possibly address the  
expanded binding pocket of AR. 
The only molecule synthesized and tested so far is the racemate of  5 which shows an 
IC50 value of ~700 μM. However, this value has to be regarded with some caution, since 
the assay is not designed to measure inhibition at this low affinity range. Furthermore, due 
to the low amount of substance (~1 mg) which was obtained from synthesis and the thus 
only achievable low molar concentrations applied under the assay conditions, the standard 
deviation for this IC50 determination is of approximately the same size as the value itself. 
In addition, the compound was produced as trifluoro-acetate salt and it cannot be ruled out 
whether the weak inhibition is caused by the anion rather than 1 itself. 
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Figure 53: Docking solution of a benzodiazepine like molecule in an MD snapshot of  
the Pfizer compound complex simulation. 
Upon summarizing this manuscript, a further crystal structure of AR in complex with a 
benzodiazepine-type inhibitor (Figure 54) was solved186. This compound was published by 
Klebe et al. as a result from a virtual screening. In this complex the χ1 angle of Phe 122 is 
rotated to almost to the flipped orientation to partly match the conformation seen in the 
MDs, thus this is the first experimental indication that this Phe 122 orientation is indeed 
possible. However, the crystal structure does not perfectly match the conformations seen in 
the MD simulations. The flip of the Phe 122 side chain does not result in the suggested 
opening of an additional sub-pocket in this region. Instead the Phe 122 side chain stills 
forms contacts with Trp 79. Crystals suitable for structure determination could only be ob-
tained using cocrystallization techniques, soaking the compound into preformed crystals 
failed. Due to the different space group (P1 for cocrystallization compared to P21 usually 
obtained from soaking experiments) the crystal packing in the neighborhood of Phe 122 is 
different. This gives an indication that indeed crystal packing effects might be determinant 
in restricting Phe 122 in the conformation usually seen in crystal structures.
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Figure 54: Benzodiazepine-type inhibitor234 which induces a conformation-
al change of Phe 122 similar to the ones observed in the MD simulations.
However, despite promising docking results and initial indications from a crystal struc-
ture, the experimental validation for the new binding pocket conformers indicated by MD 
simulations is still to be provided and remains as a goal for the future of the project.
Summary and Conclusions
The conformational space available to the enzyme AR has been investigated by compara-
tive crystal structure analysis and ten different MD simulations (seven different complexes 
plus three additional simulations of the holo enzyme starting from different pocket confor-
mations). Compared a previous analysis of crystal structures of AR, many new high quality 
structures have been deposited with the PDB and several in-house structures have been de-
termined. The analysis of the available crystal structures included only structures of the hu-
man enzyme, any mutated species have been discarded. Based on these crystal structures, 
the overall properties of the binding pocket of AR have been analyzed. The binding pocket 
can be divided into two sub-pockets: the catalytic and the specificity pocket. The catalytic 
sub-pocket shows almost no flexibility and the spatial positions of the individual residues 
are very well conserved between the distinct crystal structures. However, AR exhibits an 
'induced-fit' binding mechanism to accommodate structurally deviating ligands. The speci-
ficity pocket can either be opened in two major conformations or entirely closed. Only a 
few residues of a flexible loop region next to Ala 299/Leu 300 are involved to produce the 
different pocket conformations. 
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A more detailed analysis of the structures exhibiting the same overall binding mode and 
accessing one of the three major protein conformers showed that despite the high similari-
ties of the structures there are subtle difference between the individual structures which 
make them incompatible to each other in the majority of the cases. In light of docking at-
tempts these findings are rather obstructive results. They provide the important message 
that docking has to consider conformational adaptability of the protein to produce success-
felly relevant binding modes. The protein conformation adopted with the inhibitor tolrestat 
has shown to be unique and requires the largest amount of adaptations compared to the 
holo structure. 
The comparative analysis of the ten MD simulations showed an overall good agreement 
with the findings from the crystal structure analysis in terms of conformational variability 
in different parts of the binding pocket. The residues within the catalytic pocket showed 
only minor thermal motions and do not indicate conformational flexibilty. For residues 
where fluctuations have been recorded in the MDs, this flexibility was in agreement with 
the crystal structure analysis in the majority of cases. Phe 122, Trp 219, and Tyr 309 exhib-
ited conformational changes in the MD simulations which are not observed in the crystal 
structures. In case of Phe 122 and Tyr 309 this was to some degree attributed to contacts 
formed between symmetry-related molecules in the crystal-packing environment, which 
probably imposes additional restraints on these regions compared to the simulations which 
are carried out under conditions to reflect the properties in solution. For Trp 219 huge mo-
tions can be seen between crystal structures of the apo and holo form of AR. Thus, these 
motions indicated by MD are likely to be reasonable also with respect to the required open-
ing of the cofactor binding pocket upon exchange of NADP+/NADPH. 
The movements of Phe 122 one the one hand, and the combined movements of Tyr 309 
and Ala 299/ Leu 300 suggested binding pocket conformations which have not yet been 
observed in crystal structures. The docking experiments carried out to find small molecule 
inhibitors which stabilize these new binding pocket conformations led to reasonable bind-
ing modes. However, the experimental validation is still an ongoing project.
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AR test case
Introduction
Scoring functions for assessing protein-ligand binding affinities suffer from many deficien-
cies. They lack sound physico-chemical fundamentals and are inevitably based on many 
assumptions and simplifications. However, for many cases scoring of protein-ligand com-
plexes works reasonably well and many drug-design projects greatly benefited from their 
performance. The main advantage of scoring functions are their extremely low computa-
tional costs. Scoring a protein-ligand complex is a matter of seconds. Hence, they can be 
applied to large datasets and are therefore valuable at the stages of a drug development 
project where computational methods are typically used: finding of initial hits and their op-
timization to useful leads.
Throughout a structure-based drug design project scoring functions are typically faced 
with two different challenges: selecting a near-native binding geometry out of set of decoy 
conformations and predicting the binding free energy of a putative ligand. Concerning the 
discrimination between decoy docking poses and a near native binding geometry, recent 
scoring functions perform rather well. Up to 87% success rate187 can be achieved using as 
criterion to define a near-native docking pose a threshold of 2 Å rmsd with respect to the 
crystal structure. Concerning the prediction of binding constants for putative ligands, the 
accuracy of scoring functions has on the mean reached about one pKi unit deviation from 
the experimental value. Usually, regression-based scoring functions188 perform best for this 
task. The reason for this is that affinity information is included in the process of deriving 
these functions. 
However, scoring functions fail in many cases for a variety of reasons. On the one hand, 
a dependence of the success rate on the type of protein can be registered. One the other 
hand, more fundamental problems arise which prohibit scoring functions to succeed in ev-
ery case. From thermodynamics it is known that the formation of protein-ligand complexes 
is an equilibrium process. Assessing the involved energies based only on a single rigid 
structure of the bound state is not an adequate model for the process. Furthermore, impor-
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tant contributions to the free energy of binding of a ligand to a protein are often neglected 
or only rudimentary included in scoring functions. Among them are (de-)solvation and en-
tropic effects as well as conformational adaptations of protein and ligand upon complexa-
tion. The latter is especially important for proteins which are known to exhibit an 'induced-
fit' binding mechanism for different ligands. In many cases the only energy contribution to 
the free energy of binding considered by scoring functions is the interaction energy be-
tween protein and ligand. Sometimes an energy term which covers the conformational en-
ergy of the ligand is also included in the calculations. However, the conformational energy 
of the protein is rarely included, likely on purpose since there is no method available to 
even estimate this term within a readily available time frame. However, it is reasonable to 
assume that different binding pocket conformations differ in their free energies, and this 
fact would have to be considered when calculating binding affinities.
Methodology
Within the last decades several approaches to more rigorously calculate free energies of 
binding have been developed based on different levels of physical theory. These methods 
provide in many cases reliable results, however, at the cost of significantly increased com-
putational demands. Among these methods are: free energy perturbation (FEP)189, thermo-
dynamic integration (TI)190, ligand interaction energy (LIE) approaches191,  λ-dynamics192, 
and MM-PBSA. 
The MM-PBSA method introduced by Kollman and Case193 has probably gained the 
greatest interest in recent years. Its largest advantage over many of the other methods is 
probably its broad applicability. MM-PBSA combines force-field derived molecular me-
chanics (MM) energies, a continuum solvent Poisson-Boltzmann (PB) model for modeling 
polar solvation effects, and a solvent-accessible surface area (SA) dependent nonpolar sol-
vation term to obtain the absolute free energy G of a system. The binding free energy of a 
complex is computed using equation (1) (see Methods for details):
Gbinding=〈G complex〉−〈Greceptor 〉−〈Gligand 〉 . (1)
The angle brackets indicate averaging over an ensemble of different conformations. The 
corresponding trajectories are usually derived using explicit-solvent molecular dynamics 
(MD) simulations. In recent years, several publication have emerged, showing excellent 
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agreement between calculated and experimental binding affinities. The scope of these stud-
ies covers protein-protein194;195, protein-ligand196-203, RNA/DNA-ligand interactions204, pro-
tein folding205, or comparison of the stability of different DNA/RNA conformations206;207. 
As expected for such a broad spectrum of studies, these publications differ in many of the 
applied settings and parameters. Although there is no need to parameterize the method for 
every system under investigation, there are many settings can be adjusted in an MM-PBSA 
study.
Setup and workflow
The calculation and assessment of binding free energies using MM-PBSA can be rough-
ly divided into four steps: 
1) finding suitable starting structures for generating the ensemble;
2) sampling the conformational space of the system;
3) carrying out the actual MM-PBSA calculations;
4) evaluating the results. 
To obtain starting geometries for the MD simulations several approaches are possible. 
The most reliable method is to start from an experimentally derived X-ray structure for 
each system. This implies solving a crystal structure for each complex plus one structure 
for the apo/holo enzyme. A second method is to propose the starting geometries via com-
putational methods. Starting from an X-ray structure of the protein, the protein-ligand com-
plex structures are generated via computational methods such as docking, or, alternatively, 
the ligands are placed manually into the binding pocket. If no structure of the target protein 
is available, a modeled structure obtained from homology modeling is also a possible alter-
native. The reliability, however, decreases dramatically when moving from experimental 
structures to homology models and the quality of the latter strongly depend on the degree 
of homology between template and candidate structure. Of course, one has to distinguish 
between different types of studies. In many cases the only reasonable way is to start from a 
modeled complex structure. However, for test systems which serve as examples to evaluate 
a method, the only reasonable way is to start with crystal structures. 
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The second step in the MM-PBSA work flow, the calculation of the ensemble trajecto-
ries, introduces many more possible variations. Among them, the most important are: 
a) preparation of input files; 
b) choosing different simulation models and parameters;  
c) carrying out the simulations. 
The settings and parameters chosen here can have substantial impact on the results of 
MM-PBSA  calculations.  The  preparation  of  protein  structures  for  MD  simulations  is 
straightforward with most MD simulation packages. Consistent parameters and charges are 
available for every MD force field suitable to simulate proteins. The challenging part is the 
setup of the ligand(s) and/or cofactors. Despite some recent force field and program devel-
opments160, not every ligand structure can be setup in a consistent and automated fashion, 
due to the high structural diversity in small molecules. 
To establish consistent partial charges for the individual atoms of the ligand imposes 
one of the two most challenging tasks. For the Amber force field158, the RESP162 method is 
the most widely accepted approach to derive charges, which are consistent with the param-
eterization of the force field itself. Therefore, the electrostatic field around the ligand is 
calculated using ab-initio methods. After that, partial charges are assigned to the individual 
atoms in a restrained iterative procedure. The target function of the optimization is the ab-
initio electrostatic potential. The entire procedure is time consuming, not fully automated 
and requires access to an ab inito program, such as GAUSSIAN161. In the Amber program 
suite208 methods are available via the antechamber module;  they try to produce similar 
charges in shorter times without having to perform high-level ab-inito calculations. While 
usually providing similar results, they introduce additional inconsistencies into the setup 
procedure. 
The second problem of ligand preparation is the assignment of consistent force field pa-
rameters.  Especially  problematic  is  the  assignment  of  parameters  for  dihedral  angles, 
which usually have the highest impact on the accuracy of a simulation. Furthermore, man-
ual  parameterization  of  ligands  is  a  tedious  process,  prohibiting  application  to  large 
datasets. 
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Besides the force field parameters themselves, there are various other parameters and 
models to be chosen when preparing and setting up a system for MD calculations. Assign-
ment of the solvation procedure is one of these critical steps. Most MM-PBSA studies use 
explicit solvent models, where the solvent is represented by separate molecules. Alterna-
tively, implicit water models can be used, there the solvent is represented by a continuous 
medium with certain properties. The almost exclusively used model for generating MD tra-
jectories used for MM-PBSA is the TIP3P164 water model. To add water molecules to the 
system different approaches exist. The best choice is to embed the solute in a box of pre-
equilibrated water molecules with a sufficiently large margin of several Å around the so-
lute. To avoid edge effects, methods such as periodic boundary conditions can be utilized. 
A computationally less expensive solution is to use only a small cap of water molecules 
around the active site atoms of the solute. Solvent effects for the remaining part of the sys-
tem are modeled via a continuum approach. To prevent explicit water molecules from pen-
etrating into the area of implicit solvent, an additional force is added counteracting this be-
havior, but introducing a further non-physical component to the system. Problematic is also 
the treatment of the transition between the explicit water molecules and the implicit solva-
tion model. The computationally cheapest approach is to choose an implicit solvent model 
for the whole system. However, this approach is rarely applied in the context of MM-PB-
SA. 
Besides the treatment of the solvent, an appropriate setup of how to model the atoms of 
the solute is required. To save computational time, restraining some atoms in position is a 
commonly used strategy for MM-PBSA trajectories. To achieve thisvgoal, artificial forces 
are introduced, which lack any kind of physical justification. 
The treatment of non-bonded interactions and especially the electrostatic interactions is 
another important factor. For van-der-Waals interactions simple cutoff-based schemes are 
used. In principle, these schemes could also be applied to model electrostatic interactions 
at low computational costs. However, as electrostatic interactions decline very slowly with 
the interatomic distances, these arbitrarily defined cut-offs result  in non-negligible arti-
facts. Nowadays, Ewald summation methods (PME)167 are an elegant solution to circum-
vent most of these problems. However, not all MM-PBSA studies have used PME to cover 
electrostatic effects. 
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Besides assigning parameters and choosing a model, the procedure used to equilibrate 
the system and to run the simulations is of importance. In most cases, the system is first 
subjected to an energy minimization, followed by a short MD simulation in the pico-sec-
ond time range to equilibrate the system. 
Finally, the simulation period is crucial for obtaining meaningful results since represen-
tative ensembles for equilibrium thermodynamic properties can only be expected if a suffi-
cient time window is selected. Given the current computer power, simulation times in the 
low nano-second range are feasible for most simulations of macromolecular systems. As 
such periods are too short to record large-scale movements, e.g., of domains, analyses of 
systems governed by such large-scale motions have to be interpreted with sufficient cau-
tion.
Once the trajectories are calculated, the next step is to carry out the MM-PBSA calcula-
tions. Although in contrast to other free energy methods such as LIE191, no empirical pa-
rameterization is necessary, there are multiple options available to set up an MM-PBSA 
run. 
The most fundamental question is, whether the snapshots for complex, protein, and lig-
and are taken from one single trajectory or whether they are derived via separate simula-
tions. If conformational adaptation processes of either the protein or the ligand occur upon 
binding, taking the snapshots from separate trajectories is the only way to consider these 
effects. By using only one trajectory for all species involved, their corresponding confor-
mational spaces cannot be sampled independently. Hence, one of the main advantages of 
the method compared to single-structure scoring functions is lost: the ability to handle ap-
propriately 'induced-fit' effects. At first sight, the main advantage of the single-trajectory 
approach are the lower computational costs. If a series of calculations is anticipated for the 
same protein, however, this advantage diminishes, since the reference trajectory for the un-
complexed protein needs to be calculated only once and can later on be re-used for every 
calculation. Furthermore, as pointed out by Pearlman in his seminal study203, the calcula-
tion of the trajectories is not the only time-consuming step in an MM-PBSA study. The 
computation of the electrostatic contribution to the solvation energy via the Poisson-Boltz-
mann equation is also a computationally expensive process. In case of single-trajectory 
128 Evaluating MM-PBSA in case of a flexible binding pocket: the AR test case
sampling it needs to be re-done for every receptor trajectory, but for the separate trajectory 
approach the receptor trajectory needs to be processed only once. To reduce the computa-
tional costs required to solve the PB equation, methods using the Generalized Born (GB) 
approximation have also been used for MM-PB(GB)SA studies and compared with PB re-
sults209-211. 
A further computationally very expensive part of an MM-PBSA study is the estimation 
of the entropic contribution of the solute to the free energy of binding. Several different ap-
proaches are available to calculate this term212-215: normal mode analysis, quasi-harmonic 
analysis and the quasi-Gaussian approach. Only the first two are of relevance for biological 
macromolecules. The main difference between the two methods is that the matrix of the 
atomic fluctuations is in the first case the result of a normal mode analysis and only in the 
second (i.e. quasi-harmonic analysis) it is directly obtained from the MD trajectories. The 
advantage of quasi-harmonic analysis is that not only the harmonic contribution is taken 
into account. However, one will face inadequacies once the overall sampling of the differ-
ent microstates is poor, a situation that is quite likely to occur with large biological systems 
such as protein-ligand complexes.  Due to the very high computational costs, the calcula-
tion of entropic contributions is often omitted in MM-PBSA studies. For the sake of a rela-
tive ranking within a series of related ligands, this approximation is normally justified by 
the assumption that in these cases the entropic effects should be comparable in magnitude 
and, thus, negligible. However, exactly the same assumptions are made in using empirical 
scoring functions, thus one important relief to be recovered by sophisticated MM-PBSA 
calculations will be canceled. The number of snapshots used to estimate the entropic con-
tribution is significantly lower than for the remaining calculations. In addition, the calcula-
tions are often restrained to a spherical region around the binding pocket. The calculation 
of entropic effects is probably the most cucial and least satisfying part of MM-PBSA. 
The final step in an MM-PBSA study is the evaluation of the results. The procedure de-
pends on the aim of the study and the available data. Ideally, in test studies the computed 
results are compared to experimental data, available as Ki or ΔG values. For relative rank-
ing, IC50 values are also acceptable. However, since they are dependent on the exact assay 
conditions they should be treated with caution.
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Literature overview
Having these points in mind, a short summary of some selected publications dealing with 
MM-PBSA  shall  be  discussed  briefly.  Srinivasan  et  al.206 introduced  the  MM-PBSA 
method in its current form, although the basic approach had been described earlier216-222. 
The authors used MM-PBSA to computationally analyze the relative stability of the A and 
B form of DNA, RNA, and modified DNA sequences depending on different salt condi-
tions. The study is based on previous investigations223 where the authors were able to show 
that MD simulations starting with either of the possible starting geometries converged to 
the corresponding experimentally  preferred conformation.  The obtained results  were in 
good qualitative agreement with experimental findings. Since MM-PBSA provided inter-
pretable results in terms of partitioning the interaction energy into individual contributions, 
the authors were able to rationalize the different preferential helix formations depending on 
varying conditions. 
Massova et al.194 expanded the scope of the method to investigating protein-protein in-
teractions and introduced an extension to the method: computational alanine scanning. In 
this study, the binding of the oncoprotein Mdm2 to the tumor supressor protein p53 was 
analyzed. Again, the calculated binding free energies were in reasonable qualitative agree-
ment with experiment, independent whether single or separate trajectory sampling was ap-
plied. Starting from the wild-type, all 11 residues of a peptide derived from the Mdm2-
binding stretch of p53 were computationally mutated and the effects of these mutations on 
the binding free energy were analyzed. Instead of re-calculating the MD trajectory for each 
mutant, the mutations were performed in-place using only the wild-type trajectory. Along 
the binding peptide three hot-spot residues were known from experiment. Computationally 
mutating each of these consecutively resulted in large losses of the corresponding binding 
free energy. Thus, Massova et al. were able to show that the method is capable of identify-
ing key residues for protein-protein interactions.
Gohlke et al. published two papers209;210 presenting a study of protein-protein interac-
tions using Ras–Raf and Ras–RalGDS complexes. Alongside these studies the authors pre-
sented some seminal methodological improvements and validations of the method. Differ-
ent implicit  solvent  methods (Poisson-Boltzmann224;225,  Generalized Born226),  as  well  as 
normal mode and quasi-harmonic analysis to estimate the entropy of binding were com-
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pared.  Using MD simulations of unprecedented 10 ns length,  the convergence of MM-
PBSA calculations was evaluated and a systematic survey of the effects of different param-
eters and settings was carefully carried out. Furthermore, an improved implementation to 
decompose the free energy on a per-residue basis was introduced. Via comparing energetic 
and entropic contributions of interface and non-interface residues as well as investigating 
dynamic and conformational changes of hotspot residues upon complexation the driving 
forces and dynamics of protein-protein interactions were elucidated. 
Luo et al.195 took the approach one step further and used MM-PBSA to study protein-
protein interactions of structures derived by homology modeling. They studied the binding 
of NRG-1β and some of its mutant peptides to ErbB3 and ErbB4 receptors. MM-PBSA's 
computational alanine scanning method was used to map the contribution of each residue 
involved in the interaction. The accordingly obtained interaction maps were in good agree-
ment with data from experimental alanine scanning studies. Thus, the authors conclude that 
the homology models used were reliable and could be consulted to guide further experi-
ments. 
In 2006 Beà et al.227 used a combined MD and MM-PBSA study to investigate the ther-
modynamic driving forces of the chelate effect in cyclodextrin dimers. Five ns of MD tra-
jectories were collected, which, due to the smaller nature of the system, provided extensive 
sampling of the conformational space available to the system. Hence, the authors were able 
to present a good agreement between the experimental finding and the computational pre-
dictions that, in this case, the complexation is an enthalpy-driven process.
Kuhn and Kollman were the first to extend the method to protein-ligand interactions. 
They applied MM-PBSA to a set of nine ligands binding to Avidin196, which had been used 
previously228 to successfully calculate binding free energies using the LIE191 method. The 
range of binding free energies covered ~15 kcal/mol, and an impressive correlation coeffi-
cient of r2=0.92 was achieved using MM-PBSA. This was superior to the correlation of 
r2=0.55 obtained using the LIE method. Considering the individual contributions to the free 
energy of binding the authors proposed that the main driving force of complex formation in 
that case were favorable non-polar interactions. However, polar groups which did not find 
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adequate bonding partners in the protein compared to the uncomplexed situation in water 
contributed significantly unfavorably to the free energy of binding. 
In recent years, a rising interest in applying MM-PBSA to protein-ligand interactions 
could be observed in literature. Wang et al.197 successfully ranked a congeneric set of 12 
HIV-1 RT inhibitors. In addition, the authors were the first to use MM-PBSA to assess the 
correct binding mode in a docking experiment of a small molecule to a protein. They were 
able to correctly predict the binding mode of efavirenz to HIV-1 RT. Huo et al.198 ranked a 
set of seven Cathepsin-D inhibitors with a correlation coefficient of r2=0.96 using single 
trajectory MM-PBSA. Gouda et al.204 used the method to predict RNA-ligand interactions. 
Absolute binding free energies as well as a relative ranking for a set of theophylline and 
five structurally close analogs were calculated and compared with the results from TI cal-
culations. As expected for a congeneric series of ligands, TI performed better (r2=0.98) 
than MM-PBSA (r2=0.51/0.82 for different setups). However, one has to note that the TI 
calculations were carried out using only a subset of four molecules from the dataset. Ac-
cording to the authors, the inadequate treatment of solvation effects especially in the first 
water shell by the PB model, is responsible for the inferior, nevertheless still reasonable, 
performance of MM-PBSA compared to TI. Additionally, the first attempt was made to es-
timate the energy needed to convert the conformation predominantly present in solution 
into the conformation adapted in complex with a ligand. The calculated values for this con-
formational energy were estimated too high to be reasonable. The authors explain the devi-
ations by errors in the force field as well as in the continuum solvent model. Suenaga et 
al.199 examined interactions between the SH2 domain of Grb2 and different ErbB phospho-
tyrosyl peptides. For their data set of five peptides a correlation coefficient of r2=0.92 was 
achieved. However, the calculated absolute values for the binding free energies were at 
least 50 kcal/mol off from the experimental values, thus limiting the success to a relative 
ranking of the ligands. Laitinen et al.200 used FEP and MM-PBSA to analyze the affinity 
and specificity of steroid binding to an anti-estradiol antibody. Both methods were able to 
reproduce the relative binding affinities of the steroids in good agreement with experimen-
tal values.
Recently, Steinbrecher et al.202 further investigated the use of MM-PBSA for structure-
based drug design. They proposed a multi-step scoring approach using human neutrophil 
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elastase as model case. MM-PBSA was successfully used as an intermediate filter to select 
docking poses for further processing using TI as a more sophisticated method. 
In another paper Kuhn et al.201, who first applied MM-PBSA to address protein-ligand 
interactions, stimulated current interest for the method, especially in an industrial environ-
ment. In this contribution, MM-PBSA was evaluated with regard to different applications, 
relevant for the industrial drug discovery process: virtual screening, de novo design, and 
ranking of related ligands.  Within their  well-designed study, the authors used different 
datasets for the different application areas. For ranking related ligands and virtual screen-
ing hits MM-PBSA performed for most datasets better than a combination of traditional 
docking and scoring. In case of de-novo design, MM-PBSA significantly supported priori-
tization and ranking of suggestions created by the de-novo program Skelgen229;230. Addi-
tionally,  they  evaluated  the  MM-PBSA  performance,  whether  multiple  MD-generated 
snapshots or only single energy-minimized structures were used as input for the calcula-
tions. The latter was found to be equally powerful while saving considerable amount of 
computational effort, thus, implying that no additional information is obtained using multi-
ple snapshots. Consequently, the computationally expensive process of performing MD 
simulations for each complex could be discarded. Hence, the most valuable use of MM-
PBSA was found to be as a force-field based scoring function with an additional term con-
sidering solvation effects. 
Pearlman203 published a critical MM-PBSA validation study in which the performance 
of the method to rank inhibitors according to their experimental IC50 values was evaluated 
in comparison to a set of different scoring functions. Furthermore, data from a previous 
study231 applying  thermodynamic  integration  and  the  one-window  free  energy  grid 
(OWFEG) method232 to the same dataset was used to compare the performances of the dif-
ferent methods. As test case a congeneric series of 16 p38 MAP kinase inhibitors was se-
lected. All ligands comprised the same scaffold with only small variations in their decora-
tions. The IC50 values ranged from 36 nM to 1.9 μM, covering roughly two orders of mag-
nitude. Within this study, several variables and parameters were modified and the results 
compared: single as well as separate trajectories sampling was carried out for either one or 
five ns using varying levels of positional restraints on the system. Outer atoms were re-
strained in all cases, atoms within a 12 Å sphere of the ligand were either free to move or 
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restraint positionally. MM-PBSA performed worse than TI and OWFEG and only slightly 
better than most of the applied scoring functions in terms of ranking the ligands according 
to their affinity. By investigating the effects of different parameters and settings, it was 
shown that leaving the protein atoms near the binding pocket unrestrained was inferior to 
further damping the motions of these atoms. A combination of deficiencies of the force 
fields and inadequate sampling if the atoms near the binding pocket are free to move is as-
sumed to be responsible for this finding. No conclusive picture was obtained concerning 
simulation length and evaluating separate or single trajectory sampling. However, the best 
overall performance was obtained for the combination of 5 ns of separate trajectory sam-
pling using additional positional restraints. From this, the author concludes that MM-PBSA 
is able to make reasonable predictions if given enough care and computer resources in 
terms of sampling. However, the author emphasizes that MM-PBSA is not cost-effective 
for the system. Considering the enormous amount of computational time spent to obtain 
the results, the performance of MM-PBSA is disappointing. Furthermore, he points out that 
multiple trajectories sampling should be the method of choice, instead of allegedly saving 
time by extracting all snapshots using one trajectory only.
In summary, MM-PBSA has been applied with reasonable success in most cases, but 
also drawbacks and failures of the method have been experienced. In general, the diversity 
of the small molecule ligands used in the studies is larger than what can be handled using 
more rigorous techniques such as free energy perturbation or thermodynamic integration. 
However, in many of the cases the ligands under investigation shared a common scaffold 
and the binding modes to the target proteins were similar. Thus, it can be concluded that 
the conformations of the proteins in the complexed states are similar to those in the un-
bound state. This is demonstrated by the fact that the majority of the studies used the single 
trajectory approach where both states are considered equal and all internal energy contribu-
tions cancel out. Some studies applied also the separate trajectory approach, but the authors 
had to realize that noise and inaccuracies introduced by independent sampling in most cas-
es outweighs the advantages. Furthermore, due to the high computational costs, especially 
when using large datasets of molecules, the MD sampling requirements are in most cases 
short. In addition, the applied protocols which restrain most atoms of the protein with re-
spect to their positions were generally rather strict. 
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SupplTable 1 and SupplTable 2 of the Supplementary Material summarize the settings 
used in the studies cited above. Usually, the production length of the MD simulation for 
MM-PBSA studies dealing with datasets of protein-ligand complexes is in the hundred pi-
cosecond range, making it difficult to achieve sufficient sampling for macromolecular sys-
tems. The movement of protein atoms is often confined to a discrete sphere around the 
binding site, thus keeping the rest of the protein rigid. Simultaneously, the presence of ex-
plicit solvent water molecules is often limited to a spherical region around the ligand. By 
commiting these simplifications it is implicitly assumed that no adaptation processes occur 
during complexation, since only then it is valid to assume that the generated trajectories are 
suitable to provide additional information compared to a single protein geometry scoring. 
Starting geometries for the complexes are in none of the cases exclusively obtained from 
X-ray crystallography. Instead, many of the input structures used for the MD simulations 
are modeled via docking, manual placements or homology modeling, thus introducing ad-
ditional structural assumptions and uncertainties. Combined with the short sampling time 
this provokes the concern, whether the system is given enough time to fully relax and sam-
ple states of a  thermodynamic equilibrium. In  addition,  entropic  effects  are omitted in 
many cases. Again, this might be justified with negligible differences between molecules 
exhibiting similar binding modes and proteins which show no significant differences be-
tween complexed and free form. A more practical reason for neglecting entropic effects are 
the large computational costs accompanied with estimating the entropy of a system by 
means of normal mode or quasi-harmonic analysis. 
Despite its apparent success in many cases, the question remains how the method per-
forms if applied to a system where most of the usual implicit assumptions and simplifica-
tions are not valid: a protein which exhibits a pronounced induced-fit adaptations upon 
binding a set of highly diverse ligands. In order to apply MM-PBSA to such a system, one 
has to increase the sampling and eliminate as many assumptions as possible. This means 
using  only  crystal  structures  as  starting  geometries  and  sampling  times  at  least  in  the 
nanosecond range for each complex. Furthermore, no restraints should be applied to the 
system and the parameters both for the MD simulations and the MM-PBSA calculations 
are must be set to maximize accuracy instead of minimizing computational costs. 
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The test system: Aldose Reductase
Aldose Reductase (AR) is an ideal test case for such a study, since it is an enzyme which 
exhibits an 'induced-fit' binding mechanism with significant differences between individual 
binding-pocket conformations. Structurally, it  is a very well  characterized enzyme with 
many high-resolution crystal structures available114;126. The enzyme comprises an α/β-TIM 
barrel fold with only little structural variations between different structures17. The binding 
pocket of AR itself can be divided into two sub-pockets: a catalytic or anion pocket and a 
hydrophobic specificity pocket. The cofactor as well as the residues involved in catalysis 
are located around the catalytic pocket (see Figure 55 A). As expected for a catalytic sub-
site, very little flexibility is observed within that part of the binding pocket (see Figure 55 
B). The specificity pocket, however, can accommodate different ligands by adjusting its 
overall shape. To accomplish this adaptation the protein utilizes only a few flexible amino 
acids. The opening and closing of the specificity pocket is regulated via a leucine residue 
(Leu 300), which acts as a gate-keeper residue. The crucial parameter to record the state of 
the specificity pocket is the distance between Leu 300 and Trp 111. Besides side-chain 
flexibility of Leu 300, backbone movements of the loop region next to this gate-keeper 
residue are involved in defining the conformation of the specificity pocket. Since no large-
scale movements are involved, multi-nanosecond MD trajectories should suffice to sample 
the different AR pocket conformations adequately. 
All AR ligands observed in crystal structures bind to one of three specificity pocket con-
formations.  Figure 55 B and C show representative structures for these three conforma-
tions. Figure 55 B shows a superposition of the binding pocket based on an all-residue Cα 
atom fit. Residues confining the catalytic pocket superimpose very well, whereas flexibili-
ty is mostly confined to the small loop region ranging from Val 297 to Leu 300. The left 
image in Figure 55 C depicts the closed form of the binding pocket (shown in green), as 
observed in complex with the inhibitor sorbinil (1). The central image (blue) represents the 
open pocket in a conformation observed in complex with tolrestat (2). In this conformation 
the Leu 300 side chain adopts a unique conformation compared to all other crystal struc-
tures. The right image (red) represents the binding pocket conformation seen with many of 
the high-affinity ligands.  The distance between Leu 300 and Trp 111 is  increased,  the 
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specificity pocket is opened and a hydrophobic moiety of the ligand penetrates into the hy-
drophobic cleft. 
AR belongs the the family of the aldo-keto reductases. It catalyzes the reduction of dif-
ferent  aldoses and aldehydes to  the corresponding alcohols  using NADPH as cofactor. 
Even though the physiological function of the enzyme is not fully understood, a role as a 
general detoxifying enzyme for miscellaneous aldehydes is discussed11. Thus, AR accepts a 
broad variety of substrates14. It is the first and rate-limiting enzyme of the sorbitol pathway. 
Within this pathway, AR is responsible for converting glucose into sorbitol. Under physio-
logical conditions the sorbitol pathway is not utilized to metabolize glucose. Under diabet-
ic conditions, however, up to 30% of the excessive glucose is processed via AR8;9;144. As a 
consequence, NADPH is depleted, inducing oxidative stress in the cells146. Additionally, 
sorbitol accumulates within the cells, causing increased osmotic stress. A variety of the 
late-onset diabetic complications have been attributed to glucose processing by AR145;149. 
Accordingly, AR has become a target for the development of anti-diabetic drugs148. The en-
zyme has proven to prolongate diabetic complications in model systems147 as well as in 
clinical studies88. However, most inhibitors have failed so far in clinical trials for various 
reasons78;148. 
Reflecting the broad variety of substrates accepted by the enzyme, inhibitors binding to 
AR are chemically diverse. To match the dual nature of the binding pocket, AR inhibitors 
exhibit a polar head group which addresses the catalytic subpocket. The second structural 
element of many AR inhibitors is a hydrophobic moiety, which addresses the specificity 
pocket. Ultra-high resolution crystal structures as well as neutron scattering experiments233 
suggest, that AR inhibitors bind with deprotonated polar head groups. 
AR has  been  targeted  successfully  in  structure-based  design  projects234 using  either 
combined virtual screening and docking approaches115;235-237 or de-novo design methods238. 
However, these studies were limited by applying the corresponding methods to one specif-
ic conformation of the binding pocket. 
AR is a threefold challenge for MM-PBSA calculations: a) small molecules binding to 
the enzyme are chemically diverse, b) inhibitors presumably bind in a charged form, which 
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has been described earlier197 to cause problems and inaccuracies, and c) ligands bind to dif-
ferent protein conformations.
Figure 55: Overview over the three known AR binding-pocket conformations. A shows a 
schematic representation of the residues around the binding pocket. B shows a superpo-
sition of the same residues. Flexible and rigid parts of the binding pocket can be distin-
guished. The binding pocket conformation of sorbinil is shown in green, the blue struc-
ture represents the conformation seen in the tolrestat complex and the red structure de-
picts the pocket conformation observed with idd 594. C shows a surface representation 
of the same three crystal structures. The color coding is the same as in B.
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Materials and Methods
Data set
The seven ligands used in this study are depicted in Table 12. Representatives for the three 
main AR conformations observed in crystal structures, as well as for the most potent polar 
head groups (carboxylic acid, hydantoin, pyridazinone) binding to the catalytic sub-pocket 
of AR are included in the dataset.
The crystal structures of human AR in complex with sorbinil  1, tolrestat  2 (pdbcode: 
2fzd)239, the Pfizer compound 4 (pdbcode: 1z89)126, zopolrestat 5 (pdbcode: 2fz9)239, 47d 6, 
as well as the JFD compound 7 were determined in our lab. For the idd 594 (3) complex 
input  coordinates  were  taken  from pdb  entry  1us0114.  Complex  structures  of  AR with 
sorbinil, tolrestat, and zopolrestat have been previously deposited with the PDB. However, 
the structures with sorbinil (pdbcode: 1ah0)120 and tolrestat (pdbcode: 1ah3)120 were derived 
from porcine AR and the structure with zopolrestat (pdbcode: 1mar)179 contains only the 
Cα trace of the protein. 
For all protein-ligand complexes ITC measurements were carried out to determine the free 
energy of binding, thus providing a consistent set of high quality affinity data. The corre-
sponding values are also given in  Table 12. Although the narrow range in affinity of 3.8 
kcal/mol is not ideal for assessing the predictive power of MM-PBSA in terms of ranking 
related ligands, the quality of the input structures and the thermodynamic measurements 
are unprecedented for evaluating MM-PBSA results. However, one has to note that the ini-
tial selection of the dataset was based on published IC50 data, since no ITC data were avail-
able at that time. Using these values, the affinity range of the dataset is from 0.84 nM for 
the Pfizer compound 4 to 4.1 µM for the JFD compound 7, thus spanning almost four or-
ders of magnitude. The main difference arises from the deviating values obtained for the 
Pfizer compound which shows the best IC50 value in literature125;184, but only a moderate 
binding free energy in the ITC experiments126.
ITC measurements
Experimental  ΔG values where obtained from Isothermal Titration Calorimetry using an 
MCS ITC-instrument from MicroCal Inc.(Northampton, USA). Details about the experi-
mental setup and data analysis have been published elsewhere126. All measurements were 
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carried out at 298 K and a pH of 8.0. Data were analyzed using the ORIGIN software (Mi-
croCal Inc.) using a single-site binding model. Experimental heats of the protein-inhibitor 
titration were corrected for heats of dilution by subtracting the corresponding data of a 
blank titration (inhibitor into buffer). Standard Gibbs free energy values were calculated 
















idd 594 (3) 30114 -9.8 2
Pfizer 
compound (4) 0.8
125, 1184 -8.2 6
zopolrestat (5) 3242, 60181 -11.3 1
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Table 12: Data set used for the MM-PBSA study. In the first two columns the names of the  
compounds and chemical formulas are given. Column three provides the IC50 values as 
found in the cited literature. In column four the free energy of binding is given as obtained  
from ITC experiments (see Materials and Methods). In column five the rank order of the 
compounds is given as obtained from the ITC derived free energy of binding. 
Molecular Dynamics Simulations 
Starting geometries for each protein-ligand complex were taken from the corresponding 
crystal structures. Starting geometries for the simulations of the holo enzymes were de-
rived by extracting the  ligands sorbinil,  tolrestat  and idd 594 from their  corresponding 
crystal structure. All preparation steps and simulations were carried out with the AMBER 
8.0157 suite of programs, using the Cornell et al.158 force field in the variant of the parm99 
parameter set159. Parameters for the ligand were taken from the GAFF force field160 and as-
signed using  ANTECHAMBER. Parameters for the cofactor NADP+ were taken from a 
previous study113. Atomic charges for both the ligand and the cofactor were calculated by 
fitting to the HF/6-31G* electrostatic potential  using the conformation observed in the 
crystal  structure.  The corresponding ab-initio calculations were performed with GAUS-
SIAN98  161, the restrained electrostatic potential fit with the  ANTECHAMBER program 
using the RESP method162;163. Hydrogen atoms were added to the protein using Amber tem-
plates. The simulated protein thus consisted of 316 amino acids or 5071 atoms, plus the co-
factor with 73 atoms and the ligand atoms. The crystal structure was subjected to a short 
initial energy minimization in vacuo using 20 steps of steepest descent followed by 180 
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steps conjugate gradient minimization. After addition of two sodium counterions to ensure 
neutrality (placed at minima of the electrostatic potential), the systems were solvated in a 
box of TIP3P164 water molecules, which resulted in box sizes of ~80Å x 65Å x 75Å and a 
total of ~9000 water molecules. The MD simulations were then started by heating the sol-
vent to 300K over a period of 20 ps and cooling to 100 K over a period of 5 ps, keeping the 
solute fixed. After this procedure, the entire system was gradually brought to 300 K over a 
period of 25 ps. The simulation was then carried on for 6050 ps under constant temperature 
and pressure (NPT),  applying periodic  boundary conditions.  The temperature was kept 
constant by coupling to a heat bath through the Berendsen algorithm165. Pressure was ad-
justed by isotropic position scaling using a Berendsen-like algorithm. Covalent bonds to 
hydrogen atoms were constrained by the SHAKE166 algorithm and a time step of 2 fs was 
used. A cutoff of 8 Å was applied to the van der Waals interactions, while the electrostatics 
were treated by the Particle Mesh Ewald method167. The simulations were carried out with 
the SANDER MD module of AMBER 8.0. For analysis, energy data were saved every 10 
time steps, solvent and solute coordinates every 0.5 ps. All results presented refer to the 6.0 
ns trajectories which exclude the first 100 ps required for temperature adjustment and equi-
libration.
MM-PBSA calculations
MM-PBSA is based on the assumption that the free energy GA of a system A can be rep-
resented as a sum of different terms. According to equation (2) GA can be dissected into a 
gas-phase contribution and a solvation energy term:
GA= GgasG solv . (2)
The energy for the gas-phase contribution Ggas can be approximated via 
G gas= E gas−TS solute (3)
where Egas is the Molecular Mechanics (MM) energy directly available from the employed 
force field. All water molecules as well as counterions are stripped off the snapshots prior 
to the MM-PBSA calculations. The terms for van-der-Waals interactions, internal energies, 
and electrostatic contributions of the solute  are calculated without applying any cutoff to 
avoid artifacts at the cutoff distance. Ssolute is the rotational, translational, and vibrational 
entropy of the solute estimated using normal mode analysis (NMA)212. T is the absolute 
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temperature in Kelvin at which the simulations took place. Gsolv from equation (2) is further 
dissected into an electrostatic as well as a nonpolar contribution (equation (4)).
G solv= GelecG nonpolar (4)
The electrostatic contribution Gelec is computed using a finite difference solution to the 
Poisson-Boltzmann (PB) equation224;225. Delphi II243 is used as PB solver applying dielectric 
constants of ε=1 for the protein and 80 for the solvent. A cubic lattice with a grid spacing 
of 0.5 Å is 80% filled with the solute. The dielectric boundary is taken as the solvent ac-
cessible surface defined by a probe atom with a radius of 1.4 Å. The radii for the PB calcu-
lations are taken from the PARSE parameter set244. Missing radii for halogens were added 
using Amber Parm99 force field parameters. Atomic charges for protein, cofactor and lig-
ands were the same as in the corresponding MD simulations described above. A salt con-
centration of 150 mM was used for the calculation and 300 iteration steps were performed. 
To test the calculations for convergence, PB energies for a subset of the data set were eval-
uated using 1000 iterations, leading to the same results as in the case of 300 iterations (data 
not shown). 
The nonpolar contribution to the solvation free energy was calculated using equation 
(5). MOLSURF was used to compute the solvent accessible surface (SASA) as implement-






In agreement with literature, b and γ were set to 0.92 and 0.00542, respectively. 
The solute entropy is estimated using the NMODE module of Amber 8. All parameters 
were kept at their standard values as provided with Amber 8. A maximum of 1000 cycles 
of minimization were applied using a 0.1 kcal/mol convergence criterion for the energy 
gradient. Despite the high computational demands, the normal mode calculations were car-
ried out for all atoms of the complex using a distance-dependent dielectric constant of 
ε=4Rij, with Rij being the distance between two atoms.
Finally, the binding free energy of a protein-ligand complex is computed using equation 
(6)
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Gbinding=〈G complex〉−〈Greceptor 〉−〈Gligand 〉 (6)
where the angle brackets indicate averaging over an ensemble of conformations. To calcu-
late Ggas (cf. eq. 2,3) snapshots were extracted every 10 ps from the generated MD trajecto-
ries, resulting in an ensemble of 600 snapshots. Due to the considerably higher computa-
tional costs of normal mode analysis calculations, the time period for the estimation of so-
lute entropies was chosen to be 300 ps, leading to an ensemble of 20 snapshots. The time 
gap of at least 10 ps ensures that only uncorrelated snapshots are used for energy calcula-
tion. 
To derive snapshots for complex, protein, and ligand two distinct approaches were ap-
plied. The more rigorous method is to generate the corresponding snapshots from separate 
trajectories, i.e. the degrees of freedom for protein and ligand as well as complex are simu-
lated independently. The second possibility is to extract the snapshots for all entities from a 
single  trajectory.  In  this  case,  no independent  sampling is  performed and the resulting 
snapshots for complex, protein, and ligand are highly correlated. At first glance, the obvi-
ous advantage of using only a single trajectory are the lower computational costs. Never-
theless, as pointed out by Pearlman203, the time savings are not significant when applying 
MM-PBSA to a series of ligands binding to the same protein, as done in this contribution.
Calculation of Predictive Indices (PI)
To assess the ability of a scoring method in terms of ranking a set of ligands in a more 
quantitative manner Pearlman and Charifson231 introduced the concept of the predictive in-
dex (PI). The PI for a given series of experimental and calculated affinities is derived ac-














=∣E  j −E i ∣ (8)
and 
C ij={1 if [E  j−E i ] /[P  j −P i ]  0−1 if [E  j −E i ] /[P  j −P i ]  00 if [P  j−P i ] = 0 } . (9)
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P(i) is the binding energy in kcal/mol calculated from MM-PBSA assigned to ligand i and 
E(i) is the corresponding binding free energy from the ITC experiment. A PI of 1 indicates 
that for any given pair of molecules, the predicted ranking of these molecules is correct. A 
PI of -1 indicates that the pairwise rankings are wrong in every case. A PI of 0 is expected 
for a series of random predictions.
Results and Discussion
MD trajectories
As known from previous MD studies113 of the system, AR is an enzyme with a compact 
globular fold that shows overall high structural integrity during the simulations. Table 13 
summarizes the Cα carbon root mean square deviation (rmsd) values of the different simu-
lations used in this study. All values are measured against the energy-minimized starting 
crystal structure. Absolute rmsd values tend to be higher in the second part of the trajecto-
ries by a small amount and some of the plots in Table 13 show a slight drift during the sim-
ulation towards higher values. However, the mean Cα movements are rather modest with 
none of them being larger than 1.4 Å for the second part of the trajectory. In addition, the 
accompanying standard deviations move towards slightly smaller values. This might indi-
cate that the system has reached an equilibrated state with respect to the force field and 
simulation conditions, which does not necessarily correspond to the local minimum confor-
mation of the starting crystal structure. 
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Cα RMSD [Å]
















































































Table 13: Cα rmsd values for the MD trajectories used in the study measured against the  
corresponding energy minimized starting structures. Values are given for the first and sec-
ond part of the trajectory as well as for the whole trajectory. The values in parenthesis in-
dicate the standard deviations of the respective values. In the final column the time course  
of the Cα rmsd is plotted: snapshots are plotted on the x-axis, the rmsd in Å is indicated on 
the y-axis.
Sampling the reference state
To compare the binding free energy of ligands which bind to different binding-pocket con-
formations and in order to examine the energetics involved in the corresponding protein 
and ligand adaptation processes upon complex formation, it is essential to sufficiently sam-
ple the uncomplexed state of the protein and the ligands. For small molecule ligands it can 
be assumed that the conformational ensemble generated with a multi-nanosecond MD cov-
ers a sufficiently large phase space to provide thermodynamically meaningful results. For 
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proteins, however, this cannot be implied. The reliability of the derived receptor energies is 
of particular importance since it is used to derive the binding free energy for every protein-
ligand complex under investigation. 
To improve sampling of the uncomplexed state, three distinct simulations starting from 
different  protein conformations  were conducted.  Representative structures  for  the three 
main  binding-pocket  conformations  were  chosen  as  templates:  sorbinil,  tolrestat,  and 
idd 594. The sorbinil complex represents the binding pocket with the specificity pocket in 
a closed conformation; it shows only slight deviations compared to a holo structure de-
posited in the PDB (pdbcode: 1ads19). The tolrestat and idd 594 complexes represent the 
two main binding-pocket conformations with an open specificity pocket. 
Removing the ligands from the corresponding complex structures  prior to starting an 
MD simulation perturbs the system by different amounts, and the trajectories will certainly 
take a different time course. However, the energies derived from simulations with varying 
starting conformations should converge to a common value, given enough sampling time. 
The question is whether 6 ns sampling are sufficient to ensure this assumption. Before ana-
lyzing the calculated MM-PBSA energies it is instructive to examine whether or not there 
are significant differences in the sampled binding-pocket conformations regarding the three 
simulations. 
Without performing a full structural analysis of the three MD simulations, one example 
shall be discussed here. The molecular dimension which indicates whether the specificity 
pocket is opened or closed is the distance between the side chains of Trp 111 and Leu 300. 
This distance is plotted for the three holo simulations in Figure 56. As can be seen from the 
green lines in the plots the starting values for the corresponding simulations differ as ex-
pected depending on whether the specificity pocket is open or closed. For major parts of 
the simulation time the distances are similar for all three simulations and correspond to the 
closed specificity pocket conformation. Therefore, one can conclude that most of the time 
the specificity pocket is indeed closed throughout the three simulations. However, differ-
ences can be seen between the simulations. Holo (sorbinil) shows hardly any variations of 
the distance. Possibly this arises from the fact that this structure was least perturbed upon 
removal of the ligand. Holo (tolrestat) shows stronger movements with respect to this dis-
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tance. However, the only simulation which intermediately returns into the opened speci-
ficity pocket is holo (idd 594). Interestingly, these open conformations do not occur solely 
at the beginning of the simulation, but is rather revisited after a few nanoseconds half way 
trough the simulation. These differences might already indicate that there is (still) a depen-
dence of the sampling on the starting geometry even though it simply expresses as a local 
difference in this case. Possibly it indicates that such systems would require a much longer 
sampling time to achieve fully equilibrated state not getting trapped by local hysteresis ef-
fects. The question remains whether these differences are also reflected in the MM-PBSA 
derived energy values for the simulations. 
Figure 56: Distance between of Leu 300 CG and the Trp 111 ring center. The start values  
from the crystal structures are depicted as green line. 
Table 14 lists the MM-PBSA energies of the holo trajectories derived for different start-
ing geometries. In addition, the receptor energies derived by the single trajectory approach 
are given. To obtain these values, the ligand is removed from the single snapshots after the 
MD simulation has been carried out (see above). In the remainder of this study these trajec-
tories will be called 'holo like' or receptor trajectories, since they do not represent a true 
sampling of the conformational space of the holo enzyme, but are treated as such for the 
MM-PBSA calculations in the single trajectory approach. 
Analyzing the values for the first three nanoseconds, it becomes evident that for holo 
(sorbinil) and holo (tolrestat) are equal in their energies whereas holo (idd 594) deviates by 
12 kcal/mol from the two former ones. Also for the 'holo-like' receptor trajectories all sim-
ulations carried out with ligands addressing the specificity pocket (all apart from sorbinil) 
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coincide in a window of 14 kcal/mol with respect to their receptor energies. The same 
holds true if one compares the values for the holo and the 'holo-like' trajectories. Only the 
receptor/sorbinil trajectory is off by more than 30 kcal/mol. This is especially puzzeling 
since sorbinil does not address the specificity pocket. Therefore, in this case conformation-
al differences concerning the binding pocket between receptor/sorbinil and holo (sorbinil) 
should be minimal. This observation appears alarming and possibly indicates that changes 
in the MM-PBSA energy caused by local changes of the binding pocket may be over-
whelmed by larger deviations in other parts of the enzyme (for example loop movements). 
Looking at the second part of the simulations, it can be recognized that almost all energy 
values  are  lower  than  in  the  first  part.  Only  the  values  for  receptor/zopolrestat  and 
receptor/sorbinil  become  more  positive.  Despite  the  surprising  offset  of  the 
receptor/sorbinil energy in the first 3 ns with respect to the other receptor trajectories, this 
energy value matches with the remaining ones for the second half is in line with most of 
the other values. The energy scatter across the trajectories of the holo simulations increase 
to 33 kcal/mol. The energies of holo (sorbinil) are the most stable, since the second part 
differs  only  by  10  kcal/mol  from the  first,  whereas  for  holo  (idd 594)  this  difference 
amounts to 31 kcal/mol. 
However, there is one aspect which should be addressed. In Table 14 the standard error 
of the mean is given for each energy as an estimate for the uncertainty in the mean values. 
In analogy to other studies210, the standard error is calculated by dividing the standard devi-
ation of the distribution by the number of data points in the evaluation (300 frames for the 
first and second part, 600 frames for the whole trajectory). Usually the standard deviations 
of the energy values are in the range of 50 kcal/mol for most of the simulations, thus the 
fluctuations of the energies obtained for single snapshots are larger than suggested by the 
standard error of the mean.
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energy 0-3ns [kcal/mol] energy 3-6ns [kcal/mol] energy 0-6ns [kcal/mol]
System mean stde mean stde mean stde
Holo (sorbinil) -8776 3.1 -8786 2.9 -8781 2.1 
Holo (tolrestat) -8776 3.0 -8803 2.9 -8789 2.1 
Holo (idd 594) -8788 3.1 -8819 2.8 -8804 2.2 
Holo (mean) -8780 1.8 -8803 1.7 -8791 1.3
Receptor/sorbinil -8820 3.0 -8808 3.1 -8814 2.1
Receptor/tolrestat -8778 3.0 -8801 2.8 -8789 2.1
Receptor/idd 594 -8787 3.3 -8806 2.9 -8797 2.2
Receptor/Pfizer compound -8782 3.2 -8802 2.6 -8792 2.1
Receptor/zopolrestat -8782 2.9 -8778 2.8 -8780 2.0
Receptor/47d -8788 2.8 -8802 2.9 -8795 2.0
Receptor JFD -8774 2.8 -8787 3.0 -8780 2.1
Table 14:  MM-PBSA energy values derived for different MD trajectories without the en-
tropic contribution. Total values for the whole trajectory as well as values for the first and 
second part of the simulation are presented. Furthermore the standard error of the mean is  
given which is defined as  X=

n
 where σ is the standard deviation and n is number of 
frames in the sample245. For the trajectories of Holo (sorbinil), Holo (tolrestat), and Holo 
(idd 594) the starting geometries were obtained by extracting the bound ligands from the  
corresponding complex structures before starting the MD simulations. The remaining re-
ceptor trajectories were generated by removing the ligand from the complex solely for  
MM-PBSA calculations, i.e. the ligands were present throughout the generation of the tra-
jectories.
The question remains, whether the three holo simulations represent an adequate sam-
pling which can be used for the MM-PBSA calculations. Considering the mean values for 
the entire trajectories (last column in Table 14) it can be seen that the maximum difference 
in energy between the three simulations is 23 kcal/mol. On a relative scale this corresponds 
to a deviation of 0.25%, which is low considering the deficiencies and differences in sam-
pling already discussed. However, on an absolute scale 23 kcal/mol are more than twice 
the expected binding  energies  for  the  ligands  and,  therefore,  non-negligible.  Thus,  the 
problem remains which energy value to select as reference state of the uncomplexed pro-
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tein? Depending on this reference value, all calculated binding energies will be shifted ac-
cordingly. Hence, hardly any reasonable and meaningful results can be expected on an ab-
solute scale for the separate-trajectories approach. To derive energies which are at least 
useful on a relative scale (i.e. for ranking), the energies derived from the three holo simula-
tions were averaged and assumed to be representative for the reference state.
An idea which was first introduced by Gouda et al.204 is to estimate the conformational 
energy associated with the adaptation of the protein to the ligand. This is achieved by sub-
tracting the receptor energy derived from the holo simulation from the energy of the corre-
sponding holo-like simulation. In the study of Gouda et al. the derived energies were too 
high to be reasonable. Transferring this idea to the current data set, it becomes evident that 
the energies for the complex derived holo-like receptor trajectories are in many cases lower 
than the ones from the holo simulations. This would result in negative energies for the con-
formational changes, which appears quite unreasonable. However, this finding is in agree-
ment with results from Gohlke et al.210, who observed a similar behavior for the RAS-RAF 
protein-protein complex. The origin of this phenomenon is not understood, but supposedly 
it indicates problems and inaccuracies in the implicit solvent representation of trajectories 
generated with explicit solvent molecules. 
MM-PBSA results
The results for the MM-PBSA calculations in terms of ranking the ligands according to 
their binding free energies are presented in  Table 15. In this table the predictive indices 
(PI) for different MM-PBSA variants (single and separate trajectories) as well as different 
sampling times (energy minimized crystal structure, 200 ps sampling, 6 ns sampling) are 
given. Furthermore, the calculated ΔG value as well as two different subsets of MM-PBSA 
terms (all but the entropy term, vdW term only) are compared with respect to their predic-
tive power for this dataset. 
Overall,  the obtained PI values for the present data set are rather disappointing. For 
many settings, the predictions are worse than random, as indicated by a negative PI. Usual-
ly, the best PI is to be expected for the calculations using the longest sampling (6 ns) and 
separate trajectories for complex, receptor, and ligand. However, the PI for these settings is 
0.15, which is only marginally above a completely random prediction. Interestingly, this 
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value is in (coincidental) agreement with a PI of 0.16 which was obtained in the study of 
Pearlman203 for his dataset using similar settings: 5ns of sampling, no additional positional 
restraints on atoms near the binding site, and separate trajectories. If the results of the time-
consuming normal mode calculations are left out, the PI decreases slightly to 0.09. Howev-
er, it is questionable whether it is meaningful to discuss slight changes of a PI which basi-
cally indicates a random prediction. For the single-trajectories sampling approach the re-
sults are worse. For 6 ns of sampling the PI of -0.29 implies a prediction which is worse 
than random. Neglecting the entropy term leads to a PI of -0.44, again a change which is 
impossible to interpret.
Considering the PIs for 6 ns of sampling, the question arises what might be responsible 
for these disappointing results. Why has MM-PBSA been applied to a variety of systems 
with great success, but is not capable to predict the present dataset successfully? To obtain 
some ideas what mightcause the failure of the method it is instructive to analyze the indi-
vidual contributions to the MM-PBSA energy. These detailed results are presented for sin-
gle-trajectory sampling in Table 16 and for separate-trajectory sampling in Table 17. Con-
sidering the calculated ΔG values in both tables, the computed variations between the dis-
tinct complexes are much larger than the experimentally determined values. The experi-
mental deviations between strongest and weakest binder is 3.8 kcal/mol. However, this dif-
ference is 19 kcal/mol for the single trajectory variant and 35.6 kcal/mol for separate tra-
jectories, respectively. Also the calculated absolute values are significantly off in many 
cases. For separate trajectories this has already been discussed in the previous section, but 
also for single trajectories this is observed. For both sampling approaches positive binding 
energies are obtained, suggesting that ligand binding parallels an endergonic process. De-
spite being rather puzzeling,  this  behavior has been observed previously in other stud-
ies196;199;203. 
Regarding the individual energy terms, it can be noticed that the main driving force fa-
vorable for binding is the van der Waals term of the force field. It is compensated by the 
electrostatic forces, which are the summed contributions of the force field electrostatics 
and the electrostatic contribution to the solvation free energy computed via PB calcula-
tions. The suggestion that the van der Waals term would be the main driving force for 
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binding is in line with many previous studies194-200;204;210;227 where either the authors explicit-
ly describe a similar behavior or it can be concluded from the provided tabulated values. 
Predictive Index
sampling time single snapshot 200 ps 6 ns
comparison single traj separate traj single traj separate traj
ΔGexp vs. ΔGMM-PBSA -0.36 -0.71 -0.18 -0.29 0.15
ΔGexp vs. ETOT, MM-PBSA 0.17 -0.42 -0.13 -0.44 0.09
ΔGexp vs. EvdW, MM-PBSA 0.62 0.74 0.34 0.52 -0.34
Table 15: Predictive Indices for different comparisons. ΔGexp is the experimental free ener-
gy of binding derived from ITC experiments. ΔGMM-PBSA is the free energy of binding from 
MM-PBSA including all terms, ETOT, MM-PBSA is the energy calculated from MM-PBSA ne-
glecting the entropic contribution, finally, EvdW, MM-PBSA is the energy from MM-PBSA using 
only the vdW force field term to estimate the binding energy. Two different sampling peri-
ods are considered: 6 ns and 200 ps as well as the variant where only the energy mini-
mized starting structure (single snapshot) is used for the MM-PBSA calculations. Predic-
tive indices are calculated using equations 7-9.
The overall unfavorable contribution of the electrostatic term result from the fact that 
the favorable force field electrostatics are overwhelmed by the unfavorable PB energies 
(which represent the interactions with the surrounding solvent). One explanation for this 
might be that for a system such as AR, where a charged ligand is desolvated upon com-
plexation, the electrostatic interactions of the protein environment cannot compensate for 
the loss of the solvation shell – at least in the computational simulations. 
Considering only the vdW contributions from Table 16 and Table 17, the PI for the sin-
gle-trajectory cases rises to 0.52 if the entire 6 ns trajectories are evaluated. In case of sepa-
rate trajectories, however, the prediction based the vdW term only is not nearly as good, 
but rather worse than random. How can such a behavior be explained? If using single tra-
jectory sampling the conformations of complex, protein, and ligand are the same for every 
snapshot. Therefore, all vdW terms cancel mutually out, except for the additional contacts 
between ligand and protein which are newly experienced upon the complex formation. 
This cancellation is not necessarily given for separate trajectories, where complex, protein, 
and ligand are sampled independently. 
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Sorbinil Tolrestat IDD594 Pfizer Zopolrestat 47d jfd
0-6ns
ΔVmm -123.6 -102.0 -109.5 -118.0 -141.8 -133.4 -152.1
vdW -30.5 -36.5 -42.2 -43.1 -50.3 -45.1 -37.1
Ele 15.7 23.9 23.4 18.4 31.3 24.4 14.4
ΔΔGsolv 105.1 84.5 85.7 88.7 117.2 107.8 125.3
Etot -18.6 -17.5 -23.8 -29.3 -24.6 -25.5 -26.8
TΔS -17.1 -23.6 -18.4 -16.4 -15.2 -26.2 -17.1
ΔG -1.4 6.1 -5.4 -12.9 -9.4 0.7 -9.8
Rank vdW 7 6 4 3 1 2 5
Rank Etot 6 7 5 1 4 3 2
Rank ΔG 5 7 4 1 3 6 2
0-200ps
ΔVmm -122.1 -100.9 -113.1 -113.2 -133.1 -144.1 -212.5
vdW -31.6 -37.2 -42.2 -40.8 -49.4 -45.3 -36.7
Ele 16.5 24.8 25.8 19.4 33.4 27.0 18.1
ΔΔGsolv 103.3 83.5 91.5 87.2 111.7 120.9 116.6
Etot -18.9 -17.4 -21.5 -26.0 -21.4 -23.2 -22.7
TΔS 5.8 0.6 -39.6 -6.0 -9.3 -39.1 2.9
ΔG -24.7 -18.0 18.1 -20.0 -12.2 15.9 -25.5
Rank vdW 7 5 3 4 1 2 6
Rank Etot 6 7 4 1 5 2 3
Rank ΔG 2 4 7 3 5 6 1
Table 16: Summary of the results of single trajectory MM-PBSA calculations. All energies  
are given in kcal/mol.  ΔVmm: energy difference arising from molecular mechanics force  
field; vdW: binding energy contribution from force field van-der-Waals term; Ele: sum of  
force field and PB electrostatics;  ΔΔGsolv: binding free energy component from solvation  
free energy; Etot: sum of ΔVmm and ΔΔGsolv; TΔS solute entropic energy calculated via nor-
mal mode analysis, sum of Etot and TΔS. Rank Etot, Rank vdW and Rank ΔG rank order of  
ligands according to the different energies.
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Sorbinil Tolrestat IDD594 Pfizer Zopolrestat 47d jfd
0-6ns
ΔVmm -117.3 -105.0 -43.8 -169.7 -141.7 -130.8 -157.1
vdW -60.2 -35.8 -54.9 -72.3 -65.9 -52.0 -67.1
Ele 31.9 34.7 39.2 40.3 67.4 40.4 52.3
ΔΔGsolv 76.1 90.6 15.5 141.6 128.6 102.2 144.4
Etot -41.3 -14.4 -28.3 -28.1 -13.1 -28.6 -12.8
TΔS -17.5 -26.3 -17.5 -28.3 -17.8 -23.5 -18.6
ΔG -23.7 11.9 -10.8 0.2 4.7 -5.1 5.9
Rank vdW 4 7 5 1 3 6 2
Rank Etot 1 5 3 4 6 2 7
Rank ΔG 1 7 2 4 5 3 6
200ps
ΔVmm -238.0 -138.7 -185.8 -95.8 -240.8 -197.7 -249.7
vdW -59.5 -38.4 -60.7 -73.0 -65.7 -63.5 -56.1
Ele 48.4 32.0 46.5 59.0 51.3 51.4 40.5
ΔΔGsolv 200.1 138.4 173.2 81.0 211.8 171.8 145.6
Etot -38.0 -0.3 -12.6 -14.8 -28.9 -25.9 -31.0
TΔS 6.0 -1.5 -2.1 -1.8 -10.4 -28.2 -2.7
ΔG -44.0 1.2 -10.5 -13.1 -18.5 2.4 -28.2
Rank vdW 5 7 4 1 2 3 6
Rank Etot 1 7 6 5 3 4 2
Rank ΔG 1 6 5 4 3 7 2
Table 17: Summary of the results of separate trajectory MM-PBSA calculations using the  
averaged 18 ns trajectory as reference.  All energies are given in kcal/mol.  ΔVmm: energy 
difference arising from molecular mechanics force field; vdW: binding energy contribution  
from force field van-der-Waals term; Ele: sum of force field and PB electrostatics; ΔΔGsolv:  
binding free energy component from solvation free energy; Etot: sum of ΔVmm and ΔΔGsolv;  
TΔS solute entropic energy calculated via normal mode analysis, sum of  Etot and  TΔS. 
Rank Etot,  Rank vdW and Rank ΔG rank order of ligands according to the different ener-
gies.
Compared to previous studies, however, the hypothesis that the vdW term alone is a 
good indicator for the binding free energy cannot be confirmed. Huo et al.198 found for a 
dataset of seven peptido-mimetic inhibitors of Cathepsin-D with common scaffold a de-
crease of the correlation coefficient r from 0.98 to 0.16 once all terms except the vdW term 
are neglected. In the study of Wang et al.197, a decrease in the PI from 0.79 to 0.22 for the 
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ranking of a series of closely related TIBO-type inhibitors for HIV-1 protease has been ob-
served. For a congeneric series of seven biotin analogs plus HABA in the study from Kuhn 
et al.196 one can see a decrease in predictive power going from PI=0.99 to PI=0.56. 
In the present case, however, the deficiencies to capture the electrostatics of binding us-
ing the PB approach seems to be most problematic. Wang et al.197 encountered a similar 
problem with electrostatics as they observed that for charged ligands the calculation of 
binding free energy does not produce correct results as for neutral species. The reason for 
this finding might be that the uncharged and charged form of a ligand molecules are sepa-
rated by a large change in the computed solvation free energies. This arises the question, 
whether such effects can be suitably handled by the MM-PBSA approach. 
As mentioned in the introduction, an important factor to obtain thermodynamically mean-
ingful results is the sampling time. With respect to this aspect, previous MM-PBSA studies 
show large variations. The studies which successfully applied the method to medium or 
larger sized data sets of ligands for a protein usually used sampling times in the low hun-
dreds picosecond range or even less (see SupplTable 1 and SupplTable 2 in Supplementary 
Material). Probably this was mostly due to practical reasons since longer sampling requires 
longer computer simulation, either for generating the trajectories or for performing MM-
PBSA calculations. However, the performance of the method should increase with longer 
sampling times in two ways. On the one hand, more snapshots can be used for the MM-
PBSA calculations, which improves the statistical significance of the derived energy val-
ues; on the other hand, the larger the generated ensemble is the more meaningful it be-
comes from a thermodynamic point of view. In order to assess the influence of different 
sampling times two additional  simulation lengths  are  compared to  the full-length 6 ns 
sampling: the first 200 ps of every trajectory and the single energy-minimized starting 
structure. 
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Sorbinil Tolrestat IDD594 Pfizer Zopolrestat 47d jfd
ΔVmm -102.8 -95.1 -98.0 -109.3 -133.3 -131.1 -126.8
vdW -34.3 -45.7 -52.7 -50.4 -60.4 -55.7 -46.2
Ele 22.7 38.0 38.4 29.3 40.7 34.5 31.5
ΔΔGsolv 87.5 82.5 78.6 83.7 108.3 105.2 108.1
Etot -15.3 -12.6 -19.4 -25.6 -25.0 -25.9 -18.7
TΔS 18.4 -25.6 -32.0 -13.0 -31.6 -36.2 -24.9
ΔG -33.7 13.0 12.6 -12.6 6.6 10.3 6.2
Rank vdW 7 6 3 4 1 2 5
Rank Etot 6 7 4 2 3 1 5
Rank ΔG 1 7 6 2 4 5 3
Table 18: MM-PBSA energies derived from the energy minimized input structure. All ener-
gies  are given in  kcal/mol.  ΔVmm:  energy difference arising from molecular  mechanics 
force field; vdW: binding energy contribution from force field van-der-Vaals term; Ele:  
sum of force field and PB electrostatics; ΔΔGsolv: binding free energy component from sol-
vation free energy; Etot: sum of  ΔVmm and ΔΔGsolv;  TΔS solute entropic energy calculated 
via normal mode analysis, sum of Etot and TΔS. Rank Etot, Rank vdW and Rank ΔG rank or-
der of ligands according to the different energies.
A period of 200 ps were chosen to represent the short sampling times usually applied in 
previous protein-ligand MM-PBSA studies of larger scale. The single energy minimized 
structure was included since Kuhn et al.201 found that for their data sets almost no enhanced 
predictive power once going from single energy-minimized structures to ensembles gener-
ated via MD simulations. The results for the 200 ps sampling are included in Table 16 and 
Table 17, the corresponding values for using only the energy minimized starting structure 
are summarized in Table 18. The general trends with respect to the main driving forces for 
the free energy of binding remain similar for these two calculations. The vdW term is still 
the main source of binding free energy and electrostatics contribute unfavorably to the 
binding free energy. Considering the corresponding PIs in Table 15, the trend that solely 
the vdW term reflects best the binding free energies of the ligands is also indicated. Includ-
ing the electrostatic terms decreases the performance significantly. The vdW term of the 
single energy-minimized structures alone, gives a good PI of 0.62. Sampling for a short 
200 ps time increases the PI to 0.74, but going to the full 6ns sampling decreases the PI to 
0.52. It seems that a single structure is sufficient to rank the ligands according to their 
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affinity, provided one correctly assumes that only the vdW terms have to be taken into ac-
count. Expanding the simulation beyond 200 ps does not increase performance under these 
assumptions, at least with respect to the vdW energies. 
Assessing the reliability of the entropic contribution to the free energy of binding is dif-
ficult. Due to the low number of snaphots used for the calculations the statistical signifi-
cance can hardly be evaluated. In the case of 6 ns of sampling using separate trajectories 
including the entropic term does improve the PI slightly (Table 15). For the single snap-
shots, however, including the entropic contribution decreases the prediction significantly. 
As a summary, the best performance was achieved considering rather arbitrarily only 
the vdW term using either short sampling or only a single energy minimized structure. 
One important point concerning the calculations of PI should be mentioned which is of 
importance to evaluate the results from this study. Due to the pairwise comparisons of all 
ligands and the weighting factor ω which accounts for the difference in the experimental 
binding free energy of each ligand pair, the predictive index is strongly dependent on rank-
ing the extrema of the dataset correctly. Ranking the extrema incorrect means that all com-
parisons including these ligands fail. Additionally, since the experimental free energy dif-
ference between the ligand pair is in most cases larger if either the best or the worst ligand 
is included in the pairwise comparison these rankings are assigned to comparably high 
weighting factors. This is especially important for a small dataset of only seven ligands 
where many of the ligands are similar in their experimental binding free energies except 
for the two extrema. The overall devastating performance of the single-trajectory approach 
can partly be explained by this phenomenon. The Pfizer ligand, which appears on sixth 
rank according to the ITC experiments obtains the best binding energy by MM-PBSA, 
whereas the JFD compound which shows the lowest affinity in the ITC experiments is pre-
dicted second best binder by MM-PBSA (cf. Table 16). 
However, the case of the Pfizer compound is interesting since according to the pub-
lished IC50 this compound would be the tightest binder within in the dataset125;184. Using 
published IC50 values and calculating a PI against the ITC data, one can end up with values 
between ~0.2 and ~0.5 for 6 ns of single-trajectory sampling depending on which of the 
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published IC50 values are taken. This emphasizes the need to take only IC50 into account 
once they are measured in a consistent fashion.
Summary and Conclusions
In the present study, MM-PBSA has been applied to an experimentally very well character-
ized data set of seven ligands binding to AR. For all protein-ligand complexes X-ray struc-
tures as well as high quality thermodynamic ITC data are available. The sampling times 
were set to 6 ns and all atoms of the system were allowed to move without any positional 
restraints. All parameters for the MDs were chosen to guarantee state-of-the-art simula-
tions. Separate trajectories were sampled for the holo enzyme starting from three different 
crystal structures. Each trajectory remains stable over the whole simulation time as shown 
by the low Cα atom movements. 
The ranking of the data set according to the calculated binding free energy, however, 
has not been successful. The experimental binding free energies correlate best with the cal-
culated vdW term. Comparison of different sampling times did not show significant im-
provements with increasing computational efforts. The energy-minimized crystal structures 
provide results which in principle would not justify the enormous computational costs as-
sociated with the generation of the nanosecond trajectories and the calculations of the sin-
gle MM-PBSA terms. Comparing ΔGMM-PBSA for single and separate-trajectories sampling, 
the latter seems to reveal slightly better results, but on a significance level which is not re-
ally apart from a random prediction. In fact, single trajectory sampling is in most cases 
worse than a random prediction, indicating systematic errors which prevents the results 
from improving with increasing level of sophistication of the theory involved.
Despite being a theoretically more solid method compared to empirical scoring func-
tions, the simplifications and assumptions inherent in the method apparently do not per-
form well in case of the present dataset of charged ligands binding to a protein performing 
'induced-fit' binding adaptations. An additional challenge is the moderate difference in the 
experimental binding free energies of the ligands in the data set. Combining results from 
rather different approaches (force field, PB, normal mode analysis), which work surpris-
ingly well for other datasets, does not produce reasonable results in the present case. Pre-
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sumably many errors mutually cancel out, if similar ligands are compared which bind with 
similar binding modes to one protein, but do not compensate each other if the binding 
modes are as different as in the present case. It might well be that much longer sampling 
times are required in order to cover the differences in the thermodynamic ensembles of lig-
ands binding to different protein conformers. However, with elongated sampling time, er-
rors in the force field as well as in the PB and normal mode calculations reveal increasing 
importance. 
Supposedly, one has to be careful in generalizing the current findings. MM-PBSA has 
been proven its value in many other studies and has been used to rank ligand data sets suc-
cessfully. Nevertheless results from MM-PBSA calculations are still strongly dependent on 
the data set and the applied parameters and settings. Kuhn et al.201, for example, obtained 
PIs between 0.15 and 0.86 for three different data sets using the GAFF force field and MD 
sampling, indicating a strong dependence on the data set under investigation. Pearlman203 
presented in his study PIs ranging from -0.04 to 0.51 for the same data set using different 
sampling times and approaches. In contrast to other empirical methods, which are compu-
tationally cheaper,  it  is  difficult  to decide  a priori whether a  data set  is  suited for the 
method or which sampling approach is the most promising one. A significant amount of 
computational time has to be spent before one can estimate whether MM-PBSA is promis-
ing for a system under investigation. Automatizing the usage of MM-PBSA would be ben-
eficial for the final users. Improving the results by modifying some of the parameters is 
also difficult and time consuming and only possible in post-modeling studies not in a pre-
dictive  analysis.  Adjusting  the  radii  or  the  dielectric  constants  for  the  PB calculations 
might be promising concepts to improve results, but is probably out of scope for routine 
drug design projects. 
In summary, MM-PBSA can be a valuable tool for a drug design project according to 
previous studies, however this study suggests difficulties with systems for which it should 
be the method of choice, i.e. a protein with a flexible binding pocket and a heterogeneous 
data set of ligands.
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program Amber 7 Amber 6 Amber 5 Amber 7 Amber 5 Amber 6 Amber 6
force fields Parm94/Gaff/ MAB Cornell et al. Parm94 Parm99 Parm99 parm96
extended 
parm96
ligand charges AM1-BCC RESP RESP - RESP RESP RESP
solvation model TIP3P, 24 Å sphere a. BS
TIP3P, 11 Å 
box
TIP3P, 20 Å 
sphere a. lig.





TIP3P, 15 Å 
sphere around 
protein#
TIP3P, 25 Å 
cap around lig 
center
restraints 12 Å sphere - 18 Å a. lig. - 20/30 Å form lig. center -
12 Å around 
ligand
nb cutoff 12 Å ? dual (12/17 Å) 8 Å 9/12 Å ? 12 Å
electrostatics nb cutoff PME nb cutoff PME nb cutoff ? nb cutoff
equilibr. length 150 ps 75 ps 90-180 ps 40 ps 100/300 ps 700 ps 350 ps
prod. sim. lengt 50 ps 1 ns 300 ps 1100/900 ps 200 ps 300 ps 700 ps
MM-PBSA calculations
single/separate 
trajectories single single single single single separate single
atomic radii n.a. PARSE PARSE PARSE PARSE PARSE PARSE
dielec. const. 
(solv/solute) 80/1 80/1 80/1 80/1 ? 80/4 80/1
PBSA solver MEAD Delphi II Delphi Delphi Delphi* MEAD Delphi
no of snapshots 10 50 50 100 100 30 50
time btw. 
snapshots (ps) 5 10 6 4 2 10 14
entropy 




6 - - - 10 ? -
Results
exp. validation yes yes yes yes yes yes yes
* only residues within 30 Å (40 Å) were used for PBSA calculations # no periodic boundary conditions were 
used 
SupplTable  1: Overview over the MD and MM-PBSA settings used in literature studies.  
Data were extracted from the original papers. If specific data was not given in the original  
publication a “?” is put into the table. 
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al.194 Huo et al.
198 Pearlman D 
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geometries Docking modelled x-ray modelling modelling X-ray, NMR -
MD simulations
program Amber 8 Amber 4.1§ Amber Amber Amber 5 Amber 7 Amber 7




Cornell et al. parm94/99
ligand charges RESP - - RESP ESP RESP RESP
solvation model TIP3P, 12 Å box TIP3P
TIP3P, 10 Å 
box




TIP3P, 10 Å 
box
restraints - - - 16 Å around ligand
12 Å, centered 
on ligand - -
nb cutoff ? 9 Å§ 8 Å 12 Å 8 Å# 9 Å 9 Å
electrostatics ? PME PME ? nb cutoff PME PME
equilibration 
length 200 ps variable 40 ps 30 ps
variable 
(200ps-1.4ns) 2 ns 575 ps
production sim. 
length 2 ns 400ps-1.5ns 400 ps 450 ps 1ns or 5ns 10 ns 5 ns
MM-PBSA calculations
single/sep. traj ? (single) - both single both both separate
atomic radii ? PARSE PARSE PARSE PARSE PARSE/BONDI ?
dielec. const. 
(solv/solu) ? 80/1 80/1 80/1 80/1 80/1 ?
PBSA solver pbsa Sanner algorithm Delphi Delphi Delphi II Delphi pbsa
no of snapshots 200 100 100 300 (?) 100 or 500 500 500
time btw. 








? - 8 Å around ligand
12 Å centered 
on ligand - -
Results
exp. validation yes yes yes yes yes yes
§ values taken from Cheatham et al., JMB223 # values taken from Pearlman et al, JMedChem231
SupplTable  2: Overview over the MD and MM-PBSA settings used in literature studies 
(continued). Data were extracted from the original papers. If specific data was not given  
in the original publication a “?” is put into the table. 
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Introduction
During the last four decades protein crystallography emerged as an essential tool to elucid-
ate the binding geometry and interaction patterns experienced in protein-protein or protein-
small molecule ligand complexes. Especially as prerequisite for drug design accurate crys-
tal structure determinations are of utmost importance138;139.  Novel leads are either discov-
ered experimentally by screening existing compound libraries (high-throughput screening) 
or computationally by screening virtual libraries against  a given target246.  For the latter 
strategy, X-ray crystallography is essential to provide the structure of the target protein and 
to analyze its characteristics with respect to ligand binding. 
However, as the following study will show, even in the case of successful crystal struc-
ture determination a unique and definite answer with respect to the binding mode resem-
bling the most relevant in-vivo situation is not necessarily given. One important explana-
tion for this complexity results from protein flexibility with respect to either side-chain or 
main-chain atoms localized in loop regions. On the one hand adaptability is an important 
feature and prerequisite for biological function98;139;246, however, on the other hand, it pro-
vides special challenge for inhibitor design strategies as flexibility complicates a reliable 
prediction of  the binding geometry adopted by potential  small  molecule  leads247.  Even 
though  atomic  B-factors  give  some  evidence  for  local  mobility,  and,  when  refined 
anisotropically, information about its directionality, it has often been discussed whether 
crystal structures only represent a static frozen-in picture of proteins, thereby underestimat-
ing their dynamic nature138;248.
In the first part of this study, the dynamic properties of a protein-ligand complex are an-
alyzed using a molecular dynamics simulation based on the binding geometry observed in 
a crystal structure determined by Holger Steuber in our laboratory. Characteristic changes 
of the binding geometry, observed by MD simulations, prompted us to collect multiple 
data sets of crystals obtained by different soaking or cocrystallization conditions in order to 
investigate whether the MD-indicated flexibility is reflected by different states in crys-
talline phase.
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By doing so,  distinct  protein-ligand complexes were obtained,  which emphasize the 
agreement between experimentally observed and computationally predicted adaptability of 
the investigated binding pocket. 
An intricate interplay between flexibility of some amino-acid side-chains and coopera-
tive packing effects  caused by symmetry-equivalent molecules enable binding of  more 
than one ordered ligand within and near  the binding pocket.  Such unexpected binding 
mode observed by X-ray crystallography is reported in the second part of this study.
Figure 57: Refinement model of the crystal structure obtained after one day soaking of the 
ligand  zopolrestat  into  AR crystals  (1d).  Residues  comprising  the  binding  pocket  are  
shown as sticks colored in yellow, the ligand is shown in magenta. H-bond interactions  
are  represented  in  orange.  The  benzothiazole  moiety  penetrates  the  specificity  pocket  
formed by Trp 111, Phe 122, and Leu 300. The phthalazinone system intercalates between 
Trp 20, Trp 79, and Phe 122, whereas the carboxylic head group penetrates into the cat-
alytic cleft. Note the formation of the H-bond donated by Leu 300 NH to the ligand`s N3.
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Results and Discussion
For the first part of this study human AR is complexed with zopolrestat (Figure 58, 1), a 
potent carboxylic-acid type inhibitor formerly investigated in clinical trials. The structure 
was obtained from preformed crystals after they have been soaked for one day with the lig-
and (1d, Figure 57). It was refined to a resolution of 1.48 Å and shows the following bind-
ing mode: The benzothiazole moiety of the inhibitor occupies the specificity pocket by 
penetrating between Leu 300 and Trp 111, whereas its phthalazinone part intercalates with 
Phe 122, Trp 111 and Trp 20. 
Remarkably, Trp 20 Νε1 forms a contact of 3.1 Å to the 5´-carbon atom of the phtha-
lazinone system which is exceptionally short for a hydrophobic van der Waals contact. The 
carboxyl group of zopolrestat is propbably deprotonated and forms electrostatic interac-
tions to the positively charged nicotinamide moiety of the cofactor. Furthermore, it partici-
pates in a charge-assisted H-bond network to Tyr 48, His 110, and Trp 111. Importantly for 
the following, the nitrogen atom of the benzothiazole moiety accepts an H-bond from the 
Figure 58: Chemical formulae of the aldose reductase inhibitors zopolrestat (1), tolrestat  
(2), sorbinil (3), and fidarestat (4).
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backbone NH group of Leu 300 facilitated by an appropriate orientation of the amide bond 
linking Ala 299 to Leu 300. The electron density observed for 1d gave no evidence for any 
split conformation relevant for the binding site residues. 
A similar binding geometry for the same complex obtained by cocrystallisation was de-
scribed by Wilson et al.179. However neither structure factors nor complete protein coordin-
ates, but rather the Cα trace are deposited with pdb entry 1mar. 
Figure 59: Selected conformational snapshots obtained from the MD simulation of the AR 
zopolrestat complex are represented for the residues Cys 298, Ala 299, and Leu 300. These  
snapshots suggest enhanced mobility in this region: while the conformations shown in green  
or magenta enable H-bond formation to the ligand`s N3, this H-bond is ruptured in the con-
formations coloured in light blue or yellow. The inhibitor as observed in co_10 is represent-
ed as grey sticks after superimposing this crystal structure with the MD snapshots using a  
Ca-fit.
However, is this binding geometry observed as frozen-in situation in our crystal struc-
ture also relevant under conditions that allow to evolve dynamic behavior? In order to ob-
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tain some insights into the latter properties, MD simulations of the described complex were 
carried out. 
Analysis of rms deviations to detect families of conformations together with the visual 
inspection of the corresponding frames (Figure 59) clearly indicate the presence of several 
distinct states differing in their orientation of the loop residues Ala 299 and Leu 300. 
Conformation 1 resembles the geometry observed in the crystal structure which served as 
starting template. It shows the described H-bond between Leu 300 NH and the inhibitor`s 
N3. However, conformation 2 displays a situation where this H-bond is ruptured as a result 
of a flip in the backbone of Ala 299. Thus, a conformation is obtained which is similar to 
one observed in the ultra-high resolution crystal structure of human AR in complex with 
the inhibitor IDD 594114. 
Additionally, Figure 59 represents two intermediates between the conformations 1 and 
2. The dominant conformation throughout the MD is the one where no hydrogen bond be-
tween Leu 300 backbone and the inhibitor is formed. Nevertheless, is this indicated mobili-
ty an artefact of our MD simulation or does it suggest enhanced flexibility in this region?
A single crystal structure can hardly provide evidence for such behaviour. Accordingly, 
we were stimulated to perform further crystallisation experiments. In particular, the influ-
ence of different crystallization conditions (soaking period and cocrystallisation) was ad-
dressed. In total nine independent data sets for crystal structures were collected.
After soaking for two hours, no appropriate electron density for zopolrestat could be de-
tected in the Fo-Fc difference map. Instead, a citrate molecule picked up from the crystalli-
sation buffer occupied the active site. The specificity pocket is closed, as indicated by short 
van der Waals contacts between the side-chains of Leu 300 and Trp 111. The backbone 
carbonyl group of Ala 299 likely accepts an H-bond from Tyr 309 OH through a 2.5 Å dis-
tance. The corresponding NH group of Leu 300 points towards the binding pocket and do-
nates an H-bond to the solvent-exposed carboxylate of the citrate. As several AR citrate 
complexes have already been described and deposited in the PDB, this citrate complex is 
not further described here.
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Figure  60: Representation of the binding pocket occupied by the inhibitor zopolrestat.  
Fo-Fc difference densities observed after excluding the corresponding residues from the 
model are shown contoured at 2.0 σ A) The electron density shows the conformation of  
the loop residues of 1d. B) The electron density observed for 3d_a confirms the loop con-
formation in Fig. 1 and Fig. 4a. c) Representation of the loop conformation found in a  
third crystal soaked for three days (3d_c). A backbone flip of the Ala 299-Leu 300 pep-
tide bond accompanied by a rupture of the H-bond to the ligand is observed in this crys-
tal structure. Additionally, a gap in the electron density within the backbone suggests en-
hanced mobility. d) Binding pocket representation obtained from crystals soaked for six  
days (6d_a). The difference density is poorly defined for some parts of the C-terminal  
loop, but it clearly shows a flip similar to the conformation found in 3d_c as well as rup-
ture of the density near Ala 299.
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Expanding the soaking period to three or even six days introduced remarkable signs of 
flexibility and even conformational changes. This behaviour is in agreement with the ob-
servations made in the MD simulations. 
Two of three crystal structures based on data collected after a soaking period of three 
days (3d_a, 3d_b) exhibit a break of the Fo-Fc electron density at > 2.8 σ level between the 
Cα-atom and the carbonyl group of Ala 299, thereby providing some evidence for exten-
ded flexibility present in this region. 
However, the conformations found in these two structures (Figure 60 b) resembles the 
one observed after short soaking (1d), thus, the H-bond donated by the Leu 300 amide 
group to N3 of the ligand is maintained. 
Figure 61: Superposition of the refinement models obtained for co_10 (blue), 6d_a (ma-
genta) and 1d (yellow). This representation clearly shows 1d and co_10 being virtually  
identical, whereas in 6d_a the C-terminal loop adopts a different conformation.
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Surprisingly, in the third crystal structure obtained from a crystal soaked for three days 
(3d_c) a backbone flip of the amide bond next to Ala 299, accordingly accompanied by a 
rupture of the respective H-bond to the ligand is observed. 
To assess the relevance of our refinement model, the Fo-Fc difference electron density 
was examined as obtained from excluding the residues 298-302 from the model (Figure 60 
c). Conformational changes and a possible distribution over multiple conformational states 
is suggested by the poorly defined electron density next to Ala 299 in 3d_c. No significant 
electron density is observed for Leu 300 Cγ, Cδ, and Cε, indicating high flexibility for this 
side-chain. 
Both crystal structures determined after a soaking period of six days (6d_a and 6d_b) 
showed a similar binding geometry as  3d_c, confirming the occurrence of the backbone 
flip observed for Ala 299. Whereas the Ala 299 φ angle is nearly unchanged in all struc-
tures (-167.8 +/- 6.6 °), the ψ angle is rotated by 120° from 66.7 +/- 2.5 ° in 1d, 3d_a, and 
3d_b to -175.2 +/- 6.9 ° in 3d_c, 6d_a, and 6d_b. Hence, the flip of the Ala 299 carbonyl 
group is facilitated, 
In order to examine which of the observed binding geometries is obtained carrying out 
cocrystallisation experiments, two additional structures of the same complex were determ-
ined. One set, co_1, was collected using a crystal grown within one day, and a second data 
set,  co_10, after crystals were exposed for ten days to the mother liquid. In contrast to 
long-term soaking, for both structures obtained by cocrystallisation the electron density 
clearly indicates the conformation resembling that in  1d, without any ill-defined electron 
density next to Ala 299. 
As summary, shown in  Figure 61, long-term ligand soaking of preformed crystals in-
duces conformational changes which are not observed after short-term soaking only or via 
cocrystallisation. 
Figure 62 visualises these changes by representing the TIM-barrel as tube diagram col-
oured by B-factors. In particular, within the ligand-binding C-terminal loop a remarkable 
increase of the B-factors is observed when comparing, e.g., the crystal structures  co_10 
and 6d_a. Despite these representations are not based on normalized B-factors, the Wilson 
Expect the Unexpected while working with AR 171
B-factor for the co_10 and 6d_a data sets are 17.7 and 16.9 Å², respectively. This suggests 
that B-factors derived from model refinement are to some degree comparable. 
To evaluate whether the enhanced mobility observed by the MD simulation is depend-
ent on the corresponding starting conformation, a second MD run was performed. The 
3d_c structure was used as initial model, where the H-bond between the inhibitor`s N3 and 
Leu 300 NH is not formed. Under these conditions, the clusters representing the conforma-
tion missing this hydrogen bond are higher populated. However, the backbone flip, which 
triggers the H-bond formation is also observed. Thus, the enhanced flexibility in this re-
gion, suggested by the MD simulation, is not dependent on the starting geometry. 
Figure 62: TIM-barrel of AR represented as tube, emphasizing the local mobility with re-
spect to the refined B-factors. The tube is colored by B-factor: blue regions correspond to  
low temperature factors, whereas green, yellow and red color characterize regions of sub-
sequently increasing B-factor. Additionally, gain of temperature factor is represented by  
increasing radius of the tube. The inhibitor zopolrestat is shown in magenta. A represents 
the corresponding tube representation for co_10, in B) the one for 6d_a is given. Note the 
remarkable gain of local mobility within the C-terminal loop region lining the ligand bind-
ing pocket observed in 6d_a compared to co_10. These comparison suggests that extended  
soaking periods provoke increasing mobility with respect to distinct regions represented  
by higher B-factors.
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In the second part of this investigation, the incorporation of several ligand molecules 
into the same complex depending on the crystallization conditions will be reported. The 
binding of the additional ligands is accompanied by cooperative changes of residues partic-
ipating in crystal packing. The corresponding crystal structures have been determined as 
part of this thesis (Appendix B).
The structure of tolrestat (Figure 58, 2) has been determined previously in complex with 
porcine AR (pdbcode: 1ah3) to a resolution of 2.30 Å by Urzhumtsev et al.120 in 1997 (Fig-
ure 63). 
Figure  63: Binding mode of  tolrestat  in pig AR as described in literature120.  The car-
boxylic-acid head group occupies the catalytic pocket, whereas the naphthyl moiety forms 
hydrophobic contacts to Trp 111, Phe 122, and Leu 300. Note the kinked conformation of  
Leu 300 allowing the aromatic system of the ligand to adopt an edge-to-face orientation.
In order to elucidate the crystal structure with the corresponding human enzyme, crys-
tals of the complex were obtained by soaking for three days. The crystal structure was re-
fined to 1.48 Å. Data collection and refinement statistics are given in Appendix B (page 
197). The overall structure is very similar to the complex with porcine AR, showing a Cα 
rmsd of 0.37 Å.
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Surprisingly, the final structure comprises four bound ligand molecules in and next to 
the binding pocket (Figure 64). One ligand, L1 adopts the same binding mode as the single 
ligand in the deposited pig aldose reductase structure (0.1 Å rmsd). 
Figure 64: Representation of ALR2 in complex with four tolrestat molecules, Fo-Fc densi-
ties are colored in blue and contoured at 1.5 σ. Ligand L1 occupies the binding pocket as  
observed in the 1:1 complex with the enzyme. However, in the present complex, a second 
ligand, L2 is placed in front of the binding site of L1, forming an edge-to-face interaction  
with each other. Two additional tolrestat molecules, L3 and L4, occupy a binding cleft  
formed by crystal contacts.
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A second tolrestat molecule, L2, is placed in front of the binding pocket perpendicular 
to L1. The carboxylate group of this molecule forms two hydrogen bonds with the back-
bone nitrogen atoms of Leu 301 and Ser 302. The naphthalin moiety adopts T-shaped hy-
drophobic π−π stacking geometry with respect to the corresponding part of ligand L1. 
The two additional ligands L3 and L4 are placed in a small pocket created by crystal 
contacts. They form hydrophobic stacking interactions with each other, most likely further 
stabilizing their binding mode. The carboxylate moiety of L3 forms a salt bridge to Lys 
194 of a symmetry equivalent molecule, while the carboxylate group of L4 accepts an H-
bond from Asn 292 ND2 of the same symmetry equivalent molecule. 
In order to further analyze how the protein adapts to the additional ligands, two further 
datasets using crystals with soaking times of two hours and four days were collected, keep-
ing all other parameters constant. The long-term soaked crystal was measured at a syn-
chrotron beamline to improve data quality and resolution of the putative multi-ligand com-
plex structure. As expected the structure determined from crystals of a short-term soak 
comprises only one ligand. It is placed in the binding pocket as already found in singly 
complexed tolrestat crystal structures (Figure 63). Surprisingly, also the crystal structure 
derived from the four-day soak reveals only one bound ligand, thus leaving the four ligand-
bound structure as an unique observation. 
The most striking difference between the crystals is a change in the length of the b axis 
of the unit cell of about 2 Å, probably one feature resulting from the incorporation of the 
additional ligands. Screening for further crystals with a similar expansion of the cell di-
mensions was not successful as suggested by data collected from five other crystals soaked 
for three days. 
A close comparison of the one and four ligand-bound structure reveals how the addi-
tional ligands are accommodated in a cleft formed between the protein molecules (Figure
65). The interactions experienced between the ligands and the protein (see above) are ac-
companied by additional changes.
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Figure  65:  Interactions  of  the  additional  ligands  with  ALR2 and its  symmetry  related 
molecules. Fo-Fc densities of the inhibitor molecules are coloured in blue and contoured  
at 1.5  σ. The carboxylate moiety of L3 forms a salt bridge to Lys 194 of one symmetry 
equivalent, while the carboxylate group of L4 accepts an H-bond from Asn 292 ND2 of this  
symmetry equivalent. The adoption of the additional ligands requires significant changes  
of the protein structure: The helix formed by the residues Ser 282 - Tyr 291 performs a Ca 
shift of about 7.0 Å RMSD away from the binding site, whereas the helix Lys 195 - Lys 203 
moves 6.2 Å towards L3. For comparison these helices representing the conformation ob-
served in the four-ligand complex are colored in blue, whereas the spatial location of these  
helices known from the one-ligand structure is shown by red ribbons.
The C-terminal residues Glu 313 – Phe 315, in the one-ligand structure significantly dis-
ordered and difficult to localize in electron density maps, become better ordered upon in-
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corporation of the additional ligands. The C-terminal carboxylate oxygens at Phe 315 form 
an interaction with the backbone nitrogen of His 163, while the phenyl moiety is involved 
in a π-π stacking interaction with the imidazole moiety of the latter residue. The residues 
which directly interact with L3 and L4 adopt different conformations to facilitate these in-
teractions. 
In order to expand the pocket to accommodate L3 and L4 the helix formed by the 
residues Ser 282 – Tyr 291 performs a Cα shift of about 7.0 Å rmsd. The spatial location of 
this helix adopted in the one-ligand structure would clash with both, L3 and L4. 
Additionally, the helix comprised of residues Lys 194 to Lys 202 moves 6.2 Å towards 
L3 in order to facilitate the salt bridge between Lys 194 and the carboxylate group of L3. 
During this process the otherwise disordered residue Lys 194 becomes ordered. The space 
created by the motion of the helix is occupied by the C-terminal residue Phe 315, which 
also becomes ordered (see above). 
These features clearly indicate that remarkable conformational changes apart from the 
induced-fit adaptations of the binding pocket take place in order to bind the additional lig-
ands. Even though the occurrence of two ligands, both located within the binding pocket, 
have been reported for a double mutant of AR249, such a phenomenon as described in this 
study was never observed before in AR crystals.
Conclusions
Several conclusions can be drawn from our studies. It is widely assumed that the same 
binding mode is found for a protein-ligand complex crystallized from the same mother liq-
uid under constant conditions.
This immediately provokes the question under which conditions the most relevant ge-
ometry resembling the in-vivo situation may be obtained in order to develop meaningful 
ligand design hypotheses. Even though an explanation for the results of this study cannot 
be given, it provides a caveat to structural studies. Usually, crystals are grown under condi-
tions that turn out to be successful. The best diffracting crystal is subjected to data collec-
tion and the data are evaluated. Once the structure has been determined successfully, usual-
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ly no further analysis of this structure in dependence of the crystal growth conditions is 
performed. This is a quite acceptable strategy, in particular, since the systematic re-evalua-
tion of a structure can be rather tedious. 
For the present case study, in total 17 complete data sets had to be collected, 12 of those 
were subsequently refined. However, as indicated, the relevance of the resulting structures 
with respect to drug design can be different. Furthermore, such multiple structure determi-
nations can indicate the intrinsic flexibility of some portions of a protein that are in particu-
lar influenced and modified upon ligand binding. The present multiple structure determina-
tions have been combined with MD simulations to generate a conclusive picture among the 
individual frozen-in snapshots seen in the different crystal structures. 
Appropriate handling of protein flexibility in structure-based drug design remains one 
of the major challenges. Even though a generally applicable protocol is not yet available, 
this study suggests that more relevant hypotheses can be produced if crystal growth and 
protein-ligand complex generation is performed under varying conditions and crystal struc-
ture analysis is combined with MD simulations. The latter is particularly important if only 
one crystal structure is available. 
Visual  inspection and thorough comparison of  multiple  crystal  structures and NMR 
studies complemented by the analysis of frames generated by MD simulations might help 
to estimate, in which regions enhanced protein mobility can affect ligand binding.
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Summary and Outlook
Protein flexibility is an important, but still barely understood phenomenon. It is recognized 
as a crucial factor to be included in any design of small-molecule protein inhibitors97-99. 
In the first part of this work the relevance of considering protein flexibility in structure-
based drug design was highlighted.  Docking experiments  were carried out  for  two in-
hibitors which were originally designed118 to mimic the unique binding mode of the AR in-
hibitor tolrestat119;120. Instead of using only the complex structure of tolrestat as template, 
the three known binding-pocket conformations of AR were considered as putative pocket 
conformations to be addressed by the ligands. 
Separate docking simulations were carried out for each combination of pocket and lig-
and using AutoDock 3.0122 with its default scoring function. For both ligands the obtained 
energy scores indicated that the tolrestat binding pocket was unlikely to be the preferred 
pocket conformation. Instead, AutoDock suggested that the ligands adopt a binding mode 
similar to the inhibitor sorbinil120;240 where the specificity pocket is in a closed conforma-
tion. 
After the crystal structures became available this hypothesis could be verified. In both 
X-ray  structures  the  specificity  pocket  was  closed  and  the  inhibitors  adopted  binding 
modes which are most compatible with the one of sorbinil. 
However, the predictions were by no means perfect. One of the compounds induced a 
conformational change in the catalytic sub-site of the AR binding pocket. Previously this 
part of the enzyme had always been regarded as being relatively rigid. Since no crystal 
structure appropriate as template for the docking experiments was available at the time 
they were carried out, there was no chance to correctly predict the exact binding mode of 
this compound. The other compound did not induce an unexpected conformational change. 
However, with this molecule the importance of considering water during docking could be 
emphasized. The region of the binding pocket where AutoDock placed one hydrophilic 
side chain of the inhibitor was occupied by three water molecules in the corresponding 
crystal structure. 
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Thus, it could be shown that, despite the limitations of the available methods, it is rec-
ommendable to include multiple pocket conformations into the docking process. 
In the second part of this thesis a new method to simplify the tedious process of docking 
to multiple targets was evaluated in the context of protein flexibility: in-situ cross-dock-
ing124. With this method, instead of performing sequential docking experiments of multiple 
ligands into multiple protein structures, several protein conformations can be addressed in 
one docking run. Hence, the number of docking experiments is reduced significantly and 
the time needed for setting up the docking runs, carrying out the actual calculations, and 
analyzing the results is shortened. If docking a large compound library to a set of multiple 
protein conformations this can significantly save computing time.
During the docking process with AutoDock the protein is represented by a set of grids 
with preassigned energy values. These grids are derived by placing probe atoms on each 
intersection of a regularly spaced grid and calculating the interaction energy for that probe 
with the entire protein. Therefore, each set of grids represents exactly the pocket conforma-
tion it was derived from. The main idea of 'in-situ' cross-docking is to paste multiple of 
these grids together in a linear fashion, thus providing a joined 'super-grid' which repre-
sents all the protein conformations in one grid. 
Using representatives of the three main binding-pocket conformations of AR, it could 
be shown in a first step that for the three inhibitors, whose complex protein structures were 
used to generate the single grids, the correct binding mode was found. In a second step it 
was demonstrated that ligands which adopt binding modes similar to one of the three repre-
sentative ligands, but whose complex crystal structures were not used to calculate the grids 
could also be docked correctly. As a last step the binding mode of an inhibitor125 for which 
at that time no crystal structure was available could be predicted correctly. 'In-situ' cross-
docking proposed a  binding mode similar  to  idd 594114 which addresses the specificity 
pocket. The crystal structure solved subsequently verified the predicted binding mode. The 
best-scored docking solution and the ligand in the crystal structure deviated by only 0.49 Å 
rmsd. 
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In the next part of this thesis the flexibility of the AR binding pocket was examined in 
detail. To provide insight into this issue the available crystal structures were superimposed 
and analyzed using Relibase+ in a first step. 
In agreement to previous studies113 it was shown that with respect to the binding pocket 
flexibility is limited to only a handful amino acids close to the specificity pocket. It was 
elucidated how the enzyme performs its 'induced-fit' binding mechanism. Only a small C-
terminal loop region is utilized to facilitate most of the adaptation process necessary to ac-
commodate different ligands. 
In addition, a detailed comparison of the binding modes of different ligands addressing 
the specificity pocket was carried out. This analysis was enabled by the availability of 
many high-quality crystal structures of human, wild-type AR available. The analysis ex-
ceeds previous ones significantly with respect to the number and the quality of the crystal 
structures considered. It was found that despite similar binding modes of many inhibitors, 
there are subtle differences between the corresponding binding-pocket conformations.
To further explore the conformational space available to the AR binding pocket, multi-
ple MD simulations were carried out. While crystal structure analysis is a powerful tool to 
analyze binding pocket  features determined under certain experimental  conditions,  MD 
simulations are the method of choice to computationally examine the dynamic properties 
of a protein. In total, ten MD simulations (seven AR complexes plus three different holo 
simulations) were carried out. All simulations were started from crystal structure geome-
tries and the parameters were set according to the current state of the art. Two of the crystal 
structures required to perform the MD simulation project were solved in the context of this 
thesis.
MD simulations produce vast amounts of data, which have to be post-processed and an-
alyzed. This task can easily become impracticable if multiple trajectories have to be con-
sidered. To facilitate comparative analysis, an MD database (MDDB) based on Python and 
MySQL has been developed. It allows to store results from multiple simulations. The pow-
erful query features of the database helped to analyze different aspects from the same tra-
jectory on the one hand and enabled comparison of features from different MD simulations 
on the other. 
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The MDDB tool developed as part of this study has built-in functionalities to automati-
cally analyze distances, different rmsd measures as well as torsion angles. These features 
have proven useful in the comparative analysis of the ten MD simulations described in this 
thesis. However, there is room for future developments, since there are many more aspects 
of an MD simulations which are of putative interest depending on the aim of the study car-
ried out.
The ten MD simulations mentioned above were analyzed with respect to the dynamic 
behavior of the binding pocket. Good overall agreement between the results from the MD 
simulations and the crystal structure analysis was found. Residues which exhibited elevat-
ed levels of flexibilities in the MD simulations showed in most cases also differences be-
tween the single crystal structures. However, a few residues showed unexpected behavior 
in the MD simulations: Phe 122, Trp 219, and Tyr 309. 
In an attempt to explain this observation, an analysis of the effects of crystal packing on 
the binding-pocket residues was carried out. Under the special conditions of the tightly 
packed  crystal  environment,  additional  contacts  are  formed  which  are  not  necessarily 
present in solution. These contacts impose additional restraints on a protein, thus presum-
ably altering its dynamical behavior. The results from the packing analysis showed that 
Phe 122 and Tyr 309 are involved in such contacts, thus providing a putative explanation 
why the conformations observed in the MD simulations are not seen in the crystal struc-
tures. Trp 219 is attached to a loop region which is also involved in crystal packing. The 
flexibility seen in the MD simulations is reasonable, since it is important for the biological 
function of the enzyme that this loop region is flexible. After each turn-over of the catalytic 
reaction the loop has to move as a prerequisite.
Further analysis of the flexibility of the binding pocket revealed that through the move-
ment  of Phe 122 an additional hydrophobic sub-pocket above the specificity pocket is 
opened. Additionally, the combined movements of Tyr 309 and the C-terminal loop region 
create extra space in the lower part of the AR binding pocket. Therefore, the next step was 
to search for small molecules which are suitable to induce or stabilize the binding pocket in 
one of the novel conformations observed in the MD simulations. 
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In the literature an interesting compound from Pfizer was presented184. Docking studies 
using an MD snapshot as protein template suggested that the bulky phenyl group of the lig-
and may potentially address the additional space generated in the lower part of the binding 
pocket.  However,  the  crystal  structure  which may confirm or  disprove  this  hypothesis 
could not be obtained in the time frame of this study, thus this has to be clarified in future 
investigations. 
To address the space generated by the Phe 122 movements different approaches were 
considered. A benzodiazepine scaffold was chosen, due to its easy synthetic availability 
and variability. Docking a small library of benzodiazepines with different side-chain deco-
rations helped to prioritize the molecules for synthesis. One compound could be synthe-
sized so far in the group of Prof. Schlitzer. The measured IC50 value indicates only very 
moderate binding in the high µM range. Also this part of the project leaves room for future 
investigations. If one of the proposed molecules shows considerable affinity towards AR, 
the determination of a crystal structure would be desirable to verify the binding mode pro-
posed by the docking experiments. If none of the benzodiazepines is sufficiently active for 
crystallization experiments, the idea of modifying an AR inhibitor with known binding 
mode to address the putative new pocket conformation, provides an alternative concept. 
This strategy could not be followed in this study, after considering the elaborate chemistry 
needed to produce appropriately altered AR inhibitors to address this region of the pocket.
In a further project, the generated MD trajectories were used to energetically analyze the 
process of 'induced-fit' adaptation. The method MM-PBSA194 was chosen for this purpose, 
since at first glance it seemed to be ideally suited. It calculates the binding free energies for 
a protein-ligand complex from ensembles of MD-generated conformations rather than us-
ing only one single rigid structure. By incorporating separate trajectories for the complexed 
and uncomplexed states of the protein as well as the ligand it should be possible to capture 
the interactions as well as the conformational energies involved in the 'induced-fit' binding 
process. Compared to other more rigorous methods to calculate binding free energy differ-
ences, it  is applicable to larger data sets of diverse molecules. In addition, it  had been 
shown in numerous previous studies194-202;204;206;207;210;223;227 that it can be a valuable tool to 
analyze various aspects of structure-based drug design and related topics. Up to date only 
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one study has been published203 where the method provides results of reduced predictabili-
ty.
However, despite thorough testing of different MM-PBSA variants, binding free energy 
predictions were ,  at  best,  only slightly better  than random. Considering the enormous 
amount of computational power required to perform the necessary calculations and the re-
markable time needed to analyze the results, MM-PBSA did not turn out to be a cost-effec-
tive method to predict binding free energies for the dataset of AR inhibitors used in this 
study. Since a correct prediction of the binding free energies is a prerequisite for further in-
terpretation in order to estimate the conformational energies involved in 'induced-fit' bind-
ing, this issue could not be further investigated.
Although many variations of the method have already been tested,  a few additional 
points could possibly be considered in the future. One issues is the systematic parameteri-
zation of a consistent set of radii for the calculations. In the recently released new version 
of Amber250 this has been done, and it might be of interest to investigate the influences on 
the results. A second topic would be to analyze the effect of different dielectric constants 
on the PB calculations with respect to the predictions. However, keeping the overall rather 
disappointing results in mind it remains questionable whether significant improvements 
could be achieved to justify the high computational costs.
In the final section of this thesis a study was presented where in the first part aspects of 
flexibility of the C-terminal loop of AR were examined. In a combined study using MD 
simulations and multiple crystal structures, determined in the thesis of Holger Steuber, it 
was shown that there are clear differences between individual crystal structures of the same 
protein-ligand complex in this region of the enzyme. The MD simulation part of this study 
was performed as part of this thesis. A nice agreement between the observations made in 
the MD and multiple crystal structures derived from different experimental crystallization 
conditions was found. This is one of the rare examples which emphasizes the fact that pro-
tein flexibility might be underestimated by protein crystallography. 
In the second part of this section the unexpected occurrence of multiple ligands in and 
close to the binding pocket of AR was described. The determination of the corresponding 
crystal structures was part of this work. Four tolrestat molecules occupied the space in and 
184 Summary and Outlook
next to the binding pocket. The binding of the additional ligands was accompanied by 
structural changes in large parts of the protein which had not been observed to this extent 
before. 
In summary, this has analyzed many aspects of protein flexibility using AR as a model 
system. The importance of incorporating protein flexibility into docking experiments was 
shown. A new method to include multiple protein structures into the docking process has 
been presented. To characterize the binding-pocket flexibility of AR an exhaustive com-
parative analysis of the available crystal structures was carried out. To further explore the 
AR binding-pocket flexibility multiple MD simulations were carried out and analyzed us-
ing a database tool especially developed for this purpose. The analysis suggests two new 
putative binding-pocket conformations. Subsequently, initial trials were made to stabilize 
these  new conformations  using small  molecules.  In  addition,  energetic  analysis  of  'in-
duced-fit'  binding was carried out,  thereby evaluating MM-PBSA for  flexible proteins. 
Furthermore, the flexibility of parts of the binding pocket was examined in a joined MD/X-
ray study. Again, excellent agreement was detected between the two approaches. Finally, 
the binding of a set of multiple inhibitor molecules to AR provides further insights into 
flexibility since large movements and adaptations take place which are totally unexpected. 
AR proves to be a valuable test system to investigate different aspects of protein flexibility.
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Zusammenfassung
Die Flexibilität  von Proteinen und deren Bindetaschen ist  ein  wichtiges,  aber  bis  zum 
heutigen Tag nur schlecht verstandenes Phänomen. Insbesondere für das strukturbasierte 
Ligandendesign ist eine Berücksichtigung dieser Plastizität von enormer Bedeutung. 
Aldose Reductase (AR) ist das erste und geschwindigkeitsbestimmende Enzym des sog. 
„Sorbitol-Stoffwechselweges“.  Es  reduziert  unter  Verbrauch von NADPH als  Kofaktor 
verschiedene Aldehyde zu den entsprechenden Alkoholen.  Um diese Aufgabe  effizient 
durchführen zu können, zeigt seine Bindetasche eine intrinsische Flexibilität. Diese geht 
im wesentlichen von einem kleinen Bereich der Bindetasche aus, dessen Bewegungen es 
erlauben, eine sog. „Spezifitätstasche“ zu öffnen oder zu schließen. Dadurch wird es dem 
Enzym erlaubt, eine ganze Reihe von strukturell verschiedenen Aldehyden als Substrate 
akzeptieren zu können. 
Der erste Teil der Arbeit dokumentiert ein Beispiel, anhand dessen sich die Auswirkun-
gen einer  flexiblen  Bindetasche  auf  die  Zuverlässigkeit  von  Dockingexperimenten  ab-
schätzen  lassen.  Die  Experimente  wurden  für  zwei  Moleküle  durchgeführt,  die  ur-
sprünglich  dafür  konzipiert  wurden,  den  bis  zum  heutigen  Tag  einzigartigen 
Bindungsmodus des AR Inhibitors Tolrestat zu kopieren. Anstatt die Dockingexperimente 
jedoch  ausschließlich  mit  der  Bindetaschenkonformation  des  Tolrestat-Komplexes 
durchzuführen, wurden beide Inhibitoren unter Verwendung des Programms AutoDock 3.0 
einzeln in die drei bekannten Hauptbindetaschenkonformationen der AR gedockt. 
Für keines der beiden Moleküle sagte die in AutoDock implementierte Bewertungsfunk-
tion einen tolrestatähnlichen Bindungsmodus als besonders günstig voraus. Im Gegenteil, 
die  abgeschätzten  Bindungsenergien  waren  jeweils  in  der  Tolrestat-Bindetasche  die 
schlechtesten.  Vielmehr  wurde  ein  Bindungsmodus  ähnlich  zu  dem  von  Sorbinil 
vorgeschlagen, bei dem die Spezifitätstasche sich in geschlossenem Zustand befindet. 
Diese Hypothese konnte durch die später erhaltenen Kristallstrukturen der jeweiligen 
Komplexe bestätigt werden. In beiden Fällen ist die Spezifitätstasche geschlossen und die 
erhaltenen Bindungsmodi waren am ehesten mit dem von Sorbinil zu vergleichen. 
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Trotz dieser zunächst erfreulichen Ergebnisse waren die Vorhersagen des Dockingpro-
gramms alles andere als perfekt. Eines der beiden Moleküle verursachte eine strukturelle 
Veränderung in einem Teil der Bindetasche, der bis dahin als rigide betrachtet wurde. Da 
unter  den  bekannten  Kristallstrukturen  kein  geeignetes  Templat  für  den  gefundenen 
Bindungsmodus vorhanden war, war eine exakte Vorhersage des genauen Bindungsmodus 
dieses Moleküls nicht möglich. Im Gegensatz dazu induzierte das zweite Molekül keine 
ungewöhnliche Bindetaschenkonformation. Hier war es vielmehr so, dass die Stellen in der 
Bindetasche, in die AutoDock die Sauerstoffe einer hydrophilen Seitenkette des Moleküls 
platzierte, in der Kristallstruktur von drei Wassermolekülen eingenommen werden. 
Diese Beispiele illustrieren auf der einen Seite, dass die vorhandenen Methoden, um mit 
Proteinflexibilität und dem Einfluss von Wasser auf den Bindungsmodus umzugehen, noch 
stark verbesserungswürdig sind. Auf der anderen Seite hat sich aber auch gezeigt, dass es 
empfehlenswert  ist,  mehrere  bekannte  Bindetaschenkonformationen  beim  Docken  von 
kleinen Molekülen zu berücksichtigen. 
Im zweiten Teil der Arbeit wurde ein kürzlich neu vorgestelltes Dockingverfahren im 
Zusammenhang mit Proteinflexibilität getestet. Hierbei handelt es sich um das sog. „in-situ 
cross  docking“.  Anstatt  Dockingexperimente  in  mehrere  Bindetaschen  sequentiell 
durchzuführen,  können  bei  diesem Verfahren  multiple  Proteinkonformationen  simultan 
adressiert werden. Dadurch wird zum einen die Anzahl der notwendigen Rechnungen re-
duziert, zum anderen wird auch die Auswertung solcher „cross docking“ Experimente erle-
ichtert.  Betrachtet  man  eine  größere  Bibliothek  von  kleinen  Molekülen,  die  man  an 
mehrere Bindetaschenkonformation docken möchte, so stellt  sich ein signifikanter Zeit-
gewinn ein.
Das Verfahren basiert darauf, dass das Protein während des Dockens, um Rechenzeit 
einzusparen, in Form eines Satzes von vorberechneten Energiegittern repräsentiert wird. 
Diese werden dadurch erhalten, dass verschiedene Sondenatome auf den Schnittpunkten 
eines definierten Gitters platziert werden, welches die Bindetasche umschließt. Von diesen 
Gitterpunkten aus wird die Wechselwirkungsenergie der jeweiligen Sondenatoms mit dem 
gesamten Protein berechnet und abgespeichert. Eine Konsequenz dieser Methode ist, dass 
ein  Satz  von  Energiegittern  genau  die  Proteinkonformation  repräsentiert,  aus  der  er 
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abgeleitet  wurde.  Die  Idee  des  „in-situ  cross  docking“  ist  nun,  mehrere  solcher  Gitter 
aneinander zu reihen und somit eine Art „Super-Gitter“ zu erzeugen, das mehrere Pro-
teinkonformationen gleichzeitig repräsentiert.
Um die Methode in Bezug auf Proteinflexibilität zu validieren, wurde ein vereinigtes 
Gitter aus repräsentativen Strukturen der drei bekannten Hauptbindetaschenkonformatio-
nen  erzeugt.  Dann  konnte  zunächst  gezeigt  werden,  dass  die  Bindungsmodi  von  In-
hibitoren korrekt berechnet wurden, deren Komplexstrukturen in die Berechnung der Gitter 
eingeflossen waren. In einem zweiten Schritt konnten die Bindungsmodi von Inhibitoren 
reproduziert  werden,  welche  ähnliche  Bindetaschenkonformationen  induzieren  wie  die 
ausgewählten repräsentativen Strukturen, deren Komplexstrukturen aber nicht zur Berech-
nung der Gitter verwendet wurden. Als letztes wurde schließlich mit dieser Methode ein 
Bindungsmodus für einen damals neuen AR Inhibitor vorgeschlagen. Diese Vorhersage 
konnte  später  anhand  einer  Kristallstruktur  verifiziert  werden,  wobei  die  Abweichung 
(rmsd) zwischen dem vorhergesagten und dem experimentell bestimmten Bindungsmodus 
nur 0,49 Å betrug. 
Der nächste Teil  dieser Arbeit  untersucht detailliert  das Ausmaß der Flexibilität  der 
einzelnen  Aminosäuren  der  AR  Bindetasche.  Dafür  wurde  zunächst  ein  Analyse  der 
vorhandenen Kristallstrukturen mit Hilfe des Programms Relibase+ durchgeführt. 
In  Übereinstimmung  mit  vorangegangenen  Studien  konnte  gezeigt  werden,  dass 
lediglich einige wenige Aminosäuren für den Hauptteil  der Anpassung an verschiedene 
Liganden verantwortlich sind. Es wurde im Detail beleuchtet, wie der „induced-fit“ Anpas-
sungsmechanismus  der  Bindetasche  funktioniert.  Dabei  zeigte  sich,  dass  hauptsächlich 
eine kleine Schleifenregion, welche die Bindetasche von einer Seite begrenzt, dafür be-
nutzt wird. 
Zusätzlich wurde ein genauer Vergleich der Bindungsmoden verschiedener Liganden 
durchgeführt, welche alle die Spezifitätstasche adressieren. Diese Auswertung wurde er-
möglicht durch die große Anzahl an qualitativ hochwertigen Komplexstrukturen der huma-
nen AR, die in den letzten Jahre veröffentlicht oder intern gemessen wurden. Der verwen-
dete Datensatz ist signifikant größer und qualitativ hochwertiger als alle bisherigen. Als 
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Ergebnis konnte festgehalten werden, dass trotz großer Ähnlichkeiten zwischen den einzel-
nen Bindungsmoden doch zum Teil subtile Unterschiede festzustellen sind.
Um den für das Enzym zugänglichen Konformationsraum weiter abzudecken, wurden 
zehn Molekulardynamik (MD) Simulationen durchgeführt. Für alle Simulationen wurden 
als  Startpunkte  die  entsprechenden  Kristallstrukturen  gewählt.  Von  den  verwendeten 
Strukturen wurden zwei im Rahmen dieser Arbeit gelöst. Die Einstellungen und Parameter 
für  die  Simulationen  wurden  so  gewählt,  dass  sie  dem  aktuellen  Stand  der  Technik 
entsprechen. 
Die unmittelbare Herausforderung vor die man von MD Simulationen gestellt wird, sind 
die ungeheure Mengen an Daten, die durch das Verfahren generiert werden. Diese müssen 
nach Ende der Simulation aufbereitet und analysiert werden. Beim Vergleich der Daten 
von mehreren Simulationen stößt man schnell an die Grenzen des Handhabbaren. Um eine 
solche Analyse dennoch zu ermöglichen, wurde als Teil dieser Arbeit eine MD Datenbank 
(MDDB) entwickelt. Diese enthält Routinen, um automatisiert verschiedene Größen aus 
unterschiedlichen MD Simulation analysieren und vergleichen zu können. Diese Daten-
bank hat sich als sehr hilfreich bei der vergleichenden Analyse der einzelnen MD Simula-
tionen herausgestellt. 
Die bereits erwähnten zehn MD Simulationen wurden in Bezug auf das dynamische 
Verhalten  der  einzelnen  Aminosäuren  innerhalb  der  Bindetasche  hin  analysiert.  Dabei 
wurde eine gute generelle Übereinstimmung zwischen den Ergebnissen der Simulationen 
und der Kristallstrukturanalyse festgestellt. Aminosäuren, die erhöhte Flexibilität in den 
Simulationen zeigten, waren in der Regel auch in mehreren unterschiedlichen Konforma-
tionen in den Kristallstrukturen zu finden. Dennoch verhielten sich einige Aminosäuren in 
den Simulationen anders, als man es zunächst nach der Analyse der Kristallstrukturen er-
wartet hätte. Diese waren im einzelnen: Phe 122, Trp 219 und Tyr 309. 
Um eine Erklärung für dieses unerwartete Verhalten zu finden, wurde eine Analyse der 
Auswirkungen der  Kristallpackung auf  die  Aminosäuren der  Bindetasche durchgeführt. 
Die eng gepackte, symmetrische Umgebung in einem Kristall generiert zusätzliche Kon-
takte, die in Lösung nicht notwendigerweise existieren. Diese Kontakte können strukturelle 
Umlagerungen bedingen oder das dynamische Verhalten des Proteins beeinflussen.  Die 
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Packungsanalyse zeigte, dass sowohl Phe 122 als auch Tyr 309 an solchen Packungskon-
takten beteiligt sind. Dies könnte eine mögliche Begründung dafür sein, warum in den MD 
Simulationen  teilweise  Konformationen  auftreten,  die  noch  nie  in  Kristallstrukturen 
beobachtet  wurden.  Auch  Trp  219  ist  in  einer  Schleifenregion  lokalisiert,  die  an  der 
Kristallpackung beteiligt ist. Die in den Simulationen für diesen Rest beobachtete erhöhte 
Flexibilität ist sinnvoll, da die Schleifenregion um Trp 219 wichtig ist für die biologische 
Funktion des Enzyms: Sie öffnet und schließt die Kofaktorbindetasche. Nach jedem kat-
alytischen Zyklus muss der Kofaktor ausgetauscht werden, daher ist eine intrinsische Flex-
ibilität dieser Region notwendig. 
Bei der genaueren Analyse der Bewegungen innerhalb der Bindetasche fiel auf, dass 
durch die Konformationsänderung von Phe 122 eine zusätzliche kleine Subtasche geöffnet 
wird. Weiterhin erzeugen die konzertierten Bewegungen von Tyr 309 und der Schleifenre-
gion um Leu 300 zusätzlichen Raum im „unteren“ Teil der Bindetasche. Daher war der 
nächste Schritt, geeignete Liganden zu identifizieren, welche eine oder beide dieser neuen 
Bindetaschenkonformationen  stabilisieren  und  damit  experimentell  zugänglich  machen 
können. 
Ein erster interessanter Ligand konnte in der Literatur identifiziert werden. Dockingex-
perimente,  die  mit  einer  aus  einer  MD  Simulation  extrahierten  Proteinkonformation 
durchgeführt wurden, lassen vermuten, dass eine sterisch anspruchsvolle Phenyl-Gruppe 
dieses Liganden in den zusätzlich generierten Raum im „unteren“ Teil der Bindetasche 
ragt. Innerhalb dieser Arbeit konnte von dem entsprechenden Komplex keine Kristallstruk-
tur erhalten werden. 
Um die neue Subtasche zu adressieren, die durch die Bewegung von Phe 122 entsteht, 
wurde eine andere Herangehensweise gewählt. Ein Benzodiazepin-Grundgerüst wurde als 
Ausgangspunkt für eine kleine Bibliothek von Molekülen mit unterschiedlichen Substitu-
tionsmustern  gewählt.  Benzodiazepine  zeichnen  sich  durch  ihre  leichte  synthetische 
Zugänglichkeit und Variabilität aus. Durch Docking wurde eine Vorauswahl und Prior-
isierung der zu synthetisierenden Moleküle getroffen. Bis zum Ende dieser Arbeit konnte 
im Arbeitskreis von Prof. Dr. Schlitzer eines dieser Moleküle hergestellt werden. Dieses 
zeigte eine moderate Bindung an das Enzym. Eine Verbesserung der Affinität und das an-
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schließende Lösen einer Kristallstruktur verbleiben als zukünftige Ziele bei der Weiter-
führung des Projektes. 
Ein weiterer Teil dieser Dissertation beschäftigt sich mit der Fragestellung, ob MD Sim-
ulationen genutzt werden können, um die an der „induced-fit“ Anpassung beteiligten En-
ergien zu quantifizieren. Zu diesem Zweck wurde die Methode MM-PBSA gewählt, da sie 
auf den ersten Blick geeignet dafür erschien. MM-PBSA berechnet die freie Bindungsen-
ergie eines Komplexes aus MD Trajektorien anstatt nur eine einzige Kristallstruktur dafür 
zu verwenden. Durch die Verwendung von unabhängigen Trajektorien für den Komplex, 
den Apo-Zustand des Proteins und den freien Liganden sollten theoretisch sowohl die In-
teraktions- als  auch die beteiligten Konformationsenergien erfasst  werden. Ein weiterer 
Vorteil ist die breitere Anwendbarkeit von MM-PBSA im Vergleich zu anderen Methoden 
der theoretischen Chemie zur Berechnung von freien Bindungsenergien. Weiterhin findet 
man in der Literatur eine ganze Reihe von Studien, die MM-PBSA erfolgreich für die un-
terschiedlichsten Aspekte des rationalen Wirkstoffdesigns einsetzen. 
Im Falle der AR hat sich MM-PBSA trotz intensiver Tests verschiedener Varianten als 
nicht zuverlässig herausgestellt. Das berechnete Ranking der verwendeten Liganden war 
bestenfalls leicht besser als komplett zufallsbasierte Vorhersagen. Bedenkt man den enor-
men Rechenaufwand, sowie die nicht unerhebliche Zeit, die für die Analyse der Ergebnisse 
notwendig  ist,  bleibt  festzustellen,  dass  diese  in  keinem Verhältnis  zu  den  erhaltenen 
Ergebnissen stehen. Da bereits die Vorhersage der freien Bindungsenergien scheiterte, ver-
boten sich alle weiterführenden Analysen in Bezug auf Konformationsenergien. 
Obwohl viele Varianten der Methode evaluiert wurden, verbleiben noch ein paar weit-
ere Punkte die weiter untersucht werden könnten. Einer dieser Punkte ist sicherlich eine 
systematische Parametrisierung der für die Rechnungen verwendeten Atomradien. In der 
vor kurzem veröffentlichten neuesten Version des Amber Programmpaketes wurde dies 
durchgeführt  und  eine  Untersuchung  der  Auswirkungen  dieser  neuen  Radien  auf  die 
Ergebnisse  wäre  sicher  interessant.  Weiterhin  wäre  eine  systematische  Analyse  der 
Auswirkungen unterschiedlicher  Dielektrizitätskonstanten  auf  die  Ergebnisse von Inter-
esse. Betrachtet man aber die in diesem Fall sehr ernüchternden Ergebnisse der Methode, 
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so  ist  es  fraglich,  ob  ausreichende  Verbesserungen  zu  erzielen  sind,  die  den  hohen 
Rechenaufwand rechtfertigen. 
Im letzten Abschnitt dieser Arbeit wird eine zweiteilige Studie präsentiert. Der erste 
Teil beschäftigt sich mit mit einem weiteren Aspekt der Flexibilität des bereits erwähnten 
Schleifenbereiches, der für die „induced-fit“ Adaptionen verantwortlich ist. In einer kom-
binierten Studie aus MD Simulationen und mehreren Kristallstrukturen, die von Holger 
Steuber für seine Dissertation angefertigt wurden, konnte gezeigt werden, dass zwischen 
mehreren Strukturen des gleichen Protein-Ligand-Komplexes signifikante Unterschiede zu 
sehen waren. Eine exzellente Übereinstimmung zwischen den Befunden der Kristallstruk-
turen und den MD Simulationen wurde gefunden. 
Im zweiten Teil dieses Abschnittes geht es um die unerwartete Bindung mehrerer Lig-
andmoleküle in und in der Nähe der Bindetasche. Die entsprechenden Kristallstrukturen 
wurden als Teil dieser Arbeit gelöst. Insgesamt vier Tolrestat-Moleküle konnten deutlich in 
der Elektronendichte lokalisiert werden. Die Bindung dieser zusätzlichen Liganden ging 
mit konformationellen Änderungen in weiten Teilen des Proteins einher, die in dieser Form 
vorher noch nicht beobachtet wurden. 
Insgesamt hat sich diese Arbeit mit vielen Aspekten der Proteinflexibilität beschäftigt. 
Dabei wurde AR als Modellsystem verwendet. Die Bedeutung der Proteinflexibilität für 
das Docken von kleinen Molekülen wurde gezeigt. Anschließend wurde eine neue Dock-
ing-Methode evaluiert, mit der sich mehrere Proteinkonformationen simultan adressieren 
lassen. Um das Ausmaß der Flexibilität von AR zu charakterisieren, wurden Kristallstruk-
turanalysen und vergleichende MD Simulationen durchgeführt. Zur Analyse der Simulatio-
nen wurde ein eigens dafür entwickeltes Datenbanktool verwendet. Durch diese Analyse 
zeigten sich zwei neue potentielle Bindetaschenkonformationen. Anschließend wurden er-
ste Versuche unternommen, diese Konformationen durch geeignete Liganden zu stabil-
isieren. Weiterhin wurde versucht, den Prozess der „induced-fit“ Bindung energetisch zu 
beschreiben. Dabei wurde die Methode MM-PBSA an einem Protein mit flexibler Binde-
tasche evaluiert. In einer kombinierten Studie aus Röntgenstrukturen und MD Simulatio-
nen wurde im letzten Teil der Arbeit auf spezielle Aspekte der Proteinflexibilität näher 
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eingegangen. Dabei wurde exzellente Übereinstimmung zwischen Experiment und Simula-
tion erzielt. 
Insgesamt hat sich diese Arbeit am Beispiel der AR mit einer Reihe von Aspekten der 
Proteinflexibilität beschäftigt. Dabei hat sich AR als wertvolles Testsystem herausgestellt, 
um solche Phänomene mit unterschiedlichen Methoden zu untersuchen. 
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The Molecular Dynamics Database (MDDB)
Introduction
The primary results of a Molecular Dynamics (MD) simulation are the positions of all 
atoms of the system under investigation over the course of the simulation time. At regular 
time intervals defined by the user the positions of the atoms are stored in a file. A single set 
of coordinates belongs to a certain instant in time, called a snapshot. The series of snap-
shots collected during the simulation is called the trajectory of this simulation. Using ap-
propriate visualization software such as PyMol251 or VMD252, MD trajectories can be load-
ed and visualized. If loaded sequentially, the individual snapshots create a movie of the 
movements occurring within the system. While visualizing the trajectory is a valuable tool 
to get a qualitative overview of the development of the system, other methods are required 
to analyze the simulation in a more quantitative manner. Depending on the goal of the 
study, the analysis of torsion angles, distances between atoms or groups of atoms as well as 
different rms values are normally required to investigate the flexibility of the protein bind-
ing pocket  based on a MD trajectory. 
Similar to other MD package, the Amber program suite157 contains routines which allow 
post-processing of trajectories to extract this kind of information from the trajectory: ptraj 
and carnal. Among other aspects, these programs allow the measurement of distances, rms 
values, and torsion angles. Both programs store their results in simple text files, but use 
slightly different file formats. If analyzing a trajectory with a priori knowledge about the 
most interesting parts of the system every parameter of interest can be measured in one 
run. However, while examining MD simulations in a rather exploratory way without any 
predefined structural parameters of interest, the problem arises that for every parameters 
investigated at a later stage, the entire trajectory has to be post-processed repeatedly. Even 
with most recent computer hardware this can be a tedious process for a multi-nanosecond 
trajectories with stored water positions. In addition, there is the problem of finding the 
most interesting parts of the simulation, thus many features have to be extracted from the 
trajectories. To perform this, the different parameters need to be plotted for graphical dis-
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play and statistically analyzed to obtain mean values and standard deviations. Furthermore, 
functionalities are needed to compare and sort different parameters according to their sta-
tistical values. 
In addition to the coordinates for all atoms, further parameters describing the state of the 
system are written to a second file, which contains information about different energy val-
ues. For example, the total, potential, electrostatic, kinetic, and van-der-Waals energies, but 
also the pressure and volume are monitored throughout the simulation. Examining these 
values is also of great importance to ensure the system remains within normal conditions. 
Again, these parameters have to be extracted from the trajectory, plotted and statistically 
analyzed.
In a comparative MD analysis between multiple simulations all these problem scale lin-
early with the number of trajectories under investigation. Moreover, there is the simple 
technical difficulty of how to compare most efficiently the same parameters obtained from 
different simulations. Usually this requires storage of all plots and statistical informations 
in separate files. With increasing numbers of simulations this becomes increasingly cum-
bersome. Thus, there is a need for a more ordered storage system, which allows easy com-
parisons of both parameters from the same MD simulation and between different trajecto-
ries: a molecular dynamics database (MDDB).
Database and program architecture
MDDB is  based  on  a  MySQL backend  machine  (version  4.1.2,  www.mysql.com).  To 
browse and query the data, phpMyAdmin (version 2.6.2, www.phpmyadmin.net) is used as 
web-interface. The post-processing of the trajectories, the data insertion into the database, 
and the analysis and plotting of the data is automatically handled using  Python (version 
2.3.5,  www.python.org).  Plots  are  generated  using  Gnuplot (version  4.0  patchlevel 0, 
www.gnuplot.info) for distance, rms, and dihedral plots. Torsdialsplots are generated using 
the pst-col package from latex (version 3.14, www.latex-project.org). The post-processing 
of the trajectories itself is handled by ptraj from the Amber suite. 
Data content
Meta data about every simulation, such as the name of the MD simulation and the location 
of the topology and trajectory files, is stored in the table md. Data from Amber topology 
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files required for MDDB data analysis are included in the database. These informations are 
stored in the tables atom and residue. The information contained within the energy 'trajec-
tory' of an Amber run is completely added to the database and plotted. The results are 
stored in the table frames_analysis. Since these energy data are especially important for the 
equilibration phase of an MD simulation, energy files of this phase are separately analyzed 
and the corresponding results are stored in the table  frames_initial_analysis. Concerning 
structural data relevant to analyze the trajectory, MDDB is able to handle the following pa-
rameters from an MD simulation:
• torsion angles: all torsions of the protein are automatically calculated and added 
to the database. Dihedral angles for ligands and cofactors need to be manually spec-
ified. The results are stored in the table dihedral_analysis. 
• distances: results are stored in the table distances_analysis.
• rms values: MDDB can handle rms values for single atoms, complete residues 
or  ligands  as  well  as  the  entire  protein.  The  results  are  stored  in  the 
rms_atom_analysis, rms_residue_analysis, and rms_all_analysis tables respective-
ly. Rms values can be automatically added to the database using ptraj. Additional-
ly, there is the possibility to pre-calculate rms values using carnal and subsequently 
add them to the database.
Using MDDB
The general work flow can be dissected into three steps:
1. preparation of input files and adding of missing group definitions to group_def 
table;
2. execution of the program to add the data, the corresponding statistical parame-
ters and the plots to the database;
3. analysis of the data.
In a first step the config files and the program script need to be adjusted to the current 
MD simulation (see the manual for technical details). Most adjustments needed (MD name, 
locations of the topology and trajectory files, ...) are self-explanatory. 
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In the next step the data are added to the database by executing the program. Depending 
on the trajectory size and the number of data sets to be added the runtime of the program 
can vary. However, in most cases the program should accomplish the job within a few 
hours. 
Figure 66: The MDDB logo.
Once the data are added, the web-interface can be used to analyze them. Through the 
web-interface the data can be browsed and standard sql queries can be submitted to the 
database. The results from these queries can be sorted according to different criteria by 
simply clicking on the corresponding column. 
MDDB enables an efficient and time-saving way to cope with the enormous amount of 
data produced by multiple MD simulations. Instead of having to handle literally thousands 
of  plots  and  text  files  with mean values  and standard deviations,  the  user  can simply 
browse through the data,  sort  them and identify  exactly those parts  of the simulations 
which are of highest interest to him. 
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Additional crystal structures for MD simulations
For every ligand in the MD data set complex crystal structures with human AR were need-
ed to guarantee the highest possible quality of the starting geometries for the MD simula-
tions. In order to complete the dataset, complex crystal structures for the AR inhibitors 
sorbinil and tolrestat were solved in the context of this work. The unexpected findings in 
the four-ligand tolrestat complex structure have already been discussed in greater detail in 
chapter 'Expect the unexpected' (page 163). For the sorbinil complex structure no unusual 
observations were made. Therefore, the description and analysis of the sorbinil and the 
synchrotron derived-tolrestat complex will be limited to a Relibase+ analysis of the differ-
ences between the binding pockets of the corresponding human (9sbi, 9tol) and porcine 
(1ah0120, 1ah3120) structures. The protocol used for superposition and analysis is analogous 
to the comparative crystal structure analysis (page 38) and based on the same settings and 
parameters. 
Structure Determination
Cloning, expression, purification, and crystallization of Aldose Reductase as well as struc-
ture determination has been done according to procedures published earlier114;253;254. 
Data were collected at 100 K using crystals previously exposed to a solution of 40 % 
(m/V) PEG 6000 in 50 mM di-ammonium hydrogen citrate at pH 5 as cryoprotectant. The 
data sets were determined with a RIGAKU copper rotating anode (Molecular Structure Co-
operation) at 50 kV, 90 mA as X-ray source and a R-AXIS IV++ image plate system. For 
each frame the exposure time and oscillation range were set to 5 min and 0.5°, respective-
ly. The data set of the tolrestat complex at 1.08 Å resolution was collected at the beamline 
X06SA at SLS, Switzerland. 
All data processing and scaling was performed using the HKL2000 package255. The co-
ordinates of human AR (pdb code 1el3256) were used for initial rigid-body refinement of 
the protein atoms followed by repeated cycles of conjugate gradient energy minimization, 
simulated annealing, and B-factor refinement using the CNS program package257. Refine-
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ment at later stages was performed with the program SHELXL258. Here, at least 20 cycles 
of conjugate gradient minimization were performed with default restraints on bonding ge-
ometry and B-values. Five percent of all data were used for Rfree calculation. Amino-acid 
side chains were fitted into sigma A-weighted 2Fo-Fc and Fo-Fc electron density maps us-
ing O259. After the first refinement cycle water molecules and, subsequently, cofactor and 
ligand were located in the electron density and added to the model. Restraints were applied 
to bond lengths and angles, chiral volume, planarity of aromatic rings and van der Waals 
contacts. Multiple side-chain conformations were built if an appropriate electron density 
was observed and maintained during the refinement. The threshold for keeping the less 
populated side-chain conformation in the model was set to 10% occupancy. During the last 
refinement cycles, riding H atoms were introduced without using additional parameters. 
The final models were validated using PROCHECK260. Data collection, unit cell parame-
ters, and refinement statistics are given in Table 19. 
Figure 67: Superpositions of human (green) and porcine (silver) AR. A shows the super-
position for the inhibitor sorbinil, B for the inhibitor tolrestat. 
The sorbinil complex structure
The porcine (1ah0) and human (9sbi) sorbinil complex structures match with an overall Cα 
rmsd value of 0.62 Å. The binding-site rmsd using all residues in a 6 Å sphere around the 
ligand is 0.21 Å. These low rms deviations already indicate that the two structures super-
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impose very well. No Cα or side-chain center movements can be observed. The ligand vol-
ume overlap between the ligands in the two structures is 96%. The only clash that can be 
measured is between one atom of the phenyl moiety of the ligand in the human structure 
and the CZ atom of Phe 122 in the porcine structure. As can be seen in Figure 67 A, Phe 
122 shows the largest deviation for all binding-site residues. This is not surprising, since in 
position 121 there is a proline in the porcine structure, whereas in the human enzyme a Phe 
is located at this position. Therefore, the largest structural perturbations are to be expected 
in this region. However, the impact on the binding-pocket geometry is rather moderate. 
The tolrestat complex structure
Since the structure with four molecules bound has already been discussed in chapter 'Ex-
pect the unexpected' (page 163), it will be omitted here and only the synchrotron structure 
will be compared to the porcine PDB complex. 
The  overall  Cα rmsd between the  human and porcine  tolrestat  complex  is  0.59  Å, 
whereas the binding pocket residues superimpose with an rmsd of 0.37 Å. Compared to the 
rmsds of the sorbinil structures the overall value is in the same range, whereas the binding 
pocket deviation is slightly higher. However, the tolrestat binding pocket is larger than the 
sorbinil pocket, since only tolrestat addresses the specificity pocket.
Three Cα movements above the threshold are observed. Two of the involved residues 
(Leu 124, Val 130) are located at the upper end of the specificity pocket and are attached to 
the flexible loop region following Phe 122 in sequence. The third residue, Trp 219, is also 
part of a loop region. Therefore, it is questionable whether these are important structural 
changes or inherent fluctuations for a loop region. The same is true for the single move-
ment of the Val 130 side chain: no direct impact on the binding pocket can be observed 
from this movement (see  Figure 67 B). The volume overlap between the two ligands is 






Data collection and 
Processing
No. of crystals used 1 1 1
Wavelength [Å] 1.5418 1.5418 0.97920
Space group P 21 P 21 P 21
Unit cell parameters
a, b, c [Å] 49.4, 66.8, 47.4 49.2, 68.1, 46.7 49.5, 66.7, 47.1
β [°] 91.8 92.8 92.5
Diffraction data
Resolution range [Å] 50-1.5 (1.53 -1.5) 50-1.5 (1.53 -1.5) 30-1.08 (1.1 - 
1.08)
Unique reflections 68182 (2947) 43 631 (1 920) 123 403 (5 449)
R(I)sym [%] 6.0 (20.0) 8.3 (22.5) 5.2 (8.7)
Completeness [%] 91.9 (84.1) 88.2 (78.7) 94.5 (83.3)
Redundancy 1.6 (1.7) 2.4 (2.3) 2.8 (1.9)
I/σ(I) 17.6 (5.8) 10.2 (3.9) 17.9 (8.9)
Refinement
Resolution range used 
in refinement [Å]
8-15 20-1.5 10-1.08
Reflections used in 
refinement (work/free)
42 909 / 1942 41 439 / 2 163 116 227/6 130
Final R values for all 
reflections (work/free) 
[%]
15.5 / 18.9 16.9 / 22.0 11.2/13.9
Final R values for 
reflections with F > 4 σ 
(work/free) [%]
15.2 / 18.3 16.2 / 21.0 11.0/13.6
Protein residues 316 316 316
Coenzyme 1 1 1
Inhibitor 1 4 1







Bonds [Å] 0.012 0.011 0.017
Angles [°] 2.6 2.3 2.4
Ramachandran plot




Generously allowed [%] - - -
Mean B factors [A²]
Protein 11.4 19.4 11.7
NADP+ 6.9 15.0 5.5
Inhibitor 18.1 26.1 8.2
Water molecules 21.7 29.1 21.8
Table 19: Crystallographic parameters for the three AR complex crystal strucutres solved 
in context of this work. The structure labeled 'tolrestat four ligands' corresponds to the one  
discussed  in  chapter  'Expect  the  unexpected'  (page  163)  where  in  total  four  ligand 
molecules were found near the binding site, whereas 'tolrestat synchrotron' corresponds to  
the second structure mentioned in the same chapter.
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Usage of crystal structures from collaboration partners
The determinations of some crystal structures used as input geometries for the MD simula-
tions (Pfizer compound126, 47d, JFD compound), the structures used to validate the docking 
experiments presented in the first chapter as well as the zopolrestat bound structures (1d, 
3d_a, 3d_b, 3d_c, 6d_a, 6d_b, co_10)153 of AR described in the chapter 'Expect the unex-
pected' are not part of this thesis. They were determined by Holger Steuber, PhD student in 
the Klebe group, as part of his PhD project. All other structures used in this thesis are ei-
ther taken from the PDB154 or were solved as part of this thesis (sorbinil, tolrestat, tolrestat 
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